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Abstract 
 
 VACV gene C16L encodes a 37-kDa protein that is highly conserved in 
orthopoxviruses and functions as an immunomodulator. Intranasal infection of mice with a 
virus lacking C16L (vC16) induced less weight loss, fewer signs of illness and increased 
infiltration of leukocytes to the lungs compared with wild-type virus. 
 To understand C16’s mechanism of action, tandem affinity purification and mass 
spectrometry were used to identify C16 binding partners. This revealed that Ku70, Ku80 and 
PHD2 interact with C16 in cells. 
Ku70 and Ku80 constitute the Ku heterodimer, a well characterised DNA repair 
complex. MEFs lacking Ku, or the other component of the DNA-dependent protein kinase 
(DNA-PK) complex, the catalytic subunit of DNA-PK (DNA-PKcs), were shown to be 
deficient in the upregulation of IRF-3-dependent genes such as Cxcl10, Il6 and Ifnb in 
response to transfection of DNA, but not poly (I:C). Furthermore, following infection of 
MEFs with VACV strain MVA the activation of Cxcl10 or Il6 transcription was dependent on 
DNA-PK. Therefore, DNA-PK is a DNA sensor capable of detecting poxvirus DNA and 
activating IRF-3-dependent innate immunity. 
 C16 inhibited the binding of Ku to DNA, and therefore inhibited DNA-mediated 
induction of Cxcl10 and Il-6 in MEFs. The role of C16 in vivo was also examined: infection 
with vC16 led to increased production of Cxcl10 and Il-6 following intranasal infection of 
mice compared with wild-type virus. C16 is therefore an inhibitor of DNA-PK-mediated 
DNA sensing and innate immune activation. 
 C16 was also shown to bind to PHD2, an enzyme involved in regulation of hypoxic 
signalling. VACV was found to activate the transcription of hypoxia-related genes, and C16 
expression in cells was also capable of doing this. The role of hypoxic signalling in VACV 
infection remains poorly understood. 
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Chapter 1: Introduction 
1.1. Vaccinia virus (VACV) 
 
1.1.1. Study of poxviruses 
 
Poxviruses have had a profound influence on human history. Smallpox, caused by 
variola virus (VARV), was a highly contagious disease with a mortality rate approaching 
40% and accounted for millions of deaths worldwide (Mack, 1972; Fenner, 1993). The 
eradication of smallpox was achieved by a dedicated effort from a World Health Organisation 
(WHO) team led by D.A. Henderson, using VACV as the live vaccine (Henderson, 1976; 
Henderson, 2009). The last natural case of smallpox was in Somalia in 1977, and the 
eradication was announced in 1980 (Henderson, 2009). 
Although the initiation of vaccination against smallpox is widely attributed to the 
1796 report of Edward Jenner inoculating a child with cowpox virus (CPXV) and 
demonstrating subsequent protection against smallpox, important advances predate this. 
Firstly, the direct inoculation of material from smallpox scabs into a recipients skin, termed 
variolation, was widely practiced in China and India in the 16
th
 century, and this practice was 
introduced to the west from Turkey by Lady Montagu (Dinc and Ulman, 2007; Henderson, 
2009). Secondly, others such as surgeon John Fewster and Benjamin Jesty, a Dorset farmer, 
practiced the inoculation of CPXV to prevent the development of smallpox many years prior 
to Jenner’s report (Hopkins, 2002; Pead, 2003). The unique contributions of Jenner to the 
field, however, were the direct demonstrations of protection against smallpox, of the 
effectiveness of person to person inoculation of CPXV (circumventing the need for a cow for 
vaccination) and eventual publication of his studies (Hopkins, 2002). 
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Infection with CPXV conferred protection against smallpox owing to the antigenic 
similarity between the viruses (Macdonald and Downie, 1950). In 1939, Alan Downie 
showed that smallpox vaccines being used in the 20
th
 century were distinct to CPXV, and 
thereafter the term VACV was used to describe this emerged virus. The exact origin of 
VACV is an enigma of virology.  
The eradication of smallpox has been heralded as the greatest humanitarian 
achievement to date. Whilst many years have passed since the last naturally occurring case of 
smallpox, there are compelling reasons to continue studying VACV.  
First, it is commonly used as a recombinant expression vector for vaccine 
development, because of the relative ease of constructing recombinant VACVs (Panicali and 
Paoletti, 1982), the wide range of cells that can be infected and the high expression levels of 
desired protein obtained with VACV (Moss et al., 1983; Smith et al., 1983; Mackett and 
Smith, 1986).  
Secondly, VACV expresses multiple proteins which have increased the understanding 
of host-pathogen interactions involved in immunity and cell biology, and further study of 
these and additional host-pathogen interactions may have important implications for fields 
beyond virology (Smith et al., 1999; Bowie and Unterholzner, 2008).  
This study involves the characterisation of the role of the VACV protein, C16, during 
infection by identifying interacting ligands and analysis of their potential roles in VACV 
infection. 
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1.1.2. Classification of VACV 
 
The family Poxviridae, of which VACV is a member, is a family of large, double 
stranded (ds) DNA viruses which replicate exclusively in the cytoplasm of infected cells. 
Poxviruses are divided into Chordopoxvirinae and Entomopoxvirinae based upon, 
respectively, their vertebrate and insect host ranges. VACV belongs to the Orthopoxvirus 
genus of the Chordopoxvirinae. As well as the Orthopoxvirus genus, there are seven other 
genera belonging to the Chordopoxvirinae, these are Parapoxvirus, Avipoxvirus, 
Capripoxvirus, Molluscipoxvirus, Suipoxvirus, Yatapoxvirus and Leporipoxvirus. VACV is 
the prototypical Orthopoxvirus because it is the most extensively studied member of this 
genus and it has been used as the smallpox vaccine for over 150 years. VACV is no longer 
thought to exist in a natural host, although there are reports of VACV strains circulating 
amongst cattle in Brazil (Leite et al, 2005) and buffalo in India (Dumbell and Richardson, 
1993). 
The Western Reserve (WR) strain of VACV is the most frequently used strain in the 
laboratory and is the strain used principally in this study. Another strain used is modified 
vaccinia Ankara (MVA), a highly attenuated strain of VACV, derived from chorioallantois 
virus Ankara (CVA) and passaged more than 570 times in chicken embryo fibroblasts. As a 
result of the high number of passages, MVA has six major deletions of the parental virus 
genome (Antoine et al., 1998; Meisinger-Henschel et al., 2007) and has lost multiple 
virulence factors (Blanchard et al., 1998), as well as acquiring mutations in many more (Mayr 
et al., 1978; Meyer et al., 1991; Antoine et al., 1998). MVA cannot replicate fully in most 
mammalian cell lines yet is able to synthesise antigen within infected cells and is a popular 
vaccine vector (Moss et al., 1996; Carroll et al., 1997; Drexler et al., 1998). The fact that 
17 
 
MVA cannot replicate fully in mammalian cells makes vaccination with MVA safe even in 
the context of immunosuppression (Mayr and Danner, 1978). 
 
1.1.3. VACV morphogenesis, entry and spread 
 
 There are two infectious forms of VACV called intracellular mature virus (IMV) and 
extracellular enveloped virus (EEV). EEV particles are IMV particles surrounded by an 
additional lipid envelope and associated viral antigens. During entry, enveloped viruses 
usually fuse their membranes with the plasma membrane or fuse with endocytic vesicles after 
endocytosis, and there is evidence to suggest that both methods are utilised by both the IMV 
and EEV forms of VACV (Moss, 2007).   
IMV entry remains an intensively studied aspect of VACV biology. An IMV particle 
is surrounded by a single lipid envelope and can enter cells by fusion of its membrane with 
either the cell plasma membrane or the membranes of endoyctic vesicles. Electron 
microscopy studies have demonstrated direct fusion of IMV with the plasma membrane, 
allowing for the transfer of virus core into the cytoplasm of infected cells (Carter et al., 
2005). In addition, there is evidence for a dependence on low pH during virus entry, which 
implicates an endosomal entry method (Townsley and Moss, 2007). Furthermore, a study has 
also provided evidence for an entry pathway based on apoptotic mimicry and 
macropinocytosis (Mercer and Helenius, 2008). 
EEV, which contains an extra lipid envelope surrounding IMV, is thought to use 
separate entry mechanisms from IMV because the existence of an extra membrane raises 
topological difficulties. Two EEV entry models have been proposed. The first involves the 
endocytosis of the infecting virion, and the subsequent disruption of outer membrane by 
acidification which allows the second membrane to fuse directly with the endosomal 
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membrane (Ichihashi, 1996; Vanderplasschen and Smith, 1999; Townsley et al., 2006). The 
second model, termed ligand-dependent non-fusogenic dissolution of viral membrane, is 
based upon observations of rupture of the outer membrane of EEV at the point of contact 
with the infecting virion. This rupture allows direct contact and fusion of the IMV of  the 
plasma membrane (Law et al., 2006)  
 
1.1.4.  VACV uncoating 
 
 After binding and entry, proteolysis of some virion proteins as well as hydrolysis of 
the virion phospholipid occurs (Zaslavsky, 1985). Subsequently, the disruption of the viral 
core commences. In the absence of early viral mRNA and/or proteins the complete disruption 
of the virus core does not commence, suggesting that release of the VACV genome from the 
virus core requires nascent viral proteins (Pedley and Cooper, 1987; Pedersen et al., 2000) 
 
1.1.5. VACV genome structure  
 
The VACV genome consists of a continuous, linear dsDNA molecule approximately 
190 kilobase-pairs (kbp) in length, although this varies between strains (Table 3.2). At the 
two termini of the genome, all known poxviruses have inverted terminal repeats (ITRs) which 
vary in length between strains and contain identical yet oppositely orientated sequences. At 
the genome termini there are hairpin loops connecting the two DNA strands to complete the 
continuous genome (Baroudy et al, 1982). In addition to the hairpin loop, the ITRs also 
contain a highly conserved region less than 100- base pairs (bp) in length which is required 
for the resolution of concatameric replication intermediates termed the concatamer resolution 
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site. The ITRs contain a series of tandemly repeated sequences, and the number of repetitions 
of these sequences differs between strains of VACV and other poxviruses (Table 3.2).  
Based upon published sequences of Chordopoxvirinae members, the overall genome 
structure (in terms of gene arrangement) can be generalised into two parts, (i) a central and 
highly conserved region of genes encoding proteins involved in essential replication 
functions such as transcription, replication and morphogenesis, and (ii) the regions located 
toward the ends of the genome, which tend to be involved in host interactions such as those 
concerned with modulation of the immune system (Gubser et al., 2004).  
 
1.1.6. VACV DNA replication 
 
As mentioned previously, poxvirus DNA replication takes place exclusively in the 
cytoplasm of infected cells. Discrete viral factories form during the course of infection, and 
each infectious particle has the potential to initiate the formation of a viral factory, thus the 
number of viral factories observed is a function of the multiplicity of infection. VACV DNA 
replication begins between 1 – 2 hours after infection, resulting in approximately 1 × 105 
genome copies per infected cell (Salzman, 1960).  
VACV encodes multiple enzymes involved in DNA replication, including those 
involved in DNA precursor metabolism such as thymidine kinase (Bajszar et al., 1983; Hruby 
et al., 1983), thymidylate kinase (Smith et al., 1989), ribonucleotide reductase (Slabaugh et 
al., 1988; Tengelsen et al., 1988) and a dUTPase (Broyles, 1993). Also, enzymes involved in 
DNA replication are produced by VACV such as a DNA polymerase, DNA topoisomerase, 
DNA ligase, a single stranded (ss) DNA binding factor and a processivity factor (Moss, 
2007).  
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Whilst there is incomplete understanding of how poxvirus DNA replicates, several 
lines of evidence point toward a rolling hairpin strand displacement mechanism such as that 
proposed for parvovirus DNA (Tattersall and Ward, 1976). Briefly, this model involves the 
introduction of a nick near the genome terminus, with the terminal 200-bp being particularly 
important for the introduction of the nick (Du and Traktman, 1996). The nick provides a 3’ 
end for priming of the replication complex (consisting of the VACV DNA polymerase, uracil 
DNA glycosylase, nucleotide triphosphate (NTP)-ase and the VACV A20 protein). The 
newly synthesised DNA strand then, by virtue of replicating the ITRs (including the hairpin 
loop), folds back on itself and the remainder of the genome is replicated (Moss, 2007).  
 
1.2. The innate immune system 
 
 The interaction between a virus and the host immune system is of considerable 
interest, and much understanding of the function of the immune system has been derived 
from studies of viruses. Furthermore, future design of vaccines might benefit enormously 
from a better understanding of how a virus interacts with its host and, importantly, how a host 
detects infection. 
The rapid detection of invading pathogens and the recruitment and activation of cells 
of both the innate and the adaptive immune system outlines the remit of the innate immune 
system. This system is comprised of both germ-line encoded molecules, such as Toll-like 
receptors (TLRs), and cells such as macrophages and neutrophils.  
 The recent advances in the study of innate immunity have been driven by the concept, 
developed over many years, including more recently by Charles A. Janeway, regarding the 
capability of the innate immune system to detect and respond to certain unchangeable 
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features of pathogens (Janeway, 1989; Medzhitov, 2009). Pathogens often have a series of 
molecules, termed pathogen-associated molecular patterns (PAMPs) which are essential for 
their existence, and the innate immune system has evolved to recognise these PAMPs with 
the use of pattern recognition receptors (PRRs). Examples of PAMPs include viral nucleic 
acid and lipopolysaccharide (LPS) of gram-negative bacteria.  
 Pattern recognition receptors (PRRs) are germline encoded molecules which detect 
PAMPs. Activation of PRRs leads to the activation of a number of transcription factors such 
as nuclear factor-B (NF-B) and the interferon regulatory factors (IRFs) which activate pro-
inflammatory gene transcription. In addition, intracellular signalling molecular complexes 
such as inflammasomes, involved in the post-translational modification of pro-inflammatory 
molecules, are also activated during the course of infection. The activation of these factors 
results in a coordinated response against the invading pathogen such as the initiation of 
inflammation (Medzhitov, 2008) and the recruitment and activation of the adaptive immune 
system (Iwasaki and Medzhitov, 2010). The coordination of the resulting immune response is 
largely due to the production of cytokines and chemokines. Chemokines are involved in the 
recruitment of leukocytes to the site of infection, whereas cytokines play a more diverse role, 
such as initiating cell death and inducing an antiviral state within cells, and among the 
cytokines are the interleukins (IL), tumour necrosis factor (TNF) and the interferons (IFNs).  
 The role of the innate immune system during VACV infection has been studied by 
many groups and various facets have been examined, from cellular to molecular mechanisms. 
Cellular contributions are of paramount importance and these are described here, however 
much work is dedicated to the understanding of the initial detection events and the role of 
cytokines, such as IFNs, produced during virus infections. 
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1.2.1. Cells of the innate immune system 
 
The cells of the innate immune system are ultimately responsible for dismantling of 
pathogens and also the activation of the adaptive immune system. Various cell types are 
employed during the course of infection to fulfil different roles and are briefly described here. 
 
Neutrophils 
 
 Neutrophils (also termed polymorphonuclear cells, PMNs) are granular leukocytes of 
myeloid origin and are a key cell type in various inflammatory processes. PMNs are an 
important element in bronchial defence following infection, and are recruited rapidly to the 
airway epithelium (Malech, 2007), therefore suggesting importance in some poxvirus 
infections since smallpox was transmitted principally via airborne droplets. PMNs may play a 
role in phagocytosing VACV since a study using radiolabelled VACV showed uptake of 
VACV particles by PMNs in vivo (West et al., 1987).  
One of the key effector mechanisms utilised by PMNs is the production and secretion 
of an enzyme termed neutrophil elastase upon stimulation of the neutrophil PRRs. Neutrophil 
elastase induces the production of pro-inflammatory mediators by bronchial epithelial cells 
(Korkmaz et al., 2008). VACV counters this role of neutrophils by inhibiting neutrophil 
elastase signalling pathways via two proteins, A46 and A52, which were found to inhibit both 
IL-1 and neutrophil elastase mediated NF-B activation (Carroll et al., 2005). 
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Macrophages 
 
 Macrophages (MΦs) are another leukocyte population of myeloid origin which play a 
key role in inflammatory processes. MΦs  represent 95% of resident phagocytic cells in the 
respiratory tract and lungs, the major route of VARV infection, and are derived from 
infiltrating monocytes (Curtis and Kaltreider, 1989). MΦs act as phagocytes but also activate 
T cells via cross presentation of antigens following phagocytosis of infected cells and in 
addition can secrete large amounts of IFNs and pro-inflammatory cytokines.  
Cross presentation by MΦs to T cells occurs within 1 h of VACV infection (Ramirez 
and Sigal, 2002), and depletion of MΦs from mice during intranasal infection of VACV 
using liposomal clodronate led to increased weight loss of the mice and decreased viral 
clearance (Rivera et al., 2007), suggesting that MΦs play a protective role during VACV 
infection.  
Natural killer (NK) cells 
  
 NK cells are granular cells of lymphoid origin that contribute to immediate antiviral 
immunity. NK cells act in two main ways to clear viral infection. Firstly, by secretion of IFN-
, which then induces an antiviral state and activates other cell types, such as macrophages to 
undergo phagocytosis; and secondly, by direct lysis of infected cells (Vivier et al., 2008).  
 NK cells have been found to participate in the immune response to VACV. Firstly, 
VACV infection induces the accumulation and activation of NK cells at the site of infection 
following intradermal injection of virus (Jacobs et al., 2006), suggesting that chemokines and 
cytokines produced during VACV infection result in the chemoattraction of NK cells. 
Secondly, depletion of NK cells renders mice more susceptible to VACV infection 
(Bukowski et al., 1983), suggesting a protective role of NK cells.  
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Dendritic cells (DCs) 
 
 DCs are a fundamentally important cell type in the immune system and are needed for 
the full activation of naive cluster of differentiation- (CD) 4+ and CD8+ T cells, via antigen 
presentation, which results in the initiation of adaptive immune responses against viruses, 
including VACV. DCs can be broadly divided into two categories, conventional DCs (cDCs) 
and plasmacytoid DCs (pDCs). Using a quantitative proteomics approach, the responses of 
different subsets of cDCs to certain viruses have been studied, and distinct PRR expression 
profiles have been found amongst different DC populations, indicating complexity in the 
methods of virus detection among different cDCs (Luber et al., 2010).  
 DCs are important for defence against virtually all pathogens, and there are several 
lines of evidence suggesting a critical role for DCs in VACV infection. Depletion of DCs led 
to a decreased production of IFN- during VACV infection (Liu et al., 2008), and also DCs 
produce large quantities of type I IFN in response to VACV infection (Yao et al., 2007; Liu 
et al., 2008). 
 
1.2.2   Extracellular molecules of the innate immune system 
 
 As well as powerful cellular components, the innate immune system also employs a 
complex series of molecules. These molecules are important for a diverse range of functions, 
for example enhancing phagocytosis in the case of complement, or chemoattraction of 
leukocytes to the sites of infection in the case of chemokines. These molecules are also 
therefore a prime target for viral countermeasures and there are multiple examples of 
interference by VACV in the following sections. 
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Complement 
 
 The complement system comprises a series of zymogens that are involved in the 
opsonisation of invading pathogens as well as serving as anaphylatoxins and chemoattractant 
proteins (Ricklin et al., 2010). The complement system is activated via three main pathways 
termed the classical, alternative, and lectin pathways.  
 The classical pathway of complement activation involves the binding of C1q to 
antibody-antigen complexes and activation of a sequence of complement components C4, C2 
and C3. Activation of the lectin pathway involves recognition of microbial associated lectins 
by mannose-binding-lectin and ficolins. Activation of the alternative pathway is initiated 
through a proteolytic activation of C3 on microbial surfaces (a process which is inhibited on 
host cells by cell membrane bound factor H). 
 
Complement & VACV 
 
 During VACV infection, complement is activated via the alternative pathway (Leddy 
et al., 1977). IMV is sensitive to complement in the absence of antibody. EEV, on the other 
hand, has an additional cell-surface membrane containing proteins, and is insensitive to 
complement in the absence of antibody due to the incorporation of host-cell complement 
regulatory proteins, such as CD55 and CD59 (Vanderplasschen et al., 1998). 
 One complement countermeasure is the VACV complement control protein (VCP), 
which is secreted from infected cells and consists of four copies of a repeated amino acid 
sequence, termed short consensus repeats (SCRs) which are found in host complement 
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regulatory proteins (Kotwal and Moss, 1988; Kotwal et al., 1990). VCP contributes to 
virulence by binding C4b and C3b and accelerating the decay of complement convertase 
enzymes critical to both the classical and alternative pathways (Isaacs et al., 1992). A second 
VACV protein, B5, contains short consensus repeats (SCRs) which are also found in 
complement regulatory proteins (Takahashi-Nishimaki et al., 1991), however no role in 
complement regulation has been reported.  
Thus, as well as being of fundamental importance to the host, the complement system 
is also the target of pathogen countermeasures (Lambris et al., 2008). 
 
Chemokines  
 
 Chemokines are a family of small (8-13 kDa) molecules involved in the recruitment 
of leukocytes to areas of infection and inflammation. After reaching the site of infection, 
chemokines on the luminal surface of the endothelium induce leukocytes to undergo 
diapadesis. Alternatively, chemokines can guide leukocytes through tissue matrix by binding 
to glycosaminoglycans (GAGs) and establishing a concentration gradient from the site of 
infection (Murphy, 2008).  
Chemokines are grouped into C, CC, CXC or CX3C subfamilies, where C represents 
highly conserved cysteine residues (Bacon et al., 2002). The biological actions of chemokines 
are mediated through their interactions with G-protein coupled receptors on leukocytes, and 
therefore a degree of specificity as to which leukocytes are recruited in a given inflammatory 
processes can be observed since the distribution of chemokine receptors can be differentially 
expressed depending on the cell type. Whilst a degree of specificity is observed, there is a 
high level of redundancy in the chemokine system, however, with multiple chemokine 
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receptors on single cells, multiple chemokines able to bind individual receptors and multiple 
receptors able to bind individual chemokines (Murphy, 2008).  
 
Chemokines and VACV 
 
VACV encodes proteins which modulate the function of chemokines because 
chemokines mediate the recruitment of leukocytes to sites of infection and as such they play a 
critical role in immunity and in VACV infection.  
The CC chemokine inhibitor (CCI, also termed ‘viral CC chemokine binding protein’ 
– vCKBP) is expressed by VACV and is secreted from infected cells (Graham et al., 1997; 
Smith et al., 1997; Alcami et al., 1998). CCI binds to multiple CC- chemokines including 
CCL2 (Beck et al., 2001), CCL3, CCL5 and CCL11 (Seet et al., 2001) and secretion of this 
molecule inhibits recruitment of inflammatory cells to sites of VACV infection leading to 
decreased morbidity and reduced weight loss in mice (Reading et al., 2003).  
VACV A41 is a 30-kDa glycoprotein secreted by infected cells that blocks the 
binding of chemokines to GAGs (Ng et al., 2001; Bahar et al., 2008). Interestingly, while this 
molecule does not inhibit the binding of chemokines to their receptors, the binding of 
chemokines to GAGs is inhibited. Consequently, the establishment of a chemokine gradient 
is obscured by A41. The obscuring of the chemokine concentration gradient results in 
decreased leukocyte chemotaxis in mice infected intranasally with VACV. Expression of A41 
by VACV, compared to a deletion mutant, is associated with slightly increased virulence and 
increased immunogenicity in vivo (Clark et al., 2006). 
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1.2.2.1. Interferon (IFN) 
 
 IFNs are a powerful cytokine family described originally by Isaacs and Lindenmann 
(Isaacs and Lindenmann, 1957; Isaacs et al., 1957). There are three types of IFN, termed type 
I IFN, type II IFN and type III IFN and can be distinguished based upon their activating 
receptors. IFN is thought to be important for the control of most animal viruses, and is also 
often important for the clearance of other pathogens such as mycobacteria.  
Type I IFN  
 
Type I IFNs consist of a group of molecules termed IFN -
and, however IFN- and IFN- have only been described in pigs 
and cattle and are not thought to have human counterparts (Pestka et al., 2004). The best 
characterised amongst the type I IFNs are IFN- (of which there are 13 subtypes in man) and 
IFN- both of which are induced during the course of viral infection. There are less well 
characterised roles for the other type I IFNs in viral infection. 
 
Type I IFN activates a receptor complex termed IFNAR consisting of an IFNAR1 and 
IFNAR2 heterodimer. Each receptor subunit is physically associated with a member of the 
Janus activated kinase (JAK) family. IFNAR1 is associated with tyrosine kinase-2 (TYK2), 
whereas IFNAR2 is associated with JAK1 (Figure 1.1). After binding of the heterodimeric 
receptor by type I IFN, the JAK family kinases are activated by a conformational change 
leading to autophosphorylation and activation of signal transducer and activator of 
transcription (STAT) -1 and STAT-2, leading to STAT-1/STAT-2 heterodimerisation (the 
JAK-STAT signalling pathway) (Platanias, 2005; Randall and Goodbourn, 2008).  IFN 
regulatory factor (IRF)-9 subsequently becomes associated with the STAT-1/STAT-2 
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heterodimer (Horvath et al., 1996; Martinez-Moczygemba et al., 1997) and the complex of 
STAT-1/STAT-2 and IRF-9 is referred to as interferon-stimulated genes (ISG) factor 3 
(ISGF3) (Schindler and Darnell, 1995). ISGF3 is a transcription factor complex which 
translocates to the nucleus and binds to interferon stimulated response element (ISRE) sites 
within promoters of ISGs (Kessler et al., 1990), as illustrated in Figure 1.1. 
Type II IFN 
 
There is only one type II IFN, IFN-and this is typically produced in mitotically 
active T cells and NK cells after activationDimericIFN- activates the IFN- receptor 
(IFNGR) consisting of a heterodimer of IFNGR1 and IFNGR2. Ligation of the IFNGR leads 
to activation of JAK1 and JAK2, associated with IFNGR1 and IFNGR2, respectively. The 
activation of these JAKs leads to the phosphorylation and homodimerisation of STAT-1, 
resulting in a complex referred to as IFN- activated factor (GAF) (Decker et al., 1991). After 
translocation to the nucleus, GAF binds to a specific DNA sequence termed IFN- – activated 
sequence (GAS) within gene promoters (Lew et al., 1991). Type I and type II IFN signalling 
has been reviewed extensively (Platanias, 2005; Randall and Goodbourn, 2008) and is 
illustrated in Figure 1.1.   
 
Type III IFN 
 
Type III IFNs represent a more recently described group consisting of IFN1, IFN2 
and IFN3 (also known as IL-29, IL-28A and IL-28B, respectively). The role of these 
molecules are not as well characterised in the context of virus infection as type I or type II 
IFNs. Type III IFN activates a receptor consisting of a heterodimer of IL-10 receptor 
(IL10R)-2 and IFN- receptor (IFNLR)-1, which displays a limited tissue distribution, 
30 
 
notably to epithelial cells, and activate similar signalling pathways to IFN-/ (Meager et al., 
2005; Zhou et al., 2007). Type III IFN can also signal through non JAK-STAT pathways such 
as via mitogen activated protein kinases (MAPKs) Jun-kinase (JNK) and extracellular 
regulated kinase (ERK)-1/2 (Ank and Paludan, 2009). Whilst the same cell often produces 
type I and type III IFN during virus infection, liver biopsies of patients infected with hepatitis 
C virus (HCV) demonstrated upregulation of type III IFN but not type I IFN (Mihm et al., 
2004), perhaps suggesting differential regulation of these IFNs. A fuller understanding of the 
role of type III IFN in immunity is required.  
 
Figure 1.1. Overview of type I and type II IFN signalling. A STAT-1 and STAT-2 
heterodimer is formed after binding of type I IFN to the type I IFN receptor (IFNAR) and the 
subsequent phosphorylation by the kinases JAK1 and TYK2. Subsequently, IRF-9 becomes 
associated with the complex which then translocates to the nucleus and is termed ISGF3, 
promoting the transcription of genes containing an ISRE site within the promoter. Type II 
IFN signalling is shown on the right hand side of the figure and shows that after binding of 
IFN-to the IFNGR, a STAT-1 homodimer is formed (termed GAF) and this translocates to 
the nucleus to activate transcription of genes containing a GAS in the promoter. 
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Role of IFN in VACV infection 
 
Increased mortality occurs in mice infected with VACV when lacking the type I IFN 
receptor (van den Broek et al., 1995). Additionally, intraperitoneal administration of IFN-
severely inhibited virus replication after intraperitoneal infection of mice with a VACV 
expressing luciferase, and this effect was even observed with infection 4 days after pre-
treatment with IFN (Rodriguez et al., 1991). Furthermore, studies using bioluminescence 
demonstrated a clear protective role for type I IFN during intranasal VACV infection, since 
infection of mice lacking IFNAR with a VACV expressing firefly luciferase led to increased 
bioluminescence compared with wild-type mice (Luker et al., 2005).  
Both IFN- and IFN- are found to have non-redundant roles as infection with 
VACV of mice lacking either IFNAR or IFNGR was much more severe compared with wild-
type littermate controls. In contrast, other viruses such as lymphocytic choriomeningitis virus 
(LCMV) and Semliki Forest virus were more virulent in mice lacking IFNAR but not in mice 
lacking IFNGR (van den Broek et al., 1995).  
Mice lacking IFNGR have also been demonstrated to be more susceptible to VACV 
infection (Huang et al., 1993). Importantly, this effect was independent of cytotoxic T cell 
generation since cells from IFNGR null mice showed unimpaired cytotoxicity in chromium 
release assays, suggesting that it is the action of IFN-on infected cells which has direct 
antiviral activity rather than IFN-being required for the generation of protective CD8+ T 
cells. Furthermore, treatment of mice with anti-IFN- antibodies resulted in increased 
mortality following infection with the mousepox virus, ectromelia virus (ECTV) (Karupiah et 
al., 1993).   
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In addition, whilst the roles of type III IFNs in viral infection remain to be well 
characterised, a protective effect of type III IFN in vivo in a poxvirus infection model has 
been noted, as intranasal infection of mice infected with VACV WR expressing either IFN-
2 or IFN-3 were attenuated compared to wild-type viruses (Bartlett et al., 2005).  
The importance of IFNs in the immune response to poxviruses is also illustrated by 
the many mechanisms these viruses have evolved to combat the production or function of 
IFNs, and the fact that deletion of genes responsible for these mechanisms reduces virulence. 
 
Poxvirus IFN countermeasures 
 
To combat the potent anti-viral host defence mechanisms conferred by IFNs, VACV 
employs countermeasures against different stages of the IFN response. For instance, poxviral 
IFN countermeasures include those which inhibit the upregulation of IFN (reviewed later), 
those which bind to IFN and those which inhibit IFN signalling. Examples of IFN 
countermeasures employed by VACV are illustrated in Figure 1.2.  
Firstly, VACV protein B8 is a secreted glycoprotein with sequence similarity to 
IFNGRs that binds to, and inhibits the activity of, IFN- (Alcami and Smith, 1995). B8 has a 
broad species specificity and can inhibit the activity of rat, ovine, bovine and human, but not 
murine IFN-(Mossman et al., 1995; Symons et al., 2002b).  
Secondly, VACV protein B18 is a decoy type I IFN receptor which is both secreted 
and present on the surface of infected cells. B18 binds soluble IFN-thus preventing the 
transmembrane signalling of IFN-(Colamonici et al., 1995; Symons et al., 1995). B18 
and B8 differ due to the fact that whilst B8 has sequence similarity to the IFN- receptor 
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(Alcami and Smith, 1995), B18 does not have sequence similarity to the type I IFN receptor, 
but instead belongs to the immunoglobulin (Ig) protein superfamily (Symons et al., 1995).  
Thirdly, VACV protein H1 is a phosphatase able to dephosphorylate STATs. Initially, 
H1 was found to dephosphorylate STAT-1 (Najarro et al., 2001) and later was reported to 
also dephosphorylate STAT-2 (Mann et al., 2008). Dephosphorylation of STATs in this way 
inhibits IFN-mediated signal transduction and thus dampens the upregulation of antiviral 
effectors. The H1 protein is packaged within virions, allowing for immediate STAT 
dephosphorylation without requiring nascent protein synthesis. VACV has also been shown 
to block STAT-independent IFN signalling (Mann et al., 2008), however the molecules 
involved in this have not yet been described. 
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Figure 1.2. VACV inhibition of IFN signalling. This figure demonstrates how VACV 
interferes with IFN signalling (VACV mechanisms are shown in red). Two proteins, B18 and 
B8 interfere with type I and type II IFN, respectively, binding to the endogenous receptor. 
VACV H1 phosphatase reverses the phosphorylation of STATs thereby inhibiting 
downstream IFN signalling.  
 
1.2.2.2. Interferon stimulated genes (ISGs) 
 
After binding of IFN to IFN receptors and the subsequent activation of signalling 
pathways the cell enters what is termed the ‘antiviral state’, which involves the transcriptional 
upregulation of genes containing ISRE and GAS elements within their promoters (Sadler and 
Williams, 2008), and translation of the mRNAs produced. The products of this response are 
typically referred to as ISGs. Some of the ISGs with a documented role in VACV infection 
are described here. 
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Protein kinase R (PKR) 
  
PKR recognises, and is activated by, double stranded RNA (dsRNA). Since dsRNA is 
not normally produced by the host cell, the activation of PKR usually only occurs during the 
course of infection. PKR contains a dsRNA binding domain and a serine/threonine kinase 
domain. Upon binding dsRNA, PKR becomes activated and phosphorylates eukaryotic 
initiation factor (eIF)-2, an essential component of translational initiation. Phosphorylation 
of eIF-2 by PKR inhibits the recycling of this molecule, thus inhibiting the translation of 
viral, as well as cellular, mRNA.  
Whilst VACV is a dsDNA virus, dsRNA is produced during the course of infection 
owing to transcription of the genome in opposite and complementary directions. However, 
the arrangement of genes transcribed early during the course of infection is such that these 
genes are orientated and are transcribed in the direction of the nearest genome terminus 
thereby reducing dsRNA synthesis. In addition, multiple sequences preventing transcription 
elongation are found in-between genes, thus preventing generation of complementary RNA 
strands. 
VACV encodes two molecules which inhibit the activity of PKR: E3 and K3. Whilst 
E3 binds prevents activation of PKR by sequestration of dsRNA (Rice and Kerr, 1984; Chang 
et al., 1992; Chang and Jacobs, 1993; Beattie et al., 1995; Chang et al., 1995; Shors et al., 
1998), K3 is a direct inhibitor of PKR-mediated antiviral activity by acting as a 
pseudosubstrate for PKR owing to an amino acid similarity to eIF-2Acting as a 
pseudosubstrate of PKR leads to prevention of phosphorylation of eIF-2 and therefore 
dampens the PKR-mediated translational shutdown, asdemonstrated by mutational analysis 
of residues conserved between K3 and eIF-2(Kawagishi-Kobayashi et al., 1997). 
36 
 
2’ 5’ oligoadenylate synthetase (OAS) 
 
OASs are a family of four molecules identified initially as enzymes able to inhibit 
cell-free protein synthesis (Kerr et al., 1977). OAS is activated by detection of dsRNA which 
induces the formation of an active OAS1 tetramer from inactive OAS1 monomers. Activated 
OAS inhibits protein synthesis by converting ATP into adenosine oligomers by forming 2’-5’ 
phosphodiester bonds (pppA(2’p5’A)n). These activate RNase L, which subsequently 
mediates the degradation of all RNAs, including mRNA, transfer RNA and ribosomal RNA 
(Clemens and Williams, 1978; Hovanessian and Justesen, 2007). RNase L contains two 
kinase-like domains and is constitutively inactive, however binding of pppA(2’p5’A)n leads 
to its homodimerisation and activation (Silverman, 2007). An additional feature of RNA 
degradation by RNase L is the formation of RNA molecules which may subsequently activate 
the retinoic acid inducible gene (RIG)-I like receptors (RLRs) RIG-I and MDA5 (Malathi et 
al., 2007).  
There are thought to be at least 11 OAS genes in mice, in contrast to the 4 human 
genes. Whilst the products of these genes each have dsRNA binding activity, only the OAS2 
and OAS3 murine homologs Oas1a and Oas1g have been shown to have 2’ 5’ OAS activity 
(Kakuta et al., 2002). A further study has shown that murine Oas1b negatively regulates 2’ 5’ 
OAS activity in cells, suggesting fine tuning of the OAS-RNase L system in mice (Elbahesh 
et al., 2011). However, Oas1b has been shown to be protective against flavivirus infection 
(Mashimo et al., 2002; Perelygin et al., 2002), suggesting alternative downstream pathways 
of murine OAS-like molecules.  
The role of the OAS/RNase L pathway in VACV infection is not well defined, and 
this is likely due to the effect of VACV protein E3 on preventing detection of dsRNA by 
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OAS, however the fact that E3 performs this function might suggest an importance of this 
system in VACV infection (Rivas et al., 1998; Xiang et al., 2002).  
 
 
ISG15 
 
ISG15 is a prominent protein induced by virus infection and the ensuing IFN 
response. The function of this protein has only recently begun to be established. ISG15 was 
discovered soon after the discovery of ubiquitin, and was recognised as a ubiquitin-like 
protein (Loeb and Haas, 1992). Ubiquitylation occupies an increasingly important role within 
the immune system (Bhoj and Chen, 2009). Like ubiquitin, ISG15 is attached to protein 
molecules by a series of members of the E1, E2 and E3 ubiquitin ligase enzyme families, and 
these molecules include many involved in the antiviral response, such as JAK1, STAT1, 
RIG-I, PKR and RNase L (Zhao et al., 2005). The ISG15-like modification of proteins by 
ISG15 is hereafter referred to as ISGylation. ISGylation does not lead to protein degradation, 
unlike K48-linked ubiquitylation, but instead resembles the activating effects of K63-linked 
ubiquitylation. Accordingly, ISGylation has been shown to prevent virus-mediated 
degradation of IRF-3 and therefore enhance the IFN response (Lu et al., 2006). In addition, 
Sindbis virus expressing ISG15 did not induce mortality in Ifnar
-/- 
mice, whilst wild-type 
virus induced mortality in these mice, suggesting the importance of ISG15 for control of 
virus infection (Lenschow et al., 2005).  
The role of the antiviral response mediated by ISG15 in VACV infection is only 
partially understood, however the VACV E3 protein is reported to affect ISG15 antiviral 
functions. Firstly, VACV WR infection was enhanced in  Isg15
-/-
 murine embryonic 
fibroblasts (MEFs) compared to wild-type cells, and secondly an E3 knockout virus, which 
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was unable to grow in wild-type MEFs, was able to grow in Isg15
-/-
 MEFs, suggesting 
modulation of ISG15 by E3 (Guerra et al., 2008). 
 
1.3. Intracellular innate immunity  
 
 The production of chemokines and cytokines is usually controlled at the 
transcriptional level by transcription factors activated by intracellular signal transduction 
pathways originating at PRRs. However, in some cases, for example the cytokines IL-1 and 
IL-18, processing of these molecules is required before their release and biological activity, 
and this is regulated by post-translational activation by inflammasomes. Transcription factors 
and inflammasomes play key roles in the coordination of immune responses to VACV and 
are described in the following sections. 
 
1.3.1. Nuclear factor-B (NF-B) and VACV 
 
NF-B was discovered as a transcription factor that binds to the intronic enhancer 
element of the kappa light chain gene in B cells (Sen and Baltimore, 1986a; Sen and 
Baltimore, 1986b) and was subsequently demonstrated to be a major regulatory factor in 
innate and adaptive immunity and has been reviewed recently (Vallabhapurapu and Karin, 
2009). Activation of NF-B results in the upregulation of pro-inflammatory molecules such 
as tumour necrosis factor (TNF)- 
  The NF-B family of transcription factors is composed of p65 (also called RelA), c-
Rel, RelB, p50 and p52- all of which are characterised by the presence of a C-terminal Rel-
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homology domain (RHD) that mediates homo- and heterodimerisation. Whereas p65 and c-
Rel typically heterodimerise with p50, RelB preferentially heterodimerises with p52, and its 
precursor p100 (Vallabhapurapu and Karin, 2009).  
 The subunits of NF-B contain nuclear localisation signals (NLSs) but are usually 
held within the cytoplasm by a family of inhibitors, the inhibitors of B (IBs) such as IB. 
Activation of NF-B requires degradation of these inhibitors for nuclear translocation of NF-
B to occur. 
Engagement of various receptors, such as TLR4, IL-1R or TNFR with their specific 
ligands each lead to the activation of the inhibitors of the B (IB) kinase (IKK) complex, 
consisting of IKK, IKK and IKK (also called NEMO). The IKK complex subsequently 
phosphorylates IB on serines 32 and 36 leading to its polyubiquitination and proteasomal 
degradation. This liberates the bound p50:p65, which then translocates to the nucleus to 
activate transcription of pro-inflammatory genes such as cytokines and chemokines. This 
process is illustrated in Figure 1.3. 
 The activation of NF-B is inhibited at many stages by VACV (Figure 1.3), which 
highlights its importance in the control of VACV infection. VACV strain WR protein B14, is 
a Bcl-2-like protein which binds to IKK and prevents the activation of NF-B signalling 
(Chen et al., 2008). N1 is another protein found to act intracellularly to contribute to 
virulence (Bartlett et al., 2002) by inhibiting NF-B activation (DiPerna et al., 2004). In 
addition, the M2 protein acts on an alternative activation pathway of NF-B by inhibiting the 
phosphorylation of ERK2, and importantly an endoplasmic reticulum localisation is essential 
for this function (Gedey et al., 2006; Hinthong et al., 2008). K1 is another VACV protein 
40 
 
thought to inhibit NF-B signalling by inhibiting IB degradation, though its exact 
mechanism is yet to be established (Shisler and Jin, 2004).  
 There are a plethora of molecules found to inhibit NF-B activation, however these 
are mostly thought to act at different stages of the pathway. Although multiple VACV 
proteins have been shown to inhibit NF-B activation, they are not redundant as viruses 
lacking individual genes display an attenuated phenotype during infection (Bowie and 
Unterholzner, 2008). One explanation for this might be that by acting on different 
components of the divergent signalling pathways multiple phenotypes can exist. For instance, 
VACV proteins A52 and A46 inhibit TLR and IL-1R signalling, thus affecting NF-B, IRF-3 
and mitogen activated protein kinase (MAPK) signalling via TLRs (Bowie et al., 2000), but 
not TNF-mediated NF-B activation. B14 binds to IKK and thus inhibits NF-B activation 
via TLRs, IL-1R and tumour necrosis factor (TNF) receptor (TNFR) signalling, but does not 
affect IRF-3 or MAPK activation by these receptors (Chen et al., 2008).  
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Figure 1.3. NF-B signalling and interference by VACV. Myeloid differentiation factor 88 
(MyD88) is activated by TLRs and IL-1R which in turn recruits TNF receptor associated 
factor (TRAF)-6. TRAF6 is responsible for binding and activating the TAK1 complex, which 
phosphorylates IKK. Phosphorylated IKK then phosphorylates IB, leading to its 
proteasomal degradation and the liberation of the p50:p65 heterodimer, which subsequently 
translocates to the nucleus to induce the transcription of pro-inflammatory genes. VACV-
mediated inhibition of this pathway is indicated in red. 
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1.3.2. Interferon regulatory factors (IRFs) and VACV 
 
The IRFs are major transcription factors which function in a variety of biological 
contexts and are particularly important in innate immune signalling. There are 9 members in 
humans and mice (IRFs 1-9) and these molecules each have an N-terminal DNA-binding 
domain (DBD) containing a helix-turn-helix motif which recognises a distinct DNA sequence 
(Honda and Taniguchi, 2006; Tamura et al., 2008).  
IRF3 and IRF7 are responsible primarily for the induction of type I IFNs. Activation 
of the IRFs occurs following stimulation of multiple PRRs, such as RIG-I, melanoma 
differentiation associated (MDA)-5, TLR3 and TLR4 (Section 1.3.4). IRF activation is 
achieved following phosphorylation by two kinases, TRAF family member-associated NF-B 
activator (TANK)-binding kinase-1 (TBK-1) and IKK (Fitzgerald et al., 2003; Sharma et al., 
2003; Hemmi et al., 2004; Perry et al., 2004). Whilst both TBK-1 and IKKcan both 
phosphorylate serines on both IRF3 and IRF7 at the C-terminal (regulatory) end, mutagenesis 
studies have demonstrated that TBK-1 is the major contributor to this process (McWhirter et 
al., 2004; Matsui et al., 2006).  
Five IRFs (IRF1, IRF3, IRF5, IRF7 and IRF8) have been implicated in type I IFN 
gene expression in multiple cell types.  
IRF1 
 
Originally, IRF1 was considered the main IRF activating type I IFN expression 
(Fujita et al., 1989). However Irf1
-/-
 MEFs produced comparable levels of type I IFN to WT 
MEFs in response to Newcastle disease virus (NDV), although a reduction in poly (I:C)-
induced IFN was observed (Matsuyama et al., 1993). IRF1 is important for VACV infection 
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in mice, since IFN- mediated antiviral activity was abolished in Irf1-/- MEFs, suggesting 
that a subset of IRF-1 stimulated genes are important for VACV control (Trilling et al., 
2009).  
IRF3 and IRF7 
 
IRF3 and IRF7 are now thought to be the major contributors to the RIG-I/MDA-5- 
mediated IFN activation pathway. Upon activation, TBK-1 phosphorylates IRF3 at multiple 
C-terminal residues. This causes removal of autoinhibition allowing subsequent additional 
phosphorylation at Ser385 or Ser386, resulting in dimerisation and translocation to the 
nucleus (Mori et al., 2004; Panne et al., 2007). The current model suggests that IRF3 
responds primarily to virus infection because this molecule is constitutively expressed in 
most cell types. IRF7 is only detected after induction by IRF3/IFN in most cell types (Sato et 
al., 2000; Taniguchi and Takaoka, 2002), with plasmacytoid dendritic cells (pDCs) being a 
notable exception (Gilliet et al., 2008).  
IRF3 is thought to be important to VACV infection because of its importance in type I 
IFN production (Sato et al., 1998) and also since VACV K7 targets IRF3 activation by 
binding to Asp-Glue-Ala-Asp (DEAD) box RNA helicase 3 (DDX3), a component of the 
IRF3 activation machinery whose role is incompletely understood (Schroder et al., 2008). In 
addition, another VACV protein currently being studied within our laboratory, C6 inhibits 
IRF3 activation by binding to TANK, NF-B activating kinase (NAK)-associated protein 
(NAP)-1 & Similar to NAP-1 TBK-1 adaptor (SINTBAD) (Unterholzner et al, submitted) 
which are adaptors for the activation of TBK-1 (Sasai et al., 2006; Guo and Cheng, 2007; 
Ryzhakov and Randow, 2007) .  
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1.3.3. Inflammasomes and VACV 
 
 Inflammasomes are multi-protein complexes found within various cell types, such as 
macrophages, and are involved in the processing of pro-IL-1, pro-IL-18 and pro-IL-33 into 
their biologically active forms, IL-1, IL-18 and IL-33 by caspase-1. Inflammasomes are 
activated following detection of a variety of ligands by distinct PRRs including Nod-like 
receptors (NLRs) (Lamkanfi and Dixit, 2009). Inflammasome formation begins when a PRR 
binds a PAMP, but instead of activating transcription factors, the PRR recruits caspase-1 via 
a caspase recruitment domain (CARD), either directly or via an adaptor such as apoptosis-
associated speck-like protein containing a CARD (ASC). 
 VACV can activate inflammasomes via distinct mechanisms. Firstly, the absent in 
melanoma -2 (AIM2) inflammasome has been shown to be activated during VACV WR 
infection, in vivo (Rathinam et al., 2010). AIM2 binds to cytoplasmic DNA and activates 
caspase-1 through a homotypic interaction between a CARD present on both caspase 1 and 
the adaptor ASC (Burckstummer et al., 2009; Fernandes-Alnemri et al., 2009; Hornung et al., 
2009; Roberts et al., 2009) resulting in the activation of caspase 1 and subsequent secretion of 
IL-1 and IL-18.  
 In addition, in vitro studies demonstrate that the NLRP3 inflammasome is activated 
during MVA infection (Delaloye et al., 2009) by an unknown ligand. Infection of Nalp3
-/- 
bone-marrow derived macrophages (BMDMs) with MVA resulted in significantly reduced 
production of IL-1compared to wild type BMDMs, and this was confirmed with small 
hairpin RNA (shRNA) knockdown of NALP3, ASC and Caspase1 in human THP-1 cells


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Inhibition of inflammasomes by VACV 
 
 Inflammasomes are inhibited by VACV at multiple stages. VACV WR B13 is an 
ortholog of CPXV CrmA, which was found to inhibit IL-1 processing in baculovirus Sf9 
cells (Howard et al., 1995). B13 inhibits caspase 1 in THP-1 cells, although this protein does 
not affect virulence in a murine infection model in vivo (Kettle et al., 1997).  
VACV also inhibits the cytokines produced by inflammasome activation by 
producing decoy receptors to both IL-1 and IL-18. A molluscum contagiosum virus 
(MOCV), another member of the Poxviridae, protein was found to have similarity to the 
mammalian IL-18 binding protein and was shown to bind IL-18 and prevent IL-18-dependent 
activation of IFN-(Xiang and Moss, 1999). Subsequently, other poxvirus orthologs were 
investigated and were also found to bind IL-18 (Born et al., 2000; Smith et al., 2000). The 
VACV IL-18 binding protein, C12, was shown to bind IL-18 and intranasal infection of mice 
with a C12 deletion mutant demonstrated that the virus was attenuated compared with wild-
type viruses (Symons et al., 2002a; Reading and Smith, 2003). 
 VACV WR also encodes an IL-1 binding protein, B15, which binds to and 
sequesters IL-1 (Alcami and Smith, 1992). Intracranial infection of mice with a B15 
deletion virus demonstrated decreased virulence, as demonstrated by an increased dose of 
virus required to kill 50% of infected mice (LD50) (Spriggs et al., 1992). Intranasal infection 
of mice with a B15 deletion was not shown to significantly increase the LD50, although 
infection with the B15 deletion virus lead to an enhanced febrile response (Alcami and Smith, 
1996) and an acceleration of the appearance of symptoms (Alcami and Smith, 1992), 
suggesting a role for IL-1 in generating fever in response to VACV and enhancing the acute 
phase response to VACV. 
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1.3.4. Pattern recognition receptor (PRRs) 
 
The signalling molecules described above are activated ultimately after engagement of 
PRRs by PAMPs. PRRs are therefore of fundamental importance in the activation of innate 
immune responses and serve the host by acting as the initial sensors of infection (Takeuchi 
and Akira, 2010). There are multiple types of PRRs, including TLRs and RLRs, which detect 
a multitude of different ligands, and these are of considerable interest in the innate immune 
response to VACV as the activation of innate immunity by VACV remains incompletely 
defined.   
 
1.3.4.1.  Toll-like receptors (TLRs) and VACV 
 
Toll-like receptors (TLRs) are type 1 transmembrane proteins with ectodomains 
containing leucine rich repeats (LRRs) that bind directly to PAMPs and a Toll/Interleukin-1 
receptor (TIR) intracellular domain required for downstream signalling (Kawai and Akira, 
2010). TLRs can either homodimerise or heterodimerise to form active receptors. PAMPs 
recognised by TLRs include lipopolysaccharide (LPS) from gram-negative bacteria, 
peptidogylcans and nucleic acids from fungi, bacteria, parasites and viruses. While most 
TLRs are found on the cell surface, a subset of TLRs are located on endosomes (TLR3, 
TLR7, TLR8 and TLR9).  
 
1.3.4.1.1.  Signalling pathways activated by TLRs: the MyD88-dependent 
pathway 
 
Although there is a broad overlap in downstream signalling events after stimulation of 
different TLRs, there are certain levels of specificity. These specific signalling events are 
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conferred by the Toll-interleukin-1 like (TIR) domain containing adapters myeloid 
differentiation factor 88 (MyD88), TIR containing adaptor protein (TIRAP), TIR-domain-
containing adapter-inducing interferon-β (TRIF) and TRIF related adaptor molecule 
(TRAM). TIRAP is involved in the recruitment of MyD88 to TLR2 and TLR4 (Fitzgerald et 
al., 2001; Kagan and Medzhitov, 2006). TRAM is involved in the recruitment of TRIF to 
TLR4 (Yamamoto et al., 2003b).  
After binding to ligand, TLRs can activate the NF-B or IRF transcription factors, or 
both, via two main pathways, the MyD88–dependent pathway and the TRIF-dependent 
pathway. 
The MyD88-dependent pathway (Figure 1.3) is utilised by all TLRs except TLR3, and 
activates NF-B and mitogen-activated protein kinases (MAPKs) to induce pro-inflammatory 
cytokines. Briefly, this pathway involves the recruitment of the IL-1-receptor associated 
kinases (IRAK) IRAK4, IRAK1, IRAK2 and IRAKM (Kawai and Akira, 2010). IRAK4 is 
activated first, followed by sequential activation of IRAK1 and IRAK2 (Kawagoe et al., 
2008). IRAK activation leads to the recruitment of TRAF6 that induces K63-linked 
polyubiquitination of itself and IRAK1 along with Ubc13 and Uev1A. Subsequently, NEMO 
(part of the IKK complex) and transforming growth factor (TGF)- activated kinase (TAK)-1 
binding protein (TAB)-2/TAB3 (regulatory subunits of the TAK1 kinase) are recruited to the 
polyubiquitin chains and this brings the IKK complex into close proximity with an activating 
kinase TAK1 (Bhoj and Chen, 2009; Xia et al., 2009). TAK1 can also simultaneously 
activate MAPKs ERK1, ERK2, p38 and JNK which leads to the activation of the 
transcription factor activated protein-1 (AP-1) (Yamaguchi et al., 1995; Holtmann et al., 
2001).  
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1.3.4.1.2.  VACV and the MyD88-dependent pathway 
 
During ex vivo VACV infection of pDCs, MyD88 is crucial for production of type I 
IFN (Martinez et al., 2010) and for development of CD8+ T cell responses, implicating TLR 
signalling in the development of immunity to VACV. However, MyD88
-/-
 DCs developed and 
primed CD8+ T cells normally in response to VACV WR, suggesting both a MyD88 
dependency of a full immune response and a MyD88-independent mechanism of DC 
activation (Zhao et al., 2009).  
MyD88 is the target of a VACV immunomodulator, A46. A46 is expressed early 
during the course of infection (Stack et al., 2005; Assarsson et al., 2008) and was found to 
bind to MyD88. Over-expression of A46 prevented MyD88-mediated activation of NF-B. 
Since MyD88 is a common adaptor molecule for TLRs, the role of A46 in modulating 
activation of NF-kB by multiple TLRs was examined and A46 was found to have a 
pleiotropic effect by inhibiting TLRs 1, 2, 4, 5, 6, 7 and 9 as well as IL-1R activation of NF-
B (Stack et al., 2005).   
In addition, TRAF6 and IRAK2 have been proposed as binding partners of another 
VACV protein, A52. A52 is a member of the poxvirus Bcl-2 like family (Graham et al., 
2008) and is thought to be expressed early during the course of infection (Assarsson et al., 
2008). A52 has evolved to inhibit NF-B activation by interfering with the TLR pathway by 
disrupting the interactions between TAB1 and TRAF6 and between IRAK2 and TIRAP, 
leading to inhibition of signalling mediated by TLRs 1, 2, 3, 4, 5 and 6 (Harte et al., 2003).    
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1.3.4.1.3.  Signalling pathways activated by TLRs: the TRIF-dependent pathway  
 
The TRIF-dependent pathway is utilised by TLR3 and TLR4 and is the only pathway 
utilised by TLR3, illustrated in Figure 1.4. The activation of the TRIF-dependent pathway 
culminates in the activation of both NF-B and IRF3. TRIF activates NF-B by recruiting 
TRAF6 (Sato et al., 2003), however the activation of NF-B by TRIF also involves the 
recruitment of the adaptor receptor interacting protein (RIP)-1, which itself interacts with 
TNFR-associated death domain protein (TRADD), leading to K63-linked polyubiquitination 
of RIP1 (Ermolaeva et al., 2008; Pobezinskaya et al., 2008). In addition, Pellino-1 is also 
recruited to the complex containing TRIF, TRAF6, RIP1 and TRADD, and loss of Pellino-1 
leads to loss of TRIF-dependent activation of NF-B (Chang et al., 2009). The result of this 
multiprotein complex is the activation of TAK1 which phosphorylates the IKK complex and 
p38 MAPKs leading to the nuclear translocation of NF-B and AP-1.  
The TRIF-dependent pathway leads to IRF3 nuclear translocation via the recruitment 
of TRAF3, which is required for the activation of the non-canonical IKKs IKK and TBK-1 
(Hacker et al., 2006; Oganesyan et al., 2006), which are required for the phosphorylation of 
IRF3 (Fitzgerald et al., 2003; Sharma et al., 2003; Hemmi et al., 2004; Perry et al., 2004). 
 
1.3.4.1.4.  TRIF-dependent pathway and VACV 
 
Whilst TRIF deficiency did not appear to result in impaired CD8+ T cell responses to 
VACV (Zhao et al., 2009), a thorough study evaluating the role of TRIF in VACV infection 
has not yet been conducted. However, VACV protein A46 has been demonstrated to bind to 
TIRAP and TRAM which inhibits TRIF recruitment to TLR4 (Stack et al., 2005), perhaps 
suggesting a role for TRIF in VACV infection.  
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Figure 1.4. TRIF-dependent TLR pathway and its inhibition by VACV. An overview of 
TLR3 signalling leading to the activation of p50:p65 (NF-B) and IRF3. After  binding of 
dsRNA, or potentially another ligand, VACV induces TLR3 signalling via recruitment of 
TRIF leading to the activation of TRAF3 which activates the TANK/NAP1/SINTBAD 
complex which in turn activates the non-canonical IKK complex leading to the activation of 
IRF3. The TRIF-dependent pathway also leads to the activation of NF-B via RIP1 which 
leads to the activation of the TAK1 complex resulting in nuclear translocation of NF-B. 
VACV inhibition of this pathway is indicated in red.  
 
1.3.4.1.5. Individual TLRs 
 
TLR2 
 
TLR2 has been shown to be important for activation of innate immunity in the context 
of VACV infection. TLR2 and MyD88 are required for the production of pro-inflammatory 
cytokines and control of VACV infection both in vitro (Zhu et al., 2007; Barbalat et al., 2009) 
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and in vivo (O'Gorman et al., 2011), although TLR-independent mechanisms are primarily 
responsible for the production of IFN(Zhu et al., 2007; O'Gorman et al., 2011)
Dendritic cells (DCs) deficient in TLR2 were unable to induce cytokines produced by 
WT DCs in response to VACV infection (Zhu et al., 2007). In a more recent study, 
intravenous infection with VACV induced production of IL-6 in a TLR2-dependent manner, 
which subsequently activated STAT3 signalling in DCs and T cells. However, ECTV 
infection did not elicit the production of this IL-6 (O'Gorman et al., 2011). The VACV ligand 
responsible for activating TLR2 is not known. 
TLR3 
 
TLR3 recognises dsRNA (Alexopoulou et al., 2001) and plays a key role in defence 
against many virus infections. Whilst TLR3 demonstrates quite a wide tissue distribution, 
particularly high levels are found on myeloid DCs (mDCs). The importance of TLR3 in 
protection against many viruses has been shown, including MCMV (Tabeta et al., 2004). 
However TLR3 is not required for effective protection against many other viruses such as 
LCMV, vesicular stomatitis virus (VSV) and reovirus (Edelmann et al., 2004). In the case of 
VACV, a Tlr3
-/-
 genotype confers greater resistance to infection, and this is explained by 
TLR3 involvement in recruitment of inflammatory cells to sites of infection and induction of 
immunopathology. Although it is clear that TLR3 is activated in the course of VACV 
infection, the role of this activation remains to be studied in detail (Hutchens et al., 2008). 
TLR2/6 
 
TLR2/6 is reported to be important for innate immune sensing of MVA by BMDMs. 
BMDMs from TLR2, TLR6 and MyD88 null mice were unable to produce CXCL2 in 
response to MVA infection, but CXCL2 production was normal in cells lacking TRIF, TLR4 
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or TLR1. Type I IFN production by BMDMs infected with MVA, however, was not affected 
by the loss of TLR1, TLR2, TLR4, TLR6, MyD88 or TRIF but was dependent upon MDA-5 
and mitochondrial antiviral signalling protein (MAVS) (Delaloye et al., 2009).   
 
TLR 4 
 
TLR4 inhibition by an 11 amino acid (aa) motif, termed viral inhibitory peptide of 
TLR4 (VIPER) found within the VACV protein A46 has suggested a role for TLR4 during 
the course of viral infection (Lysakova-Devine et al., 2010). VIPER inhibited TLR4 but did 
not interfere with other TLRs. The ligand responsible for the activation of TLR4 during 
VACV infection has not been identified. 
 
TLR8 
 
TLR8 has been implicated in the host response to VACV WR. The role of TLR8 in 
VACV infection was identified initially via an NF-B luciferase reporter assay in human 
embryonic kidney (HEK) cells transfected with TLR7 or TLR8 and VACV DNA added to 
the supernatant. Small interfering (si) RNA-mediated knockdown of TLR8 in pDCs 
completely ablated type I IFN production in response to VACV and AT-rich DNA (Martinez 
et al., 2010).  
TLR9 
 
TLR9 recognises hypomethylated CpG motifs (Bauer et al., 2001) within endosomes 
and activates a MyD88-dependent signalling pathway (Barton et al., 2006). Data regarding 
the role of TLR9 in VACV infection are equivocal. One study has suggested a role for TLR9-
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independent activation of pDCs in response to MVA infection, which also suggested a role 
for TLR independent activation of pDCs (Waibler et al., 2007) following ‘mildly UV-
inactivated MVA infection’. On the other hand, another study demonstrated that UV-
inactivated MVA-mediated IFN production by pDCs is entirely dependent on TLR9 
(Samuelsson et al., 2008). However, both studies concluded that MVA encoded TLR9 
antagonists, suggesting that TLR9 may be important for innate immune activation following 
VACV infection. A third study has shown a MyD88-dependent but TLR9-independent 
activation of pDCs in response to VACV WR (Martinez et al., 2010). 
 
1.3.4.2. Soluble PRRs leading to detection of RNA and their downstream 
signalling pathways 
 
 Six receptors that detect intracellular RNA have been identified and these are of 
critical importance in the activation of the immune response to many viruses. The six 
receptors are PKR, OAS, RIG-I, MDA-5, laboratory of genetics and physiology 2 (LGP2) 
and nucleotide oligomerisation domain (NOD)-2 (Barbalat et al., 2011). 
 RIG-I was discovered using a cDNA screen to identify genes that enhanced the 
activation of the IFN- promoter in response to poly (I:C) (Yoneyama et al., 2004) and was 
thus identified as a PRR responsible for the detection of viral RNA. RIG-I contains two 
CARDs and a central DEAD box helicase/ATPase domain essential for binding to RNA and 
IRF3 activation, as well as a C-terminal regulatory domain that prevents constitutive 
activation. RIG-I discriminates between self and non-self RNA by binding to uncapped 5’-
triphosphate ssRNA (pppRNA), a motif commonly found during the course of infection with 
certain viruses, but not on host RNA (Hornung et al., 2006; Pichlmair et al., 2006). However, 
more recent studies have reported that small regions of base pairing may also be required for 
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activation of RIG-I dependent innate immune responses (Schlee et al., 2009; Schmidt et al., 
2009). To complicate matters further, other studies have demonstrated that some species of 
dsRNA which lack pppRNA can also activate RIG-I (Kato et al., 2008; Takahasi et al., 2008).  
After initial detection of viral RNA, a signal transduction pathway is activated 
resulting in the dimerisation and nuclear translocation of IRF-3 (Figure 1.5). The CARD 
domains of RIG-I and MDA-5 are the domains responsible for the interaction with an adaptor 
molecule termed MAVS/Cardif/VISA/IPS-1 (Kawai et al., 2005; Meylan et al., 2005; Seth et 
al., 2005; Xu et al., 2005), hereafter termed MAVS, required for the nuclear translocation of 
IRF-3. MAVS was found to interact with an E3 ubiquitin ligase, TRAF3, responsible for K63 
polyubiquitin chain formation (Hacker et al., 2006; Oganesyan et al., 2006; Saha et al., 2006). 
TRAF3 null cells show severely impaired production of type I IFN induction after RNA virus 
infection. Subsequently, TRAF3 recruits and activates the non-canonical IKKs, TBK-1 and 
IKK which phosphorylate IRF-3 and IRF-7 leading to type I IFN induction.  
In addition to IRF3, NF-B is also activated in response to dsRNA (Visvanathan and 
Goodbourn, 1989) and this activation is mediated by TRAF6 recruitment to MAVS (Xu et 
al., 2005). In addition, RIP1 and Fas-associated death domain (FADD) are thought to be 
recruited to MAVS via TRADD, leading to the activation of NF-B (Balachandran et al., 
2004; Kumar et al., 2006; Michallet et al., 2008). 
RIG-I binds to unanchored K63-linked ubiquitin chains via the CARD domain, and an 
inability to bind K63 linked ubiquitin abolishes the ability of RIG-I to respond to 5’ 
triphosphate RNA (Zeng et al., 2010). Originally RIG-I was thought to require ubiquitination 
by TRIM25 on the K172 residue (Gack et al., 2007; Gack et al., 2008) and influenza virus 
NS1 inhibited this process (Gack et al., 2009). However, a more recent study suggests that 
the ubiquitination of the K172 residue is not required, and it is binding to unanchored 
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ubiquitin chains that is the more important factor for activation of RIG-I (Zeng et al., 2010). 
The role of ubiquitin binding versus ubiquitination in RIG-I signalling remains to be 
completely resolved.  
MDA-5 was discovered originally as a ligand of paramyxovirus V proteins 
(Andrejeva et al., 2004) and has a domain structure similar to RIG-I: N-terminal CARD 
domains, a central DEAD box helicase/ATPase domain and a C-terminal regulatory region. 
MDA-5 functions in a similar way to RIG-I by binding viral RNA and activating downstream 
signalling pathways leading to the induction of IFN (Andrejeva et al., 2004; Yoneyama et al., 
2005).   
In contrast, LGP2 lacks the N-terminal CARD domains required for IRF3 activation 
and consists only of the central DEAD box helicase/ATPase domain and C-terminal 
regulatory domain, and was thought initially to be a negative regulator of the RIG-I/MDA5 
pathways (Yoneyama et al., 2005). However, more recently it has been suggested to be a co-
receptor for the other RLRs because generation of LGP2
-/-
 mice showed that the absence of 
LGP2 leads to decreased type I IFN production in response to picornaviruses (Satoh et al., 
2010). NOD2 also contains an N-terminal CARD domain, a central nucleotide binding 
domain and a C-terminal LRR domain and was identified as a cytosolic RNA sensor 
responsible for type I IFN production in response to ssRNA (Sabbah et al., 2009). 
The different roles of MDA-5 and RIG-I have been studied extensively (Kato et al., 
2006; Loo et al., 2008) and their different ligand specificities can lead to each receptor 
detecting distinct virus families. Rig-I
-/-
 cells do not produce type I IFN in response to certain 
RNA viruses, including paramyxoviruses, VSV and influenza virus (Kato et al., 2005; Kato 
et al., 2006). Interestingly, MDA-5 was identified initially as an RNA sensor when it was 
characterised as a binding partner for the paramyxovirus PIV5 protein, and this viral protein 
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was shown to inhibit MDA-5-mediated IFN induction (Andrejeva et al., 2004). This perhaps 
explains why absence of MDA-5 does not significantly impair the response to paramyxovirus 
infection.  In contrast, cells lacking MDA-5 are unable to respond to picornaviruses such as 
poliovirus and encephalomyocarditis virus (Gitlin et al., 2006; Kato et al., 2006). Several 
other viruses, including Newcastle disease virus and Sendai virus are thought to be detected 
by both RIG-I and MDA-5 (Yoneyama et al., 2005; Kato et al., 2006; Fredericksen et al., 
2008). 
MDA-5 and MAVS are reported to play an important role in the detection of 
poxviruses in macrophages since knockdown of either of these molecules by shRNA led to 
decreased type I IFN production after MVA infection of THP-1 cells and, importantly, RIG-I 
was not required for production of type I IFN in response to MVA infection of these cells 
(Delaloye et al., 2009).  
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Figure 1.5. RNA sensing within host cells. This figure demonstrates the activation of NF-
B and IRF-3 after RNA sensing by the RLRs RIG-I and MDA-5. After binding either 
dsRNA (MDA-5) or pppRNA (RIG-I), MAVS becomes activated leading to the 
phosphorylation and dimerisation of IRF-3 via the non-canonical IKKs TBK-1 and IKK. 
NF-B is activated via TRAF6 which activates the TAK1 complex to phosphorylate IKK, 
which results in the phosphorylation and subsequent proteasomal degradation of IB, 
allowing for nuclear translocation of p50:p65 (NF-B). 
 
1.3.4.3.  Soluble PRRs leading to the detection of DNA and downstream 
signalling pathways 
 
 Whilst the mechanisms governing RNA sensing in virus infection are relatively well 
known, the sensors and downstream signalling molecules involved in DNA sensing are less 
well characterised and have recently become the subject of intense study. DNA sensing in 
poxvirus infection is likely to be of fundamental importance in the activation of the innate 
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immune response since these viruses produce large quantities of cytoplasmic DNA and this 
presents a prime target for innate immune sensing. 
In 2006, two independent papers described type I IFN induction by transfection of 
DNA (Ishii et al., 2006; Stetson and Medzhitov, 2006). Subsequently, a putative DNA sensor 
termed DNA-dependent activator of IFN (DAI) was proposed as the DNA sensor responsible 
for DNA mediated IRF3 activation (Takaoka et al., 2007). However, in further studies, the in 
vivo relevance of DAI was questioned and DAI was found to be dispensable for DNA-
mediated activation of the innate immune system both in vitro and in vivo (Ishii et al., 2008; 
Wang et al., 2008) suggesting the existence of alternative DNA sensors.  
 Absent in melanoma 2 (AIM2) was identified as a DNA sensor capable of activating 
an inflammasome (Burckstummer et al., 2009; Fernandes-Alnemri et al., 2009; Hornung et 
al., 2009; Roberts et al., 2009) in response to DNA, and the in vivo relevance of this molecule 
was later demonstrated as mice deficient in AIM2 had impaired inflammasome activation in 
response to various pathogens such as Francisella tularensis, murine cytomegalovirus 
(MCMV) and VACV WR (Fernandes-Alnemri et al., 2010; Rathinam et al., 2010). However, 
the initial observations that DNA activated IRF3 was not been explained by AIM2 since 
AIM2 was dispensable for type I IFN production, indicating that additional DNA sensors 
were also present.  
 RNA polymerase III was later identified as a DNA sensor (Figure 1.6). RNA 
polymerase III senses AT-rich DNA and transcribes this into AU-rich RNA which, 
importantly, has a 5’ triphosphate moiety and is therefore a ligand for activating RIG-I 
(Ablasser et al., 2009; Chiu et al., 2009). This pathway was only shown to be important in 
HEK293 cells and its in vivo importance is yet to be established. Importantly, the activation 
of this pathway is highly dependent on the DNA species used, and interruption of the AT rich 
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sequence leads to an abrogation of type I IFN induction (Chiu et al., 2009). Whilst poly 
(dA:dT), a synthetic ds-B-DNA molecule was used extensively in one paper demonstrating 
an IRF3-dependent activation of innate immunity by DNA (Ishii et al., 2006). Another report 
demonstrated the same effect with ISD DNA (a synthetic dsDNA molecule 45-bp in length 
engineered to contain no CpG motifs), which did not contain significant tracts of AT- rich 
DNA and therefore was incapable of activating RNA polymerase III (Stetson and Medzhitov, 
2006).  
 
Figure 1.6. DNA sensing within host cells via the RNA Polymerase III pathway. This 
figure demonstrates the activation of NF-B and IRF-3 after AT-rich DNA sensing by the 
RLRs RIG-I and MDA-5 after transcription by RNA-polymerase III. After binding either 
pppRNA (RIG-I), MAVS becomes activated leading to the phosphorylation and dimerisation 
of IRF-3 via the non-canonical IKKs TBK-1 and IKK. NF-B is activated via TRAF6 which 
activates the TAK1 complex to phosphorylate IKK, which results in the phosphorylation 
and subsequent proteasomal degradation of IB, allowing for nuclear translocation of 
p50:p65 (NF-B). 
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Later, leucine rich repeat flightless interacting protein 1 (LRRFIP1) was characterised 
as a nucleic acid sensor active within macrophages capable of activating the -catenin 
accessory pathway involved in the upregulation of type I IFN (Yang et al., 2010). DNA from 
Listeria monocytogenes and RNA from VSV both appeared to stimulate the LRRFIP1 
mediated -catenin accessory pathway. 
 Recently, a novel DNA sensor, IFI16, with similarity to AIM2 was shown to bind 
DNA and activate IRF-3 in response to DNA. This study involved principally the THP-1 
macrophage cell line, however knockdown of IFI16 in MEFs also showed a partial 
dependency on this molecule for DNA sensing (Unterholzner et al., 2010). A subsequent 
study has implicated IFI16 in the activation of the inflammasome in response to Kaposi’s 
sarcoma herpesvirus (KSHV) (Kerur et al., 2011). Interestingly, a nuclear-cytoplasmic divide 
between AIM2 and IFI16 appears to exist, with IFI16 responsible for detection of herpes 
simplex virus (HSV)-1 and KSHV in the nucleus, whereas AIM2 mediated innate immunity 
responds principally to pathogens in the cytoplasm (Rathinam et al., 2010). DNA sensing by 
AIM2 and IFI16 is summarised in Figure 1.7. 
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Figure 1.7. DNA sensing within macrophages. This figure demonstrates the activation of 
IRF-3 and the AIM2 inflammasome via DNA sensing by IFI16 and AIM2, respectively. It is 
not known with certainty where IFI16 binds DNA, but this is represented in the cytoplasm for 
the purposes of this diagram. IFI16 binds to DNA and activates a signalling pathway 
consisting of stimulator of IFN genes (STING), TBK-1 and IRF-3. Additional steps 
potentially involved in the DNA sensing pathway are indicated via red arrows and include 
TRAF3, the TANK/NAP1/SINTBAD complex and EYA4 which have not been shown 
definitively to be involved in DNA sensing as yet. AIM2 activates caspase-1 to convert pro-
IL-1 and pro-IL-18 by binding to DNA and recruiting the inflammasome adaptor molecule 
ASC. 
 
Asp-Glu-Ala-His (DEAH) box helicase (DHX)-9 and DHX36 appear to cooperate in 
pDCs to mediate upregulation of type I IFNs in response to CpG and HSV-1 DNA (Kim et 
al., 2010). These helicases act by recruitment of MyD88 and possibly IKKmediated 
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phosphorylation of IRF-7 and they represent an example of cell-type specific mechanisms 
beginning to typify this field of research (Table 1.1).  
After detection of DNA by the various DNA sensors, a signalling pathway involving 
tri-partite motif (TRIM)-56 (Tsuchida et al., 2010), Atg9a (Saitoh et al., 2009), Eyes absent 
(EYA)-4 (Okabe et al., 2009), STING (Ishikawa et al., 2009), TBK-1 (Ishii et al., 2008) and 
IRF-3 (Ishii et al., 2006; Stetson and Medzhitov, 2006) is activated.  
STING (also known as ERIS/MITA) is essential for induction of cytokines and 
chemokines after stimulation of cells with intracellular DNA. Independently, two groups 
have reported that following stimulation with DNA, STING undergoes a translocation to 
distinct sub-cellular punctuate perinuclear structures (Ishikawa et al., 2009; Saitoh et al., 
2009). Furthermore, addition of an ER retention signal to STING decreases type I IFN 
production, suggesting the translocation is of functional significance for induction of DNA-
mediated innate immune signalling (Saitoh et al., 2009). However, why the translocation of 
these molecules to distinct cellular compartments is of importance is not understood.  
STING is also subject to regulation by TRIM56 and Atg9a. TRIM56 is an E3 
ubiquitin ligase responsible for K63-linked polyubiquitination of STING, causing STING to 
dimerise, a prerequisite for recruitment of TBK-1 (Tsuchida et al., 2010), adding another 
example of the role of ubiquitin in innate immune signalling. Atg9a is a component of the 
autophagy machinery and negatively regulates DNA-mediated activation of IRF-3 by 
inhibiting the translocation of STING from the ER to the punctuate perinuclear 
p62/sequestosome 1 structures (Saitoh et al., 2009).  
EYA4 is an enigmatic protein involved in innate immune responses to both DNA and 
RNA. EYA4 is a phosphatase with unknown substrates in the DNA/RNA-mediated 
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pathways, however overexpression of this molecule leads to upregulation of various genes 
including type I IFN and other cytokines and chemokines (Okabe et al., 2009).  
DNA sensing has become the focus of intense study in recent years, yet there is much 
not yet known. An emerging theme is the segregation of different DNA sensing mechanisms 
occurring in different cell types. The information regarding the current state of knowledge is 
summarised in Table 1.1.  
Component Responds to Cell types role 
found in 
In vivo role References 
DAI Poly 
(dA:dT), not 
ISD dsDNA 
L929 cells (not 
detectable prior to 
IFN stimulation) 
Dispensable for IFN 
production in response to 
vaccinia and HSV-1. 
(Takaoka et al., 2007; 
Ishii et al., 2008; Wang 
et al., 2008) 
AIM2 Cytoplasmic, 
not nuclear, 
pathogens 
and dsDNA 
Macrophages  Important for 
inflammasome activation 
to cytoplasmic pathogens 
(Francisella tularensis and 
VACV) 
(Burckstummer et al., 
2009; Fernandes-
Alnemri et al., 2009; 
Hornung et al., 2009; 
Roberts et al., 2009; 
Fernandes-Alnemri et 
al., 2010; Rathinam et 
al., 2010) 
IFI16 Nuclear 
pathogens 
(HSV, 
KSHV) and 
dsDNA 
THP-1 cells, 
MEFs 
Not determined (Unterholzner et al., 
2010; Kerur et al., 
2011) 
LRRFIP1 dsDNA and 
dsRNA 
Macrophages Not determined (Yang et al., 2010) 
STING All DNA 
tested, HSV-
1, VACV, 
Listeria 
Multiple cell 
types 
Important for cytokine 
and chemokine 
production in response to 
various DNA pathogens 
(VACV, HSV-1, Listeria) 
(Ishikawa and Barber, 
2008; Ishikawa et al., 
2009; Saitoh et al., 
2009; Tsuchida et al., 
2010) 
RNA-
Polymerase 
III 
Poly 
(dA:dT), not 
ISD DNA 
HEK293T Not determined (Ablasser et al., 2009; 
Chiu et al., 2009) 
DHX9 CpG and 
HSV-1 DNA 
pDC Not determined (Kim et al., 2010) 
TBK-1 dsRNA, 
dsDNA, 
multiple 
pathogens 
Multiple cell 
types 
Important for cytokine 
and chemokine 
production in response to 
various pathogens 
(Ishii et al., 2008) 
Table 1.1. DNA sensors of the innate immune system.  
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Various DNA sensors have been reported as being active in different cell types, and 
also are responsible for the detection of different DNA species. The in vivo role of many 
components of DNA sensing pathways described so far is not determined and therefore the 
relative contributions of these sensors to antiviral immunity is of interest. 
DNA sensing is clearly of utmost importance in the context of VACV infection 
because VACV is a dsDNA virus. Not much is understood about the various interactions of 
VACV with the DNA sensors as these molecules have only been described recently, however 
AIM2 has been shown to be important for VACV-mediated inflammasome activation 
(Rathinam et al., 2010).  
 
1.4. VACV C16 
  
 VACV C16 is a 37-kDa molecule encoded by the C16L gene which, in the VACV 
WR strain, is located within the ITRs and is therefore diploid. Analysis of C16L mRNA 
(Assarsson et al., 2008) and C16 protein expression (Fahy et al., 2008) each showed that C16 
is produced early in the course of infection. VACV C16 was initially studied as a candidate 
immunoregulatory protein after the identification of a C-terminal six amino acid motif highly 
conserved with the IL-1 receptor antagonist, IL-1Ra (Kluczyk et al., 2002). This short amino 
acid sequence was critical for the activity of IL-1Ra to block IL-1R signalling and a 
mechanism of action of C16 was proposed based on this similarity. However, subsequently 
C16 was shown to be an intracellular protein located in the nucleus during transfection and in 
both the nucleus and cytoplasm during infection (Fahy et al., 2008), thus the primary 
mechanism of action of C16 was presumably not mediated by the IL-1Ra-like motif. 
Intranasal infection of mice with virus lacking both copies of the C16L gene lead to less 
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weight loss, decreased signs of illness, enhanced recruitment of leukocytes to lungs and 
increased virus clearance compared with wild-type and revertant viruses (Fahy et al, 2008).  
 Thus, C16 was known to be an intracellular protein made early during infection that 
contributes to virulence by an unknown mechanism. This project was to understand the 
mechanism of action of the C16 protein and how it contributes to virus virulence.   
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Chapter 2: Methods & Materials 
2.1.    Manipulation of nucleic acids 
2.1.1. Polymerase chain reaction (PCR) 
Amplification of DNA fragments was achieved using PCR. HiFi Taq (Invitrogen) and 
GoTaq (Promega) polymerases were used for molecular cloning and colony screening, 
respectively, according to the manufacturer’s instructions. Briefly, reaction mixes consisted 
of 100 ng template DNA, 200 pM forward primer, 200 pM reverse primer, 0.25 l 
polymerase enzyme, 800 M deoxynucleotide triphosphates (dNTPs- Invitrogen), 2 mM 
MgCl2, and either 10 x HiFi Taq (Invitrogen)- or 10 l GoTaq Flexi (Promega) - buffers with 
deionised distilled H2O (ddH2O) making the volume up to 50 l.   
Reactions were performed in a programmable thermocycler. Template DNA was 
melted at 95 °C for 5 min and then a cycle consisting of melting at 95 °C for 30 s, annealing 
at 50 °C for 30 s and extension at 72 °C (HiFi Taq) or 68 °C (GoTaq) for 2 min was repeated 
a further 30 times. 
 
2.1.2. Resolution of DNA fragments by agarose gel electrophoresis 
DNA was resolved on 1-2 % agarose gels in Tris-acetate ethylene diamine tetraacetic 
acid (EDTA) (TAE) [40 mM Trisma, 40 mM sodium acetate, 1 M EDTA pH 8.0] buffer. 
Gels contained SYBR® Safe (Invitrogen) at a concentration of approximately 5 l per 50 ml 
gel and were run at 80-120 V for between 30 and 100 min in TAE. Samples were mixed with 
20 % volume per volume (v/v) DNA loading buffer (Bioline), which contained glycerol and 
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bromophenol blue dye. DNA was visualised using a transilluminator and was photographed 
using the Chemi-Doc gel documentation systems (Bio-Rad) with Quantity One software 
(Bio-Rad). DNA length was assessed using dsDNA hyperladder markers (Bioline). 
 
2.1.3. Recovery of DNA from agarose gels 
DNA bands were visualised using a SYBR® Safe imager (Invitrogen)  imager and 
excised using a clean scalpel. The QIAquick gel extraction kit (Qiagen) was used according 
to the manufacturer’s protocol. Briefly, the agarose gel was dissolved in a high-salt 
concentration buffer, allowing binding of the DNA to a silica membrane in a microcentrifuge 
column. DNA was eluted using between 30 and 100 l deionised distilled H2O. 
 
2.1.4. Quantification of DNA 
DNA concentration and purity was measured using a NanoDrop ND-1000 
spectrophotometer according to the manufacturer’s instructions using the OD260 reading. 
DNA purity was assessed using the OD260/OD280 ratio, with a ratio between 1.8 and 2.0 being 
ideal.   
 
2.1.5. Restriction endonuclease digestion of DNA 
DNA was digested with restriction endonuclease enzymes in volumes of 20-50 l 
containing at least 1 unit (U) of enzyme per g of DNA. The enzymes and buffers were 
supplied by Roche and New England Biolabs. DNA was digested for at least 1 h at 37 °C and 
purified from agarose gels after electrophoresis. 
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2.1.6. Ligation of DNA fragments 
Sticky-end ligations were carried out in a volume of 20 l containing vector DNA and 
insert DNA in a 1:3 molar ratio combined with 1 U of T4 DNA-ligase (Roche) in 1 x T4 
DNA ligase buffer (Roche) and incubated for 1 h at 18 °C followed by cooling to 4 °C until 
transformation.  
 
2.1.7. Transformation of competent E. coli with plasmid DNA 
Chemically competent XL-10 cells (30 µl) were thawed on ice and between 1 and 20 
l of a ligation reaction mixture containing DNA was added. Cells and DNA were incubated 
together on ice for 30 min and subsequently were heat shocked at 42 °C for 45 sec and then 
incubated on ice for a further 2 min. Three hundred microlitres of Super Optimal Catabolite 
(SOC) medium were added per reaction and the mix was then incubated at 37 °C for 1 h and 
subsequently spread onto agar plates containing the appropriate antibiotic. Plates were then 
dried, inverted and incubated at 37 °C for 16 h. 
 
2.1.8.  Screening of colonies by colony PCR 
Colony PCR was performed by picking a colony with a pipette tip and re-suspending 
the bacteria in 20 l H2O. Then 15 l was added to Luria broth (LB) containing the 
appropriate antibiotic, and the remaining 5 l was used as template DNA for PCR using 
sequencing primers specific to the vector sequence. The presence of the correct length insert 
was determined by agarose gel electrophoresis with appropriate size markers. 
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2.1.9. Preparation of plasmid DNA (miniprep & maxiprep) 
Plasmid DNA was purified by the QIAGEN miniprep or maxiprep method according 
to the manufacturer’s instructions. Minipreps were prepared from 5 ml chemically competent 
XL-10 E. coli cultures and were used for screening plasmids. Maxipreps were prepared from 
500 ml cultures and were used in assays described in the results chapters.  
Below is a table detailing the plasmids used in this study. 
Name of plasmid Description 
pcDNA4/TO-
C16TAP 
pcDNA4/TO (Invitrogen) based with C16 inserted using BamHI and NotI 
restriction sites. The TAP-tag sequence is as follows:  
AAAWSHPQFEKGGGSDYKDDDDKDYKDDDDK.  
Ampicillin resistant. 
pcDNA4/TO-
coC16 
pcDNA4/TO (Invitrogen) based with codon optimised C16 inserted 
using BamHI and NotI restriction sites. Codon optimisation was 
performed by GenScript. 
Ampicillin resistant. 
pcDNA4/TO-
icIL-1RaTAP 
pcDNA4/TO (Invitrogen) based with icIL-1Ra inserted using BamHI and 
NotI restriction sites. The TAP-tag sequence is as follows:  
AAAWSHPQFEKGGGSDYKDDDDKDYKDDDDK. 
Ampicillin resistant.  
HRE-Luciferase pGL2 (Promega) based with three tandem repeats of HIF-response 
element (HRE) sequence (5’ TGTCACGTCCTGCACGACTCTAGT)  
upstream of firefly luciferase. 
Ampicillin resistant. Obtained from Dr. Eoin Cummins, University 
College Dublin 
TK-Renilla pRL-TK (Promega) based. Renilla luciferase is constitutively expressed, 
used for transfection control. 
Ampicillin resistant. Obtained from Dr. Andrew Bowie, Trinity College 
Dublin. 
Table 2.1. Brief descriptions of plasmids used in this study. 
 
2.1.10. Concatamerisation of oligonucleotides 
Complementary oligonucleotides were mixed in a 1:1 molar ratio, heated to 80 °C for 
30 sec and annealed at 60 °C for 15 min followed by cooling at room temperature (RT). A 1 
mg/ml solution of annealed oligonucleotides was added to an appropriate volume of 10 x T4 
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DNA ligase buffer (Roche) with 3 U of polynucleotide kinase (New England Biolabs) per 
100 g DNA and incubated at 37 °C for 2 h and subsequently left to cool at room RT. Three 
units of T4 DNA ligase were then added per 100 g of DNA and left to incubate at RT 
overnight. Successful concatamerisation was assessed using agarose gel electrophoresis. 
Concatamerised oligonucleotides were then purified using phenol-chloroform extraction and 
ethanol precipitation (see sections 2.1.9 and 2.1.10, respectively). The forward (sense) 
sequence used for stimulations in this study was as follows: 
5’TACAGATCTACTAGTGATCTATGACTGATCTGTACATGATCTACA 3’. This 
sequence was annealed to a complementary DNA molecule. 
 
2.1.11. Phenol-chloroform extraction of DNA 
An equal volume of phenol:chloroform:isoamyl alcohol at a ratio of 25:24:1 (Fluka) 
was added to a solution of DNA and mixed thoroughly to form an emulsion. The mixture was 
then centrifuged at 13,000 rpm in a microcentrifuge for 1 min and the aqueous (upper) phase 
was transferred to a fresh tube. This was repeated until no remaining protein was visible at 
the interface of the organic and aqueous phase. Once the protein had been removed, an equal 
volume of chloroform: isoamyl alcohol at a ratio of 24:1 was added, and then mixed to form 
the emulsion. The mixture was then centrifuged at 13,000 rpm once more and the aqueous 
phase was transferred to a fresh tube. Ammonium acetate solution was then added to a final 
concentration of 2.5 M. 
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2.1.12. Ethanol precipitation of DNA 
Two volumes of ice-cold ethanol were added to the solution of DNA and the ethanolic 
solution was stored at -20 °C for 30 min. The DNA precipitate was then collected by 
centrifugation at 13,000 rpm in a microcentrifuge for 10 min. The supernatant was then 
removed and the pellet was washed with 70% ethanol and re-centrifuged for a further 2 min 
at 4 °C. The supernatant was removed once again and the ethanol wash step was repeated. 
Lastly, the supernatant was removed and the tube was placed in a well ventilated area for 30 
min in so that the remaining ethanol would evaporate. The DNA was then dissolved in 
ddH2O.  
 
2.1.13. Extraction of cellular RNA 
The RNeasy kit (Qiagen) was used for extraction of cellular RNA according to the 
manufacturer’s instructions. RNA was extracted from a minimum of 3 × 105 cells in tissue 
culture and also from homogenised frozen tissue. Precautions such as the use of commercial 
purified water (Sigma-Aldrich) and RNase free filtered pipette tips were taken to avoid 
RNase contamination. 
 
2.1.14. Generation of cDNA from RNA 
RNA (500 ng) was diluted into 11 l of RNase free H2O and mixed with 1 l of 50 
M oligo dT (Qiagen) and 1 l 40 mM dNTP mix and heated to 65 °C for 5 min. Next, a mix 
consisting of 4 l 5 x First Strand cDNA synthesis buffer (Invitrogen), 1 l 0.1 M DTT, 200 
units RNaseOUT (Invitrogen) and 200 units Superscript Reverse Transcriptase (Invitrogen) 
was added to each tube, giving a total volume of 20 l. The reaction mix was then incubated 
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at 50 °C for 1 h and denatured at 70 °C for 15 min. cDNA was subsequently diluted 1:5 with 
RNase free H2O and analysed by Real Time-PCR.  
 
2.1.15. Real Time PCR analysis of cDNA 
Quantitative Real Time PCR (qRT-PCR) was performed on a 7900HT series qPCR 
machine (Applied Biosystems). Briefly, reactions were carried out on a 96-well format with a 
20 l reaction volume. Each reaction consisted of 10 l Fast SYBR® Green Master Mix 
(Applied Biosystems), 3 l H2O, 5 l template cDNA and 1 l each of specific forward and 
reverse primers (10 M). The reaction conditions were a 95 °C activation step for 20 s, 
followed by cycling of denaturing at 95 °C for 1 s and annealing/extension at 60 °C for 20 s. 
A total of 40 cycles in total were performed. Primers used are listed in Table 2.2. 
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Gene name Species Sequence (5’-3’) 
Cxcl10 Mus 
musculus 
Forward: ACTGCATCCATATCGATGAC 
Reverse: TTCATCGTGGCAATGATCTC 
Ccl5 Mus 
musculus 
Forward: ACGTCAAGGAGTATTTCTACAC 
Reverse: GATGTATTCTTGAACCCACT 
Ccl4 Mus 
musculus 
Forward: GCCCTCTCTCTCCTCTTGCT 
Reverse: CTGGTCTCATAGTAATCCATC 
Cxcl2 Mus 
musculus 
Forward: GAGCTTGAGTGTGACGCCCCC 
Reverse: GTTAGCCTTGCCTTTGTTCAG 
Ifnb Mus 
musculus 
Forward: CATCAACTATAAGCAGCTCCA 
Reverse: TTCAAGTGGAGAGCAGTTGAG 
Isg54 Mus 
musculus 
Forward: ATGAAGACGGTGCTGAATACTAGTGA 
Reverse: TGGTGAGGGCTTTCTTTTTCC 
Nfkbia (IB) Mus 
musculus 
Forward: CTGCAGGCCACCAACTACAA 
Reverse: CAGCACCCAAAGTCACCAAGT 
Xrcc6 (Ku70) Mus 
musculus 
Forward: GACAACAGGGGAAGAAGCAC 
Reverse: GGACAGAACTCGCTTTTTGG 
Xrcc5 (Ku80) Mus 
musculus 
Forward: CAGCTGTTGTGCTGTGTGTG 
Reverse: GCTGCTGAGGTCAGTGAACA 
Prkdc (DNA-PKcs) Mus 
musculus 
Forward: TCGGAGGAGGTTCATACAGG 
Reverse: CATCATGGCCTCGAATAACA 
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Il6 Mus 
musculus 
Forward: GTAGCTATGGTACTCCAGAAGAC 
Reverse: GTAGCTATGGTACTCCAGAAGAC 
Hprt Mus 
musculus 
Forward: GTTGGATACAGGCCAGACTTTGTTG 
Reverse: GATTCAACTTGCGCTCATCTTAGGC 
MVA 
quantification 
N/A (MVA) Forward: TCGCCCTAATATGGTTACCG 
Reverse: CCTAAGCGGTGTTCTTCTGC 
VEGF Homo 
sapiens 
Forward: CTTGCCTTGCTGCTCTACCT 
Reverse: CTGCATGGTGATGTTGGACT 
GLUT1 Homo 
sapiens 
Forward: TGGCATGGCGGGTTGT 
Reverse: CCAGGGTAGCTGCTCCAGC 
HIF1A Homo 
sapiens 
Forward: CACCTCTGGACTTGCCTTTC 
Reverse: GGCTGCATCTCGAGACTTTT 
18SRNA Homo 
sapiens 
Forward: GTAACCCGTTGAACCCCA 
Reverse: CCATCCAATCGGTAGTAGCG 
Table 2.2. Oligonucleotides used for qRT-PCR 
 
Expression levels were quantified by calculating Ct values relative to the 
housekeeping gene hypoxanthine-guanine phosphoribosyltransferase (Hprt), where 
Ct = Ct sample – Ct calibrator 
Data were analysed using the software RQ Manager (Applied Biosystems). 
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2.1.16.  Quantification  of MVA DNA by qRT-PCR 
Murine embryonic fibroblast (MEF) cells were infected with MVA at 2 plaque 
forming units (p.f.u.) /cell and incubated for different periods of time. The cells were washed 
three times with phosphate-buffered saline (PBS) and frozen in HiFi Taq-buffer and 50 g/ml 
proteinase K. Lysates were then homogenized by pippetting and incubated at 50 °C for 20 
min and then heated to 80 °C for a further 20 min. qRT-PCR was performed using the 
primers specific for MVA that are listed in table 2.2. MVA DNA extracted from dilutions of 
sucrose-purified and titrated MVA were used as standards for absolute quantification using 
SDS 2.3 software (Applied Biosystems). 
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2.2. Protein analysis 
2.2.1. Quantification of protein by BCA assay 
Prior to SDS-PAGE, protein concentration was often assessed to ensure equal loading 
of gel lanes. The BCA assay kit (Pierce) was used according to the manufacturer’s 
instructions. Briefly, the assay involves incubation of 5 l of protein sample with a buffer 
containing Cu
2+
, which is reduced to Cu
+
 in an alkaline buffer in the presence of protein (The 
Biuret reaction). Calorimetric detection of Cu
+
 with bicinchoninic acid is performed by 
measuring 562 nm absorbance.  
 
2.2.2. Resolution of proteins by SDS-PAGE 
Protein gels were assembled in vertical Mini-PROTEAN II apparatus (Bio-Rad) and 
consisted of approximately 1 ml of stacking gel atop 4 ml of 15 % polyacrylamide resolving 
gel. Stacking gels were composed of 5 % acrylamide solution (ProtoGel™, National 
Diagnostics), 125 mM Tris-HCl (pH 6.8) and 0.1 % SDS polymerised with 0.15 % 
ammonium persulphate (APS) and 0.001% tetramethylethylenediamene (TEMED) (both 
Sigma-Aldrich). Resolving gels consisted of 10-15 % polyacrylamide solution, 375 mM Tris-
HCl (pH.8.8) and 0.1 % SDS polymerised with 0.15 % APS and 0.001 % TEMED.  
Protein samples were mixed with 20 % (v/v) of 5 x Laemmli sample loading buffer 
(300 mM Tris-HCl (pH 6.8), 12 % SDS, 60 % glycerol and 0.6 % bromophenol blue with 10 
% beta-mercaptoethanol (ME). Subsequently, the samples were heated at 90 °C for 5 min 
and loaded into the wells of the gel after 3 min cooling at RT. The samples were then 
electrophoresed alongside pre-stained molecular mass markers (Bio-Rad) in a Tris/Glycine 
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buffer (25 mM Tris HCl, 250 mM glycine, 0.1 % SDS). Samples were electrophoresed at 180 
V for 1 h and processed subsequently for Coomassie staining or immunoblotting. 
 
2.2.3. Detection of proteins by Coomassie staining 
Acrylamide gels were stained for 30 min in Coomassie blue stain [0.25 % (w/v) 
Coomassie brilliant blue R-250 [BDH], 10 % (v/v) acetic acid, 45 % (v/v) methanol) and de-
stained in de-stain buffer (10 % acetic acid (v/v), 20 % methanol (v/v)]. Images were 
obtained using the Chemi Doc gel documentation systems (Bio-Rad) with Quantity One 
software (Bio-Rad). 
 
2.2.4.1. Detection of proteins by immunoblotting 
Proteins that had been resolved by SDS-PAGE were transferred to a nitrocellulose 
membrane (Hybond ECL, Amersham) by electro-transfer in transfer buffer (25 mM Tris-
HCl, 190 mM glycine, 0.037 % SDS (w/v) and 20 % methanol) at 300 mA for 30 min using a 
mini-electrophoretic trans-blot apparatus (BioRad) according to the manufacturer’s 
instructions. Membranes were then blocked in 5 % non-fat dried milk in PBS with 0.05 % 
Tween-20 (PBS-T) for one h at RT. 
Primary antibodies were also diluted in 5 % non-fat dried milk in PBS-T and 
incubated with the membranes for either 1 h at RT or alternatively at 4 °C overnight with 
gentle rocking.  After incubation with primary antibody, the membrane was rinsed 3 times 
with PBS-T, 0.05 %, each time for 5 min before placing the membrane into secondary 
antibody diluted in 5 % milk in PBS-T 0.05 %. Secondary antibodies were either anti-goat 
(Dako), anti-rabbit or anti-mouse (both Sigma-Aldrich) horseradish peroxidise (HRP) – 
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conjugates. The membrane was incubated with secondary antibody for 1 h at RT and was 
rinsed 3 times with PBS-T, 0.05 %. Blots were developed using the Western Pico-
Chemiluminescence kit (Thermo-Fisher) according to manufacturer’s instructions. Finally, 
the membrane was wrapped in transparent plastic and exposed to film (X-OMAT/LS, Kodak) 
for an appropriate amount of time between 5 sec and 30 min.  
Antigen Supplier Species Dilution used 
C16* Harlan Sera-Lab Rabbit 1 : 1000 
Ku70 AbCam Mouse 1 : 1000 
Ku80 Santa-Cruz Mouse 1 : 1000 
DNA-PKcs NeoMarkers Mouse 1 : 1000 
Tubulin Millipore Mouse 1 : 10000 
PHD2 Millipore Rabbit 1 : 1000 
HIF-1 BD Biosciences Mouse 1 : 250 
FLAG Sigma-Aldrich Mouse 1 : 1000 
Mouse IgG (HRP) Sigma-Aldrich Goat 1 : 5000 
Rabbit IgG (HRP) Sigma-Aldrich Mouse 1 : 10000 
Mouse IgG  (Licor) Licor Biotechnology Goat 1 : 10000 
Rabbit IgG (Licor) Licor Biotechnology Goat 1 : 10000 
Table 2.3. Details of antibodies used for immunoblotting. * Polyclonal C16 antibody was 
generated by Harlan Sera-Lab after production of recombinant C16 within our laboratory and 
described  previously (Fahy et al, 2008). 
2.2.4.2. Detection of proteins by immunoblotting & Licor development 
Detection of proteins by immunoblotting was, where mentioned, carried out with the 
Licor development system. The protocol used was identical to section 2.2.4.1 up to the point 
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of application of secondary antibody, where instead a fluorophore-conjugated secondary 
antibody was diluted in milk and incubated with the membranes for 1 h in darkness. The 
membrane was washed 3 times in PBS-T, followed by one wash in PBS and allowed to dry at 
RT for 1 h. Images were obtained using a Licor Odyssey scanner and band intensity was 
analysed using Odyssey software (Licor Biotechnology). Licor western blotting was used 
when accurate quantification was required, such as when the protein in question was of a high 
abundance (e.g. Ku70 or DNA-PKcs) 
 
2.2.5. Detection of proteins by immunofluorescent staining 
Cells were grown on 13-mm sterilized glass coverslips (borosilicate glass, BDH) in 
24-well plates. After infection or mock infection, the medium was removed and replaced with 
medium containing 4% paraformaldehyde (PFA) for 5 min. Cells were then washed 3 times 
in PBS and permeabilised in 0.1 % (v/v) Triton X-100 (Sigma-Aldrich) in PBS for 5 min. 
Cells were then blocked for 1 h at RT in 5 % milk in PBS-T and incubated with primary 
antibody in 1 % milk for 1 h at RT. The sample was then washed 3 times in PBS and stained 
with secondary antibody for 30 min at RT in darkness. Cells were then washed 3 times in 
PBS and once in ddH2O and mounted in Mowiol-4’,6-diamidino-2-phenylindole (DAPI) 
mounting medium. Samples were examined with a Zeiss Metaconfocal microscope using 
Zeiss LSM 5 software. Antibodies used for immunofluorescence are summarised in Table 
2.4. 
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Antigen Supplier Species Dilution used 
Ku70 AbCam Mouse 1 : 500 
Ku80 Santa Cruz Mouse 1 : 500 
DNA-PKcs NeoMarkers Mouse 1 : 500 
TBK-1 Millipore Rabbit 1 : 500 
Mouse IgG Invitrogen Goat 1 : 1000 
Rabbit IgG Invitrogen Goat 1 : 1000 
 
Table 2.4. Details of antibodies used for immunofluorescence.  
 
2.2.6. Immunoprecipitation analysis 
Protein G Sepharose™ 4 Fast Flow (GE Healthcare) beads (50 l per sample) were 
washed four times by re-suspension in tandem-affinity protein purification (TAP)-wash 
buffer (0.1 % NP40 in PBS) and brief centrifugation in a bench top microcentrifuge to collect 
the beads. The beads were then conjugated to approximately 10 l of antigen-specific 
antibody (Santa Cruz) or isotype control by incubating on a rotating platform for 1 h at 4 °C. 
Cell lysates were generated by the addition of 0.5 % NP40 in PBS (TAP-lysis buffer) to 10-
cm dishes of cells after removal of culture medium and washing with PBS. Cell lysates were 
spun at 13,000 rpm in a microcentrifuge for 2 min to collect the DNA and organelles, and the 
supernatant was incubated with the conjugated beads for one h at 4 °C. The beads were then 
collected by centrifugation and re-suspended in TAP-wash buffer. The wash step was 
repeated a total of five times. On the final step, NuPAGE loading buffer was added to the 
beads and the protein constituents were separated by SDS-PAGE. 
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2.2.7. Tandem affinity protein purification pull-down assay. 
A clone of stable inducible TAP-tagged cells, obtained by the process outlined in 
Section 2.3.4, was grown into twenty T175 tissue culture flasks. When the cells reached the 
level of 80 % confluency, tetracycline was added to the culture medium of ten T175 flasks to 
a final concentration of 2 g/ml. The remaining flasks were left untreated.  
The entire pull-down procedure has been described previously (Gloeckner et al., 
2007). The procedure is carried out at 4 °C. TAP-lysis buffer supplemented with protease 
inhibitors (one complete EDTA-free protease inhibitor cocktail tablet (Roche) and one 
PhoSTOP (Roche) tablet per 50 ml of lysis buffer) and TAP–wash buffer supplemented with 
the same protease inhibitors were used during the procedure. The culture medium was 
removed from the flask and the cells were washed with sterile PBS, lysed with 1 ml of TAP-
lysis buffer and incubated for 20 min. Cell lysates were then scraped and collected in a 15 ml 
falcon tube and centrifuged at 500 g for 10 min at 4 °C. The supernatant was collected and 
filtered through a 0.2 m pore filter and 100 l of Strep-Tactin superflow beads (IBA) were 
added and left to rotate slowly for 1 h. The beads were then spun at 500 g for 3 min, the 
supernatant was removed and the beads were re-suspended in 1 ml of TAP-wash buffer. The 
beads were washed a total of three times using sequential spinning, removal of supernatant 
and re-suspension in TAP-wash buffer. Protein complexes were then eluted using 10 x 
STREP-tag elution buffer (Desthiobiotin - IBA) containing desthiobiotin diluted in PBS and 
incubated on a rotating platform for 30 min. The eluate was added to 100 l of anti-FLAG 
M2 beads (Sigma) and left incubating on a rotating platform for 1 h. The wash step for the 
STREP beads was repeated for the FLAG beads and the protein complexes were eluted using 
FLAG-peptide (Sigma) at 250 g/ml for 30 min. The final eluate was then concentrated using 
Microcon® centrifugal filter devices (Millipore) with a 5 kilodalton (kDa) molecular mass 
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cut-off to a final volume of approximately 80 l. To this, 30 l of NuPAGE loading buffer 
was added and loaded onto a NuPAGE 4-12 % Bis-Tris gel (Invitrogen) to separate the 
individual proteins. 
 
2.2.8. Identification of proteins by mass spectrometry 
Coomassie stained bands from tandem affinity purification procedures were excised 
using a clean scalpel and placed in 100 l H2O (Sigma-Aldrich). Samples were analysed by 
liquid chromatography mass spectrometry (LCMS/MS) at the Centre for Systems Biology at 
Imperial College London. 
 
2.2.9. Enzyme-linked immunosorbant assay (ELISA) 
Cytokines & chemokines in supernatants from treated cells in tissue culture or 
bronchoalveolar lavage (BAL) samples were measured using Cxcl10, Il-6 and vascular 
endothelial growth factor (VEGF) DuoSET ELISA kits (R&D Diagnostics) according to the 
manufacturer’s instructions.   
 
2.2.10. Biotinylated DNA pulldown 
HeLa or HEK293T cells were transfected using with 5 g/ml of biotinylated DNA of 
the same sequence used for concatamerisation (Integrated DNA technology) and left to 
incubate at RT for at least 30 min. Cells were then lysed with VOPBA lysis buffer (see 
section 2.3.5) and the lysates were incubated with 20 l Streptactin beads, that had been 
prewashed twice with H2O and once with VOPBA lysis buffer, on a rotating wheel at 4 °C. 
The beads were then harvested by centrifugation at 3,000 rpm in a microcentrifuge and 
83 
 
washed three times with 1 ml PBS. After the final wash, NuPAGE loading buffer was added 
and the proteins were resolved by Lithium dodecyl-sulphate (LDS) - PAGE using precast 
NuPAGE gels (Invitrogen). 
2.3. Tissue culture 
2.3.1. Maintenance of cell stocks 
Mammalian cell lines used included a human cervical cancer cell line (HeLa), HEK 
293T, HEK 293 TRex and MEFs that were either wild type, or genetically matched Xrcc5
-/-
 
p53
-/-
 (provided by E. Paul Hasty, University of Texas, USA), Xrcc6
-/-
 (provided by Shigemi 
Matsuyama, Case Western Reserve University, USA), Prkdc
-/-
 (provided by Penelope Jeggo, 
University of Sussex, UK), Tmp173
-/-
 (STING knockout, provided by Glen Barber, 
University of Miami Miller Medical School, USA), Tbk1
-/-
 (provided by Felix Randow, 
Cambridge University, UK), Mavs
-/-
, Irf3
-/-
, Irf5
-/-
, Irf7
-/-
 (all provided by Kate Fitzgerald, 
University of Massachusetts Medical School, USA), MyD88/Ticam
-/-
, Zbp1
-/-
 (both provided 
by Shizuo Akira, Osaka University, Japan) or PHD1/2/3
-/-
 (provided by Peter Ratcliffe, 
University of Oxford).  
HeLa cells were cultured in RPMI buffer supplemented with 10 % foetal bovine 
serum (FBS), HEK293T and HEK293TRex were cultured in Dulbecco’s modified eagle 
medium (DMEM) supplemented with 10 % heat-inactivated (1 h at 56 FBS °C) (with the 
addition of 5 g/ml blastocidin with HEK293TRex cells), MEF cell lines were cultured in 
DMEM with 15 % FBS. All cells were grown at 37 °C in a incubator (Heraeus) in the 
presence of humidified air containing 5 % (v/v) CO2. 
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2.3.2. Passage of cell lines 
Growth medium was discarded from tissue culture flasks and the cells were washed 
with sterile PBS. Cells were detached by adding 1 ml 0.125 % trypsin 500 M EDTA (Gibco 
BRL) per 35 cm
2
 flask area and incubating at 37 °C until cells were loosened and could be 
detached by tapping. Detached cells were collected by centrifugation at 2000 g for 5 min and 
re-suspended in an appropriate volume of culture medium with FBS, which was then diluted 
and inoculated into a fresh tissue culture flask.   
 
2.3.3. Transfection of mammalian cells 
FuGene 6.0 transfection reagent (Roche) was used for transfection according to the 
manufacturer’s instructions. Briefly, 2 l of FuGene were added per g of DNA or poly (I:C) 
(Sigma-Aldrich) in OPTI-MEM (Gibco BRL). The mixture was then mixed gently, incubated 
at room temperature for 30 min and added to cells (approximately 80 % confluency) after 
dilution in the appropriate cell culture medium. Transfection media were removed after 4 h 
and replaced with appropriate culture media. 
Polyethylenimine (PEI) and (Sigma-Aldrich) and Lipofectamine 2000 (Invitrogen) 
were also used for transfection using the same protocol as for FuGene 6.0. 
 
2.3.4. Generation of stable inducible C16 TAP-tagged cell lines 
Eight micrograms of the pcDNA-4 T/O plasmid vector containing a C16-TAP-tagged 
gene under control of a tetracycline-inducible promoter (C16-TAP) was transfected into a 10-
cm dish of HEK293T-Rex cells using FuGene 6.0 as a transfection reagent.  Transfection into 
HEK-293 Trex cells places the promoter of C16-TAP under the control of a Tet-repressor 
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protein, which in turn is inactivated by the addition of tetracycline or analogs such as 
doxycycline. After initial transfection, individual clones were obtained by diluting the cells at 
a range of concentrations from 1 in 10 to 1 in 1,000 by volume and adding 5 g/ml zeocin 
(Invitrogen) to select for clones expressing the zeocin resistance protein provided by the 
pcDNA-4 T/O plasmid. Individual clones were then picked and grown into larger volumes. 
Test expression of the clones of the C16-TAP tagged protein was carried out by the addition 
of tetracycline (or the analog doxycycline) and is demonstrated in Figure 3.1.  
 
2.3.5. Cell fractionation 
Crude cell fractionation was performed by washing cells with PBS, lysing the cells in 
VOPBA lysis buffer (100 mM Tris-HCl, ph 8.0, 2 mM MgCl2, 1 mM EDTA, 0.2% Triton X-
100) and centrifuging the lysate at 600 g for 3 min to remove nuclei and cell debris. The 
supernatant was collected and was centrifuged at 20,000 g to sediment membranes and 
debris. The remaining supernatant represents the cytoplasmic fraction. 
 
2.3.6. Infection of cells with VACV 
VACV stocks that had been purified by sedimentation in sucrose density gradients 
were thawed and virus was diluted as required into a minimal volume of either DMEM 
containing 15 % FBS (for MEF infections) or MEM containing 2.5 % FBS (for all other cell 
types). The appropriate dilution was then added to the cells and incubated at 37 °C for 1 h 
with gentle rocking every 15 min to distribute the virus evenly. After this time, the inoculum 
was aspirated and the cells were incubated in pre-warmed culture medium. Mock infection 
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refers to cells treated in an identical fashion, but with no virus being included in the initial 
inoculums. 
2.4. Functional protein analysis 
2.4.1. Luciferase reporter assay 
Cells were seeded at 1 × 10
5
 cells per well of a 96-well plate the day prior to 
transfection. Each well of cells was then transfected with 70 ng of expression plasmid, 70 ng 
and a plasmid encoding a firefly luciferase reporter driven by a specified promoter and 10 ng 
TK-renilla-luciferase. Cells were lysed in passive lysis buffer (Promega) and freeze-thawed 
to lyse the cells. Firefly luciferase activity was measured by adding luciferase reagent (8 
mg/ml luciferin (Lux biotechnology) in a buffer consisting of 270 M acetyl coenzyme-A 
(Sigma-Aldrich), 530 M ATP, 33 mM DTT, 0.1 mM EDTA, 2.67 mM MgSO4, 20 mM 
Tricine) to the cell lysates. Renilla luciferase activity was measured by adding renilla 
luciferase reagent (2 g/ml coelenerazine (Lux Biotechnology) in PBS) to the cell lysates. 
The relative stimulation of luciferase activity was measured as relative light units 
(RLU’s) in a FLUOstar Omega luminometer (BMG Labtech). Reporter activity was 
calculated by normalising firefly luciferase with renilla luciferase activity.  
For details of plasmids used in luciferase reporter assays see Table 2.1. 
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2.5. In vivo assays 
2.5.1. Intranasal infection of mice 
Groups of five female BALB/c mice between six and eight weeks old were 
anaesthetised and inoculated intranasally with 5 × 10
4
 p.f.u. of purified VACV that was 
diluted in 20 μl PBS (Alcami and Smith, 1992). Mice were sacrificed at the specified time 
points. 
 
2.5.2 Harvesting bronchoalveolar lavage (BAL) fluid  
In order to harvest BAL fluid, mice were anaesthetized with isofluorane and 
sacrificed by exsanguination from the subclavian artery and vein. After removal of the lung, a 
pipette tip was inserted into the top of the trachea and the 200 l PBS containing heparin (10 
units/ml) was inoculated into the lungs and removed using the same pipette tip This process 
was repeated a further four times. BAL was collected into an eppendorf tube and centrifuged  
at 800 x g for 5 min at 4 °C to remove BAL cells and the supernatant was immediately used 
to perform cytokine analysis using ELISA (see section 2.2.9).  
 
2.5.3. Harvesting RNA from infected tissue 
Freshly harvested tissue was flash frozen in liquid nitrogen and stored at -80 °C until 
extraction of RNA. Tissue was crushed using a pestle and mortar with freezing in liquid 
nitrogen to ensure thorough homogenization of the sample. Homogenised tissue was then 
lysed with RLT buffer (Qiagen) and subjected to the RNeasy RNA extraction process 
described in section 2.1.13. 
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Chapter 3: Identification of C16 ligands 
leading to the characterisation of DNA-
PK as a cytoplasmic DNA sensor 
3.1. Identification of C16 binding partners 
 
3.1.1. Introduction 
 
Previous work in our laboratory identified VACV strain Western Reserve (WR) 
protein C16 as an intracellular virulence factor (Fahy et al., 2008). It was shown that the 
deletion of the C16L gene from VACV WR attenuated the virus, such that intranasal 
infection with a C16 knockout virus (vC16) induced fewer signs of illness, less weight loss 
and greater recruitment of leukocytes into the respiratory tract compared to wild type and 
revertant control viruses. However, the mechanism by which C16 promoted virulence 
remained unknown. 
To understand how C16 was modulating the immune response to infection and 
promoting virulence, molecules with which it interacts (binding partners) were sought since 
intermolecular interactions usually mediate the function of viral immunomodulators. Previous 
attempts at direct immunoprecipitations with known components of innate immune signalling 
cascades had not revealed any potential interactions with C16, and furthermore it was not 
entirely clear which pathway C16 interfered with. Tandem affinity protein purification (TAP) 
and identification by mass spectrometry provided an unbiased proteomics-based approach to 
identification of C16 binding partners.  
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3.1.2. Identification of C16 binding partners 
 
To identify C16 ligands, the C16 open reading frame (ORF) was cloned from VACV 
WR genomic DNA into the pcDNA4/TO vector (Invitrogen) with an engineered TAP-tag 
consisting of a C-terminal STREP and FLAG tag (pcDNA4/TO-C16TAP) for tandem affinity 
protein purification as described previously (Gloeckner et al., 2007). This process involves 
sequential purification of protein complexes by using two separate affinity tags on a target 
molecule and subsequent large scale purification to identify binding partners via mass 
spectrometry (Section 2.2.7).  
Transfection of pcDNA4/TO-C16TAP into HEK293T-Rex cells placed the promoter 
under the control of a Tet-repressor protein, as described originally by Gossen (Gossen and 
Bujard, 1992). Stable cell lines were generated in which expression of the protein of interest 
can be induced by the addition of tetracycline.  Individual clones of cells were selected in the 
presence of increasing doses of zeocin (Section 2.3.4) to generate stable cell lines that would 
express TAP-tagged C16 upon addition of tetracycline (or doxycycline) (Figure 3.1).   
 
 
Figure 3.1  Inducible expression of C16 from clones of transfected HEK293T-Rex cells. 
Clones of zeocin-resistant cells were grown in 6-well plates and either left untreated or 
treated with tetracycline at a concentration of 2 g/ml for 24 h. The protein concentration of 
the cell lysate was determined by a BCA assay and the lysates were resolved by SDS-PAGE 
and analysed by immunoblotting with anti-tubulin or anti-FLAG monoclonal antibodies. The 
positions of molecular mass markers are indicated in kDa. 
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In each of the clonal cell lines generated, there was a marked increase in the 
production of a 37 kDa band (corresponding to the size of C16) which stained positively with 
an anti-FLAG antibody following the addition of tetracycline. Furthermore, the cells showed 
a high stringency of repression when untreated with tetracycline and each clone appeared to 
express similar levels of C16. Clone 1 was selected for amplification and a large scale tandem 
affinity protein purification was performed (Section 2.2.7). As a control, a cell line inducibly 
expressing the intracellular interleukin-1 receptor antagonist (icIL-1Ra) using the icIL-1Ra 
ORF cloned into pcDNA4/TO vector with an identical TAP-tag (pcDNA4/TO-icIL-1RaTAP) 
was also generated and was used in a parallel TAP experiment.  The ic-IL-1Ra ORF was 
selected for study because C16 was thought originally to act in a similar fashion to icIL-1Ra 
due to its intracellular localisation and the conservation of a C-terminal amino acid sequence 
highly similar to IL-1Ra (VTKFYF in icIL-1Ra and VTRFYF in C16)  (Kluczyk et al., 
2002).  As a further control, another cell line inducibly expressing the TAP-tag alone was 
included in the purification procedure. 
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Figure 3.2 Tandem affinity protein purification of C16. Ten T175 flasks of each of the 
indicated cell lines were grown and after induction with tetracycline at 2 g/ml for 24 h, 
protein complexes were purified by tandem affinity protein purification. Final eluates were 
resolved by NuPAGE (Invitrogen) and stained with Coomassie brilliant blue. Panel (a.) 
shows the total gel and panel (b.) an enlarged view of the C16 lane with bands identified with 
their approximate molecular masses, which were used as identifiers for mass spectrometric 
analysis. Empty, no protein loaded. TAP-Tag, Cells expressing the TAP-Tag alone. 
 
   
Tandem affinity protein purification of C16 yielded four Coomassie stained bands 
(Figure 3.2). These had the approximate molecular masses of 37 (the mass of C16), 50, 70 
and 80 kDa. The cell line expressing the TAP-tag alone pulled down no bands visible by this 
method. The purification procedure using the icIL-1Ra cell line pulled down a band of 
approximately 25 kDa, corresponding to the predicted molecular mass of this molecule. This 
band was detected with immunoblotting with an anti-FLAG antibody (Figure 4.3), suggesting 
it was indeed icIL-1Ra with a C-terminal TAP-tag. This result indicated that the 50, 70 and 
80 kDa bands correspond to proteins which bind specifically to C16 and not to the affinity 
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beads used in the procedure or to the TAP-tag. Collectively, these data provide solid evidence 
that the proteins pulled down when C16 is expressed are specific to the induction of C16 and 
hence correspond to host-cell binding targets of this VACV protein. Furthermore, C16 bound 
to proteins which were not bound by icIL-1Ra (Figure 3.2 and 4.1), suggesting that C16 has 
distinct intracellular functions to icIL-1Ra. However, this does not rule out a role for ic-IL-
1Ra-like properties of C16 because there could be common binding partners not detected by 
this method. 
The four bands derived from the C16-TAP cell line were excised from the gel and 
sent for mass spectrometry analysis (Section 2.2.8), which provided unequivocal 
identification of proteins within the bands as Egg-laying 9 homolog 1 (Egln1)/Prolyl-
hydroxylase domain containing protein (PHD)-2 (50 kDa band), Ku70 (70 kDa band) and 
Ku80 (80 kDa band) as molecules that interact with C16 (Table 3.1).  Ku70 and Ku80 (also 
termed Ku86) form a heterodimer, which is known to be involved in DNA repair (Downs and 
Jackson, 2004; Collis et al., 2005), whereas Egln1/PHD2 is a prolyl 4-hydroxylase involved 
in hypoxic signalling (Kaelin, 2005). Mass spectrometric analysis of the excised bands did 
reveal a significant level of keratin contamination; however this was not sufficient to obscure 
the positive identification of cellular proteins in these bands.  
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Band Rank Total Ion 
Score 
Identification Molecular 
Mass (kDa) 
Peptide 
Count 
37 1 833.34 VACV C16 37.5 10 
37 2 226.19 Keratin 66.0 5 
50 1 367.28 EGLN1/PHD2 55.0 5 
50 2 216.97 Keratin 66.0 5 
70 1 1473.11 Ku70/XRCC6 69.8 26 
70 2 259.03 Keratin 66.0 4 
80 1 1369.82 Ku80/XRCC5 82.7 32 
80 2 450.39 Keratin 66.0 8 
Table 3.1. Mass spectrometric analysis of excised bands from tandem affinity 
purification assay. The two highest ranked hits for each protein are listed here. Band names 
relate to the approximate molecular masses as indicated in Figure 3.2. Samples were analysed 
by Dr. Paul Hitchen, Biochemistry Department, Imperial College London.   
 
3.1.3. Confirmation of C16-Ku70/Ku80 interaction 
 
After initial identification of putative C16 binding partners, it was essential to confirm 
these interactions by alternative methods. This confirmation was achieved firstly by 
immunoblotting of affinity purified proteins with antibodies specific to the proteins identified 
by mass spectrometric analysis. And, secondly, by reciprocal co-immunoprecipitation of 
these binding partners with C16 in the context of virus infection. The remainder of this 
chapter will focus on the interaction between C16 and the Ku heterodimer, see Chapter 4 for 
work relating to Egln1/ PHD2.  
Ku70 and Ku80 constitute the constitutively formed Ku heterodimer (Downs and 
Jackson, 2004), an abundant protein complex that is present in many organisms ranging from 
humans to Saccharomyces cerevisiae to humans (Dynan and Yoo, 1998). DNA-dependent 
protein kinase (DNA-PK) is a large heterotrimeric complex consisting of the 70 kDa Ku70, 
80 kDa Ku80 (also termed Ku86) and 460 kDa catalytic subunit of DNA-PK (DNA-PKcs) 
(Gottlieb and Jackson, 1993; Collis et al., 2005).  
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DNA-PK is involved in dsDNA-repair (Collis et al., 2005; Meek et al., 2008).  The 
most highly characterised function of DNA-PK to date is its ability to bind to disruptions of 
the DNA double helix such as dsDNA breaks (Mimori and Hardin, 1986; Paillard and 
Strauss, 1991). Upon binding to dsDNA breaks, Ku translocates along the DNA molecule, 
often resulting in multiple Ku subunits being bound to DNA, akin to beads on a string 
(Paillard and Strauss, 1991). Subsequently, the Ku heterodimer recruits DNA-PKcs via a C-
terminal domain of Ku80 (Gell and Jackson, 1999) and once this heterotrimeric complex is 
loaded onto both ends of a DNA break, the process of non-homologous end joining occurs 
(Collis et al., 2005; Weterings and Chen, 2007). 
 
 
 Figure 3.3 Ku70 co-precipitates with C16. One T175 flask of each of the indicated cell 
lines was induced with 2 g/ml tetracycline for 24 h. Protein lysates were prepared and C16 
protein complexes were purified with streptavidin beads. Whole cell lysate (WCL) and 
affinity purified proteins (AP) were resolved by SDS-PAGE and immunoblotted with 
antibodies against Ku70, DNA-PKcs or C16. –ve, C16 cell line without addition of 
tetracycline; TAG, HEK293TRex cell line expressing the TAP-tag only; C16, HEK293TRex 
cells expressing C16 induced with tetracycline.   
 
Immunoblotting was performed using eluates from a small scale affinity purification 
of C16 using streptavidin beads (Figure 3.3). Ku70 was found to co-precipitate with C16 but 
not with the TAP-tag alone. Interestingly, DNA-PKcs did not co-precipitate with C16. 
Similar data were obtained using an anti-Ku80 antibody (data not shown), and importantly 
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the co-precipitation of C16 with Ku80 was confirmed in the context of virus infection (Figure 
3.4). The Ku heterodimer is an extremely stable heterodimer. There are extensive protein-
protein interaction regions between the two subunits, demonstrated both biochemically (Wu 
and Lieber, 1996) and crystallographically (Walker et al., 2001), hence interaction with Ku70 
implies interaction Ku80 and vice versa. Additionally, absence of one subunit leads to the 
structural instability and degradation of the other subunit (Errami et al., 1996; Wu and Lieber, 
1996; Singleton et al., 1997).  
 
 
Figure 3.4 C16 immunoprecipitates with Ku80 from VACV-infected cells. HeLa cells 
were mock-infected or infected with either a C16 knockout virus (vC16) or VACV WR at 2 
p.f.u. per cell for 4 h. Cells were then lysed and anti-Ku80 or isotype control (ISO)  
antibodies conjugated to protein G sepharose beads were incubated with lysates for 1 h. 
Subsequently whole cell lysates (WCL) and immunoprecipitates (IP) were resolved by SDS-
PAGE and immunoblotted with antibodies against the indicated proteins. IP lanes represent 
complexes purified with the indicated antibody.  
 
 
Confirmation of the interaction between the Ku heterodimer and C16 was achieved by 
co-immunoprecipitation of the complex from cells infected with VACV (Figure 3.4). Protein 
complexes were precipitated from infected cell lysates with an anti-Ku80 antibody, or an 
isotype control antibody, and the precipitates were analysed by immunoblotting with 
antibodies against C16, Ku70 and DNA-PKcs. This experiment showed that C16, Ku70 and 
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DNA-PKcs were co-immunoprecipitated with anti-Ku80, but not isotype control, antibody. 
As expected, C16 was absent from mock-infected cells and from cells infected with the 
VACV strain lacking the C16L gene (vC16). These data confirm a specific interaction 
between the Ku heterodimer and C16 at endogenous protein levels found during the course of 
a virus infection. 
Interestingly, immunoprecipitation of Ku80 pulled down C16 and DNA-PKcs, yet 
purification of C16 shows binding to the Ku heterodimer, but not DNA-PKcs. This suggests 
the existence of a mixed group of complexes containing either Ku80 with DNA-PKcs or 
Ku80 with C16, but a complex containing Ku80, C16 and DNA-PKcs has not been 
demonstrated. This might suggest an inhibition of DNA-PKcs binding to Ku by C16 and this 
is explored further below. 
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3.2. Characterisation of DNA-PK as a cytoplasmic DNA sensor of 
innate immunity  
 
DNA-PK is an abundant protein complex found in most cell types (Collis et al., 
2005). DNA-PK components are essential for V(D)J recombination (Blunt et al., 1995; 
Errami et al., 1996; Jeggo et al., 1996), and loss of these components results in a severe-
combined immunodeficiency (SCID) phenotype, indicating a critical role for DNA-PK in the 
development of the adaptive immune system. The identification of Ku as an interacting 
partner of C16 was interesting, but the purpose of this interaction was not evident initially. 
Whilst V(D)J recombination is a critical aspect of immunity for generating T and B cell 
receptors, and defects in this process lead to a SCID phenotype, it was unlikely that C16 was 
binding to Ku for the purpose of interfering in this process specifically. Firstly, V(D)J 
recombination occurs early in the development of lymphocytes in the bone marrow or thymus 
for B and T cells, respectively. C16 was shown to be a virulence factor during an intranasal 
infection (Fahy et al., 2008) and cytokine production was shown to be affected by 24 h (Fahy, 
unpublished data)- which would not represent a long enough period of time for a 
derangement of B or T cell development to manifest. Secondly, VACV is a highly lytic virus 
and is not known to persist in B or T cells. Therefore, in the instance that C16 was produced 
by infection of a developing B or T cell, it is likely to have little significance since the cell 
would soon by lysed, independently of C16, before V(D)J recombination and subsequent 
lymphocyte maturation occurs. 
Consequently, it was unclear why Ku was a binding target for a VACV protein, or 
how the binding of C16 to Ku was linked to the characterisation of C16 as a virulence factor. 
Ku and the larger DNA-PK complex have been described principally as a nuclear protein, 
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however a cytoplasmic fraction has been noted (Fewell and Kuff, 1996; Collis et al., 2005) 
and the function of this cytoplasmic DNA-PK is unclear.  
DNA-PK has been shown previously to interact with IRF-3 (Karpova et al., 2002), a 
component of innate immunity critical for DNA sensing (Ishii et al., 2006; Stetson and 
Medzhitov, 2006).  
DNA-PK, therefore, is a protein complex with a well characterised DNA-binding 
activity, and in addition it is also present in the cytoplasm and interacts with IRF-3. Since 
C16 was an immunomodulator, and the effects of this immunomodulation can be observed 
early in the course of infection, it was hypothesised that DNA-PK was acting as a 
cytoplasmic DNA sensor and that C16 might be modulating a DNA-mediated innate immune 
response. 
3.2.1. DNA-PK binds to DNA in the cytoplasm 
 
 Since C16 is a VACV protein, and poxviruses replicate their DNA exclusively in the 
cytoplasm, if Ku were to play a role in DNA sensing it would have to bind cytoplasmic DNA. 
To assess the ability of DNA-PK to bind cytoplasmic DNA, biotinylated DNA pull downs 
were performed on cytoplasmic extracts. 
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Figure 3.5 DNA-PK binds to DNA purified from the cytoplasm. HEK cells were mock 
transfected (-ve), transfected with biotinylated DNA (DNA) or transfected with biotinylated 
Pam-3-Cys (Pam3cys) for 1 h. Cytoplasmic extracts were generated, incubated with 
streptavidin beads and protein complexes purified in this manner were analysed by SDS-
PAGE. The gel was stained with Coomassie brilliant blue and the stained bands were excised 
and the proteins present were identified using mass spectrometry. Molecular mass markers 
are labelled in kDa. Samples were analysed by Dr. Paul Hitchen, Biochemistry Department, 
Imperial College London. This work was carried out with Dr. Brian Ferguson. 
 
Biotinylated DNA purifications from cytoplasmic extracts of HEK cells demonstrated 
that DNA-PK bound to DNA in the cytoplasm, consistent with a previous report (Frasca et 
al., 2001). Notably, all three components of DNA-PK co-purified with biotinylated DNA but 
not with biotinylated Pam-3-Cys, indicating that DNA-PK specifically interacts with DNA 
and is not co-purified with biotin or streptavidin beads.  
Further data generated within our laboratory have shown a refined nuclear-
cytoplasmic separation with actin and tubulin immunoblotting to control for adequate nuclear 
and cytoplasmic exclusion, respectively. With this more stringent nuclear-cytoplasmic 
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fractionation, DNA-PK components are still found to be both cytoplasmic and nuclear in 
unstimulated cells (Ferguson et al, submitted).  
The ability of DNA-PK to bind to DNA in the cytoplasm is consistent with a role for 
DNA-PK in DNA sensing in the context of a poxvirus infection. However, DNA-PK had 
previously been ruled out as a candidate DNA sensor, because bone marrow derived 
monocytes from mice lacking Ku70 or DNA-PKcs demonstrated no deficit in innate immune 
sensing of DNA (Stetson and Medzhitov, 2006). This clearly directly conflicted with the 
hypothesis that DNA-PK acts as a DNA sensor. 
 
3.2.2. DNA-PK is not expressed by macrophages 
 
 
Figure 3.6. DNA-PK is expressed in MEFs, but not macrophages. Cell lysates from 
BALB/c primary peritoneal macrophages and MEFs were analysed by SDS-PAGE and 
immunoblotting with the indicated antibodies. This work was performed with Drs. Brian 
Ferguson and Daniel Mansur. 
 
Given the findings of Stetson & Medzhitov that the Ku heterodimer and DNA-PKcs 
are dispensable for DNA sensing in BMDCs  (Stetson and Medzhitov, 2006) the presence of 
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these molecules in this cell type was investigated. Whilst Ku70 and DNA-PKcs can be easily 
detected in MEFs by immunoblotting, these molecules were not detectable within 
macrophages, despite the quantities of HMGB1, a control protein, being similar between both 
cell types. This result demonstrates an uneven distribution of DNA-PK across cell types, and 
suggests that the elimination of DNA-PK as a candidate DNA sensor is premature, at least 
across all cell types.   
DNA sensing in macrophages has been studied intensively, and a recent DNA sensor, 
interferon-induced 16 (IFI16) is likely to be the major DNA sensor responsible for activating 
the innate immune system in this cell type (Unterholzner et al., 2010). However, MAVS and 
MDA-5 have also been reported to be critical for the induction of IRF-3-mediated innate 
immune signalling during poxvirus infection in macrophages (Delaloye et al., 2009), which 
suggests a complex induction of innate immune signalling and leaves open the question as to 
whether poxvirus DNA is acting as a PAMP during the course of infection.  
Poxviruses have a broad tropic range and are capable of infecting many cell types. 
Therefore, the likely sites of initial VACV replication following intranasal infection are the 
first cells which VACV encounters, and these are typically the epithelial cells and fibroblasts 
of the airways and lungs. The presence of DNA-PK in these cell types is consistent with a 
role for DNA-PK as a primary DNA-sensor during VACV infection. Additionally, the 
absence of DNA-PK in macrophages is consistent with the dispensability of the genes 
encoding these molecules for the induction of Ifnb mRNA induction (Stetson and Medzhitov, 
2006). 
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3.2.3. DNA-PK components are upregulated upon DNA stimulation 
 
 
Figure 3.7. DNA-PK component mRNAs are upregulated following DNA stimulation. 
Primary MEFs from BALB/c mice were stimulated with 10 g/ml of 200-bp ISD dsDNA for 
the indicated times. qRT-PCR analysis was performed on RNA extracted from these cells 
with primers specific for Ku80 (Xrcc6), Ku70 (Xrcc5) & DNA-PKcs (Prkdc). Stimulation was 
calculated relative to Hprt. 
  
A feature of several proteins that function in innate immune signalling is that they are 
upregulated in the presence of IFN or pro-inflammatory stimuli. To assess if DNA-PK was 
induced upon stimulation with DNA, the mRNA levels for Ku70, Ku80 and DNA-PKcs were 
measured by qRT-PCR before and after DNA transfection (Figure 3.7). This showed that by 
8 h following DNA transfection each mRNA was upregulated approximately 4 fold, relative 
to the housekeeping gene Hprt.  This relatively modest increase in mRNA is significant given 
the fact that all three proteins are already expressed at high levels in resting MEFs and are 
easily detectable by immunoblotting (Figure 3.6). Interestingly, upregulation of DNA-PK 
components upon DNA transfection was only noted in primary MEFs, and not transformed 
MEFs (data not shown). 
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Data showing that DNA-PK is able to bind DNA in the cytoplasm, is constitutively 
expressed at high levels at the sites of poxvirus infection and is also inducible upon DNA 
transfection are consistent with basic characteristics of a DNA sensor acting in the detection 
of poxvirus infection. The role of Ku and DNA-PKcs in the activation of innate immunity 
following DNA transfection was then investigated.  
 
3.2.4. Cells lacking the Ku heterodimer are deficient in DNA, but not RNA 
sensing 
 
Figure 3.8. Ku is required for innate immune signalling following DNA stimulation, but 
not RNA stimulation. MEFs lacking Ku70 (Xrcc6
-/-
), Ku80 (Trp53
-/-
Xrcc5
-/-
) or adult murine 
skin fibroblast (MSFs) lacking both Ku70 and Ku80 (far right panel) were stimulated with 10 
g/ml 200-bp ISD dsDNA or 5 g/ml poly(I:C) for 8 h. qRT-PCR analysis was performed on 
RNA extracted from these cells. ns, Non-stimulated. Stimulation was calculated relative to 
Hprt. Error bars +/- Standard error of the mean (SEM) (N≥3), * p<0.05 ** p<0.01 *** 
p<0.001. 
 
Previous reports have shown that MEFs transfected with DNA induced various IRF-3 
dependent cytokines and chemokines such as Il-6, Cxcl10 and Ifn. Wild-type MEFs and 
those lacking either Ku70 (Xrcc6
-/-
) or Ku80 (Trp53
-/-
Xrcc5
-/-
) components were stimulated 
by transfection with DNA or the dsRNA mimentic poly (I:C) (Figure 3.8).  This showed that 
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the induction of Ifnb mRNA in response to DNA was impaired in cells lacking Ku70, 
however in response to poly (I:C), transcription was equivalent between wild-type and 
knockout cells (Figure 3.8). Similarly, upregulation of the transcription of Cxcl10 mRNA in 
response to DNA was also found to be dependent on Ku70 as the transcriptional up-
regulation was severely inhibited in Xrcc6
-/-
 MEFs. Xrcc5
-/-
 MEFs were also found to have 
abrogated Cxcl10 and Il6 responses to DNA, suggesting that both Ku components are 
required for complete DNA sensing. This is consistent with the fact that loss of the Ku70 
gene, Xrcc6, leads to destabilisation and consequent absence of Ku80 protein and, and vice 
versa (Errami et al., 1996; Singleton et al., 1997).  Adult murine skin fibroblasts (MSFs) 
lacking both Xrcc5 and Xrcc6 were also found to be deficient in Ifnb mRNA upregulation in 
response to DNA, but not dsRNA.  
Together, these data confirm that cells lacking the Ku heterodimer are deficient in 
innate immune activation by DNA, but not poly (I:C) and furthermore that this response is 
found in both MEFs and adult MSFs, suggesting Ku-mediated innate immune activation by 
DNA is not specific to embryonic cells, and that the phenoytype observed is consistent 
amongst several knockout fibroblast cell lines generated independently.  
 
 
3.2.5. Cells lacking DNA-PKcs are deficient in DNA sensing 
 
C16 was found to bind to the Ku heterodimer, but not DNA-PKcs. Having established 
a requirement for the Ku70 and Ku80 proteins in DNA sensing, the requirement for DNA-
PKcs in DNA-mediated innate immune signalling was investigated. To assess the 
contribution of DNA-PKcs to DNA-mediated innate immune activation, wild-type MEFs and 
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MEFs lacking the Prkdc gene (encoding DNA-PKcs) were stimulated with DNA or control 
ligands. 
 
Figure 3.9. DNA-PKcs is required for innate immune sensing of DNA, but not RNA or 
LPS. MEFs lacking DNA-PKcs (Prkdc
-/-
) and MEFs from WT littermate controls were 
stimulated with 5 g/ml poly (I:C), 5 g/ml 200-bp ISD dsDNA or LPS at an indicated 
concentration for 8 h or indicated times. RNA was extracted and mRNAs were quantified by 
qRT-PCR. Stimulation was calculated relative to Hprt. ns, Non-stimulated; Error bars +/- 
SEM (N≥3), * p<0.05 ** p<0.01 *** p <0.001. 
 
As with the Ku heterodimer, Prkdc
-/-
 MEFs were also found to be deficient in DNA-
mediated upregulation of various genes, including Cxcl10, Il6, Ccl5, and Ccl4 but responded 
normally to both transfected poly (I:C) and LPS. ELISA analysis on supernatants from wild-
type and knockout MEFs demonstrated that Prkdc
-/-
 MEFs had a profound defect in Ifn- and 
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Cxcl10 production following stimulation with DNA for 8 h, but production of Cxcl10 was 
unimpaired following stimulation with poly (I:C).  
The dependence on DNA-PKcs-mediated innate activation by DNA was also 
observed over a range of different time points. The upregulation of Cxcl10 and Ccl4 mRNA 
was impaired in MEFs lacking DNA-PKcs at all time points tested compared with wild-type 
MEFs, yet Cxcl10 mRNA upregulation in response to LPS was found to be equivalent 
between the two cell types. Whilst upregulation of Cxcl10 mRNA peaked at 2 h after LPS 
stimulation, consistent with existing literature (Hao and Baltimore, 2009), upregulation of 
this gene continued to increase after this time following transfection with DNA. Whether this 
temporal difference was due to kinetics of transfection or whether the pathway is subject to 
less stringent regulation than the pathway activated by LPS remains to be determined. 
These data suggest that the entire DNA-PK complex is required for DNA sensing, not 
just the Ku heterodimer. Interestingly, the defect in DNA-mediated innate immune activation 
in Prkdc
-/-
 MEFs appears more severe than in MEFs lacking either Xrcc5 or Xrcc6. This is 
consistent with the reported ability of DNA-PKcs to bind to DNA in the absence of Ku, albeit 
with a lower affinity (Yaneva et al., 1997; Hammarsten and Chu, 1998). 
Cxcl10 has been shown previously to be consistently upregulated in response to 
multiple species of DNA (Ishii et al., 2006). In addition, it has been demonstrated in Figures 
3.8 and 3.9 that there is a similar dependence on Ku and DNA-PKcs for multiple cytokines 
and chemokines, including Cxcl10, Il6 and Ifnb being upregulated in response to DNA 
stimulation. Cxcl10 was therefore used as the default molecule measured in remaining 
experiments, with additional molecules assessed if necessary or informative. 
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3.2.6. DNA activates an innate immune signalling pathway involving 
STING, TBK-1 and IRF-3 
 
 
In addition to DNA-mediated innate immune stimulation of MEFs being dependent 
on DNA-PK, these responses were also found to be dependent on other components of the 
IRF-3 pathway. Previous reports have implicated components of this pathway, including IRF-
3 itself, (Ishii et al., 2006; Stetson and Medzhitov, 2006), the IRF-3 kinase TBK-1 (Ishii et 
al., 2008) , and STING (Ishikawa and Barber, 2008; Ishikawa et al., 2009) in DNA sensing 
and the requirement for these molecules was also assessed in our laboratory to confirm a 
requirement for these components. 
 
Figure 3.10. Irf3 and Tbk1 are both required for innate immune sensing of DNA. MEFs 
lacking Irf-3 or Tbk1 and those from wild-type littermate control cells were stimulated with 5 
g/ml 200-bp ISD dsDNA for 8 h and qRT-PCR was performed on RNA extracted from 
these cells. NS, non stimulated. Stimulation was calculated relative to Hprt.  Error bars +/- 
SEM (N≥3) ** p<0.01 
 
Irf3 knockout MEFs had a profound defect in innate immune responses to DNA with 
a near total abrogation of both Ifnb and Cxcl10 mRNA upregulation following DNA 
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stimulation (Figure 3.10, middle and left panels), consistent with previous reports (Ishii et al., 
2006; Stetson and Medzhitov, 2006). In addition, the upstream kinase of IRF-3, TBK-1 was 
also found to have a dramatic effect on Cxcl10 mRNA upregulation following DNA 
stimulation, since absence of the gene Tbk1 from MEFs lead to a profound deficit in innate 
immune activation (Figure 3.10, right panel), confirming the importance of TBK-1 in DNA-
mediated innate immune activation as reported previously (Ishii et al., 2008).  
 
Figure 3.11. STING is required for innate immune sensing of DNA, but not RNA. 
Primary MEFs from mice lacking STING (Tmp173
-/-
) or wild-type littermate control MEFs 
were stimulated with 5 g/ml 200-bp ISD dsDNA or 5 g/ml poly (I:C) for 8 h. qRT-PCR 
analysis was performed on RNA harvested from these cells. Stimulation was calculated 
relative to Hprt. 
 
MEFs lacking STING, encoded by the gene Tmp173, were also shown to be deficient 
in innate immune sensing of DNA (Figure 3.11). Tmp173
-/- 
MEFs had highly reduced Cxcl10 
and Ifnb mRNA upregulation compared with wild-type littermate control MEFs following 
DNA stimulation but not poly (I:C) stimulation, confirming a DNA specific defect as 
reported previously (Ishikawa et al., 2009).  
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3.2.7. DNA in primary, but not transformed, MEFs also activates NF-B 
 
 During the studies of induction of various cytokines and chemokines in response to 
DNA, it was noted that, while Cxcl10 and Il-6 were upregulated substantially following 
transfection of DNA, the upregulation of Ifnb was not robust in some instances and in several 
experiments was completely absent. Our observations correlated with a recent study which 
reported that repeated passage of MEFs lead to a loss of the inducibility of Ifnb mRNA in 
response to DNA (Chiu et al., 2009). Our study, by necessity, used MEFs of various passage 
numbers and so a cause for this loss of Ifnb mRNA inducibility by DNA was investigated. 
 It has been known for some time that the Ifnb promoter contains multiple binding sites 
for transcription factors involved in innate immune signalling including IRF-3, NF-B and 
AP-1 (Visvanathan and Goodbourn, 1989; Thanos and Maniatis, 1995; Merika and Thanos, 
2001). However, whilst IRF-3 signalling in transformed MEFs was established to be intact, 
the state of NF-B signalling in response to DNA in primary and transformed MEFs had not 
been investigated thoroughly. To examine the role of NF-B signalling in DNA-mediated 
innate immune activation Nfkbia (encoding IB) transcription was measured, because this is 
specifically upregulated by NF-B activation (Sun et al., 1993), and is therefore an indicator 
of NF-B transcriptional activity. 
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Figure 3.12. Differential NF-kB responses in primary and transformed MEFs. Primary 
BALB/c MEFs or spontaneously transformed BALB/c MEFs were stimulated with 5 g/ml 
200-bp ISD DNA or 5 g/ml poly (I:C). qRT-PCR was performed on RNA harvested from 
these cells 8 h post stimulation. Stimulation was calculated relative to Hprt. qRT-PCR of 
Nfkbia following stimulation of (a) primary MEFs, and (b) transformed MEFs, with DNA or 
poly (I:C). (c) Parallel comparison of Cxcl10, Il6, Ifnb and Isg54 upregulation in primary and 
transformed MEFs 
 
In primary MEFs it was noted that NF-B was activated in response to DNA 
transfection and poly (I:C) transfection (Figure 3.12a) as indicated by upregulation of Nfkbia 
mRNA transcription. In contrast, whilst Nfkbia mRNA was upregulated in transformed MEFs 
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in response to poly (I:C), Nfkbia was not upregulated in response to DNA transfection of 
transformed MEFs, indicating a lack of NF-B activation (Figure 3.12b). Cxcl10 and Il-6 
mRNA upregulation was still observed in transformed MEFs, however Ifnb mRNA 
upregulation in response to DNA was notably absent (Figure 3.12c). From these data, it 
appears that with transformation, MEFs lose the capability to activate NF-B in response to 
DNA, but not in response to other stimuli, and that activation of NF-B is necessary for an 
Ifnb induction in response to DNA stimulation. 
 
3.2.8. NF-B stimulation in response to DNA is enhanced by STING and 
independent of IRF-3 
 
Figure 3.13. Nfkbia transcription in Irf3
-/-
 and Tmp173
-/-
 MEFs. Irf3
-/-
,Tmp173
-/- 
and WT 
littermate controls were stimulated with 5 g/ml 200-bp ISD DNA or 5 g/ml poly (I:C). 
qRT-PCR was performed on RNA harvested from these cells 8 h post stimulation. Relative 
stimulation was calculated relative to Hprt transcription. 
 
 To ascertain the relative contributions of other signalling molecules to NF-B 
stimulation, qRT-PCR was used to test the upregulation of Nfkbia mRNA following DNA 
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stimulation of several primary MEFs.  Consistent with work published previously (Ishikawa 
et al., 2009), NF-B activation following DNA transfection was found to be enhanced by 
STING, since the absence of the Tmp173 gene led to a decrease in Nfkbia mRNA 
upregulation in MEFs (Figure 3.13, right panel). In addition, the absence of Irf3 in MEFs had 
no effect on the upregulation of NF-B by DNA (Figure 3.13, left panel). These data indicate 
that activation of NF-B is likely to be mediated intracellularly by a distinct adaptor or 
receptor, and not secondary to IRF-3 dependent gene transcription/translation and subsequent 
activation of cytokine receptors. Together, these data might indicate the existence of an 
additional DNA sensor or adaptor which activates NF-B in response to DNA stimulation.   
 The roles of other molecules identified in the DNA-sensing pathway in the DNA-
mediated NF-B activation are yet to be assessed, and study of the relative roles of other 
molecules will lead to further understanding of the innate immune response to DNA.   
Given that transcription factors such as IRF-3 are found to be activated following 
stimulation with DNA, and that DNA-PK components are also implicated, the order of the 
components in the proposed signalling pathway following DNA stimulation was investigated. 
 
3.2.9. DNA-PK is upstream of IRF-3 in the DNA sensing pathway in MEFs 
 
 To assess whether DNA-PK acts in the same pathway as IRF-3, the transcriptional 
control of Isg54 and Cxcl10 was assessed in response to DNA stimulation in MEFs lacking 
either Irf3 or Prkdc. 
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Figure 3.14. Isg54 and Cxcl10 upregulation after DNA stimulation is dependent upon 
both IRF-3 and DNA-PKcs. MEFs lacking Irf3 or Prkdc were stimulated with 5 g/ml 200-
bp ISD dsDNA or 2000 U/ml murine IFN for 8 h and qRT-PCR analysis was performed on 
RNA extracted from these cells. ns, Non-stimulated. Stimulation was calculated relative to 
Hprt. Error bars +/- SEM (N≥3), * p<0.05 ** p<0.01  
 
Transcription of the genes Isg54 and Cxcl10 was shown to be IRF-3-dependent in 
response to DNA (Figure 3.14, left panels). Stimulation of MEFs with DNA leads to a 
marked upregulation of both Isg54 and Cxcl10 mRNA levels, however in Irf3
-/-
 MEFs this 
response is completely abrogated. In addition, the transcriptional upregulation of Isg54 and 
Cxcl10 following stimulation with DNA is also dependent upon DNA-PKcs as the response 
114 
 
is also ablated in Prkdc
-/-
 MEFs, but the upregulation following stimulation with Ifn- is still 
intact (Figure 3.14, right panels). Together, these data suggest that DNA-PK and IRF-3 fall 
within the same pathway activated by DNA because the absence of either molecule ablates 
the upregulation of both Cxcl10 and Isg54 mRNA following DNA stimulation. 
Next, the ability of IRF-3 to translocate from the cytoplasm to the nucleus in the 
absence of DNA-PK was assessed by immunofluorescence (Figure 3.15).  
 
Figure 3.15. IRF-3 translocation to the nucleus in response to DNA, but not RNA, is 
dependent upon DNA-PK, but not in response to RNA. Wild-type MEFs or Prkdc
-/-
 MEFs 
were stimulated with 5 g/ml 200-bp ISD dsDNA or 5 g/ml poly (I:C) for 1 h and stained 
for IRF-3. Top panel (a) shows representative images of cells with or without stimulation. 
The bottom panel (b) represents the percentage of cells in which IRF-3 is present within the 
nucleus, n=100. NS, non-stimulated. Error bars +/- SEM (n≥3). Scale bar, 5 m. This work 
was carried out with Dr. Brian Ferguson. 
115 
 
Unstimulated MEFs showed a dispersed cytoplasmic staining of IRF-3, consistent 
with its cytoplasmic location in resting cells (Lin et al., 1998). Both wild-type and Prkdc
-/-
 
MEFs showed a strong translocation of IRF-3 to the nucleus of approximately 70% of cells 
following stimulation with poly (I:C), as expected.  However, Prkdc
-/-
 MEFs displayed no 
translocation of IRF-3 to the nucleus following stimulation with dsDNA, whereas Prkdc
+/+
 
MEFs showed IRF-3 translocation in more than 90% of cells (Figure 3.15a). The 
translocation of IRF-3 was quantified (Figure 3.15b) and a statistically significant effect of 
DNA-PKcs on DNA-mediated, but not poly (I:C)-mediated, IRF-3 translocation was 
demonstrated. These data are consistent with DNA-PKcs having a role in DNA, but not 
RNA, sensing. This suggests that DNA-PKcs is upstream of IRF-3 in the DNA sensing 
pathway operating within MEFs, and is consistent with DNA-PK binding to DNA in the 
initial event of DNA sensing within infected cells. 
 
3.2.10. DNA sensing in MEFs is independent of DAI/ZBP1, MyD88/TRIF, 
MAVS, IRF-5 and IRF-7 
 
 Whilst DNA sensing in MEFs was found to involve a pathway involving, at a 
minimum, DNA-PK, STING, TBK-1 and IRF-3, a large cohort of innate immune signalling 
components had not been assessed for a role in DNA-mediated innate immune signalling. To 
address the input, if any, of these molecules to intracellular DNA sensing, knockout MEFs 
and genetically matched controls were transfected with DNA and the upregulation of Cxcl10 
mRNA was used as a marker for DNA stimulation (Figure 3.16). 
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Figure 3.16. DNA sensing is not impaired in the absence of MyD88, Trif, Mavs, Irf7, Irf5 or 
Dai/Dlm1/Zbp1. MyD88/Ticam1
-/-
, Mavs
-/-
, Irf7
-/-
, Zbp1
-/-
, Irf5
-/-
 & WT littermate controls were 
transfected with 5 g/ml DNA or 5 g/ml poly (I:C), infected with MVA (5 p.f.u. per cell) or treated 
with murine Ifn-2000 U/ml) for 8 hQuantitative RT-PCR analysis was performed on RNA 
extracted from these cells. Fold-stimulation was calculated relative to Hprt. 
  
 MEFs from a mouse with both Myd88 and Ticam1 (encoding TRIF) genes knocked 
out demonstrated no deficiency in upregulation of Cxcl10 mRNA compared to wild-type 
controls in response to MVA infection, DNA or poly (I:C) transfection (Figure 3.16, upper 
left panel), consistent with literature published previously (Ishii et al., 2006). Since removal 
of these molecules ablates all known TLR signalling (Yamamoto et al., 2003a), a role for 
TLRs in intracellular DNA sensing in MEFs can be ruled out. 
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The role of RNA-polymerase III, RIG-I and MDA-5 in these assays was assessed 
using MEFs deficient in MAVS (Mavs
-/-
) since this molecule is a common signalling adaptor 
to each of the aforementioned nucleic acid sensors. MEFs deficient in Mavs showed no 
reduction in Cxcl10 mRNA upregulation following DNA transfection (Figure 3.16, upper 
centre panel), suggesting that the RLRs were not involved in DNA-mediated innate immune 
activation as described in this study. Interestingly a trend toward upregulation of Cxcl10 in 
response to both DNA and MVA the absence of Mavs was observed (n=2). Although this 
observation requires reproduction to confirm the trend, it could suggest a regulatory role of 
Mavs in DNA sensing. There was, however, a marked reduction in Cxcl10 mRNA following 
poly (I:C) transfection in Mavs knockout MEFs compared to wild-type cells in accordance 
with its documented role RNA sensing (Kawai et al., 2005; Meylan et al., 2005; Seth et al., 
2005; Xu et al., 2005). Interestingly, despite VACV having an A:T rich genome (67% A+T), 
Mavs
-/-
 MEFs demonstrated no impaired Cxcl10 mRNA upregulation following MVA 
infection, suggesting that RNA-polymerase III is not involved in the detection of MVA in 
MEFs, at least at the time point tested, consistent with previous reports that MAVS is 
dispensable for poly (dA:dT)-mediated upregulation of Ifnb mRNA in MEFs (Kumar et al., 
2006; Sun et al., 2006). A report published previously suggested that MDA-5 and MAVS 
were required for the MVA-mediated induction of IFN in macrophages (Delaloye et al., 
2009). This provides further evidence for differential mechanisms of DNA sensing in 
alternate cell types, the reason for this is unknown. 
 Similarly, Irf5 (Figure 3.16, lower right panel), Irf7 (Figure 3.16, upper right panel) 
and Dai/Dlm1/Zbp1 (Figure 3.16, lower left panel) null MEFs did not display a reduction in 
Cxcl10 mRNA upregulation following DNA stimulation compared with WT littermate 
controls, which suggests IRF-5 and IRF-7 are not involved in DNA sensing in MEFs. As with 
Mavs, there appears to be an increase in Cxcl10 upregulation in the absence of Irf7. This data 
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has not yet been reproduced and may not withstand further scrutiny, however in the context 
of this study both IRF-7 and Mavs can likely be excluded from DNA sensing since there is 
not a profound impairment of Cxcl10 upregulation following DNA stimulation as is the case 
for MEFs lacking Irf3, Tmp173, Tbk1 or Prkdc. In the case of Dai/Dlm1/Zbp1 this is in 
agreement with data published previously (Ishii et al., 2008; Wang et al., 2008). DAI is only 
present at very low quantities in resting cells, but is induced upon activation of cells by IFN 
(Takaoka et al., 2007; DeFilippis et al., 2010), suggesting that DAI might play a secondary 
role in DNA sensing and is dispensable for initial DNA-mediated innate immune activation. 
 Collectively, these data provide evidence that DNA-mediated upregulation of Cxcl10 
mRNA following DNA stimulation of MEFs is dependent upon DNA-PK, STING, TBK-1 
and IRF-3 and  independent of TLRs, RLR’s, IRF-5, IRF-7 and DAI. 
 
3.3. DNA-PK is essential for innate immune responses to VACV 
 
3.3.1 DNA-PK components co-localise with VACV virus factories 
 
Since DNA-PK was found to bind DNA in the cytoplasm, it seemed possible that it 
might also bind to VACV factories in the cytoplasm that contain many copies of VACV 
genomic DNA. To address this, the location of DNA-PK components was compared in 
infected and mock-infected cells by immunofluorescence.  In uninfected cells, Ku70 is found 
predominantly within the nucleus (Figure 3.17a.). However, Ku70 was shown to have an 
additional location within an infected cell. In keeping with a role in the nucleus there was a 
strong signal from the nucleus of HeLa cells stained with Ku70 antibody, but there was also a 
clear co-localisation with DAPI stained viral DNA factories in the cytoplasm. Likewise, 
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DNA-PKcs also had a predominantly nuclear localisation in uninfected cells, but co-localised 
with viral DNA factories in the cytoplasm (Figure 3.17b). 
These data represents the first demonstration of a candidate DNA sensor associated 
with sites of VACV replication.  
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a) 
 
b) 
 
 
Figure 3.17. DNA-PK components co-localise to viral DNA factories. HeLa cells were 
infected with MVA for 16 h at 2 p.f.u. / cell or mock-infected. Cells were then fixed with 
paraformaldehyde and stained with DAPI and antibodies raised against either (a) Ku70 or (b) 
DNA-PKcs followed by an anti-mouse-FITC-conjugated secondary antibody. Scale bars, 5 
m. 
These data are consistent with data presented in Figure 3.5 showing that DNA-PK 
components are capable of binding to DNA in the cytoplasm and suggests that DNA-PK is 
recruited to sites of viral DNA replication, presumably to viral DNA itself. 
MVA 
Mock 
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3.3.2. DNA-PK components are essential for MVA-mediated innate 
immune signalling in MEFs. 
 
To investigate if DNA-PK was needed for innate immune sensing in response to 
poxvirus infection, wild type MEFs or MEFs lacking components of the DNA-PK complex 
were infected with differing amounts of MVA, and the amounts of mRNA for specific 
markers of innate immune activation (Cxcl10 and Il6) were measured by qRT-PCR (Figure 
3.18). 
 
 
 
Figure 3.18. Upregulation of Cxcl10 and Il-6 following infection by VACV MVA is 
dependent upon DNA-PK components. MEFs lacking either Ku80 (Xrcc5
-/-
, top panel) or 
DNA-PKcs (Prkdc
-/-
, bottom panel) and MEFs from wild-type littermate controls were 
infected with MVA at the indicated p.f.u. per cell. RNA was extracted after 8 h and analysed 
by qRT-PCR with primers specific for Il6 or Cxcl10. ni, non-infected. Stimulation was 
calculated relative to Hprt. Error bars +/- SEM (n ≥3), ** p<0.01 . 
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An increased production of Cxcl10 and Il6 mRNA was observed with increasing 
quantities of MVA used to infect cells (Figure 3.18, left-hand panels). Whilst MVA infection 
induced cytokine and chemokine production in wild-type MEFs, this response was markedly 
reduced in MEFs lacking Ku80 (Figure 3.18, upper panels). A defect in chemokine and 
cytokine up-regulation was also observed in MEFs lacking DNA-PKcs (Figure 3.18, lower 
panels), indicating that loss of these components of DNA-PK caused impaired innate immune 
responses to VACV. The deficiency in chemokine and cytokine upregulation following 
infection appeared to be more severe in MEFs lacking DNA-PKcs than Ku80, though both 
were statistically significant. Quantification of these changes showed that MEFs lacking 
Ku80 showed at least a 60% decrease in production of Il6 mRNA compared to wild-type 
cells, whereas this figure approached 95% in MEFs lacking DNA-PKcs (Figure 3.18).  
These data suggest that upon MVA infection of fibroblasts, viral genomic DNA is 
itself the PAMP responsible for the activation of transcriptional upregulation of pro-
inflammatory cytokines and chemokines. 
 
3.3.3. DNA-PK is not required for VACV replication 
 
Whilst DNA-PK components were shown to be important for the upregulation of pro-
inflammatory cytokines and chemokines, it was important to assess whether this complex 
was important for VACV replication since one interpretation of Figure 3.18 could be that 
VACV DNA simply does not accumulate at similar levels in MEFs with or without DNA-
PK. However, it was known already that viruses with or without C16 replicated well (Fahy et 
al., 2008), suggesting that C16 and therefore Ku are not principally involved in a replicative 
process within infected cells. In order to determine the replicative capacity of VACV DNA 
during infection with MVA in the presence or absence of the Ku heterodimer, wild-type and 
123 
 
Xrcc5
-/-
 MEFs were infected with MVA and levels of viral DNA were measured at different 
time points (Figure 3.19). It should be noted that if either Ku70 or Ku80 is absent, the other 
component of the Ku heterodimer is unstable and is essentially also absent. As such, Xrcc5
-/-
 
cells can be considered Ku null cells (Errami et al., 1996; Singleton et al., 1997).  
 
 
 
Figure 3.19. MVA DNA replication is not affected by the absence of the Ku 
heterodimer. Wild-type and Xrcc5
-/-
 MEFs were infected with MVA with 2 p.f.u./cell for the 
indicated times. Cells were lysed, treated with proteinase K and the number of VACV 
genomic DNA copies was assessed with qRT-PCR using primers specific to the MVA 
genome. The absolute quantification based upon dilutions of proteinase K-treated purified 
virus of a known infectious titre (for a detailed description of the experimental procedure 
refer to section 2.1.16). Error bars +/- SEM (n≥3). 
 
Whilst the copy number of MVA genomes increased over time, there was no 
statistically significant difference in MVA DNA replication in the presence or absence of 
Ku80, although there was a slight tend towards increased viral DNA loads in Xrcc5
-/-
 MEFs 
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(Figure 3.19). This shows that the Ku heterodimer is not required for VACV DNA replication 
and that the defect in Cxcl10 mRNA upregulation noted in Figure 3.18 is not likely to be due 
to a lack of viral DNA accumulation.  
The fact that Ku is targeted by the VACV C16, an immunomodulatory VACV 
protein, further supports the hypothesis that Ku has an alternative role during the course of 
VACV infection, such as DNA sensing.   
 
3.3.4. Cxcl10 mRNA upregulation in MEFs upon MVA infection is 
dependent on IRF-3 and TBK-1.  
 
  
Figure 3.20. Response to MVA is abrogated in cells lacking Irf3 and Tbk1. Irf3
-/-
, Tbk1
-/-
 
and wild-type littermate control MEFs were infected with MVA at 5 p.f.u. per cell for 8 h. 
qRT-PCR analysis was performed on RNA extracted from these cells with primers specific 
for Cxcl10. ns, non-stimulated. Stimulation was calculated relative to Hprt. Error bars +/- 
SEM (n ≥3), *** p<0.001, * p<0.05. 
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Next, the pathway through which DNA-PK sensing of MVA signalled was 
investigated using MEFs lacking specific signalling molecules or transcription factors. 
Whereas, infection of MEFs with MVA induced the upregulation of various chemokine and 
cytokine RNA species, such as Cxcl10 & Il-6, in MEFs lacking Irf3 there was no detectable 
Cxcl10 upregulation (Figure 3.20).  
Since IRF-3 is phosphorylated at its C terminus by TBK-1 (Fitzgerald et al., 2003; 
Sharma et al., 2003), the role of TBK-1 in MVA induced Cxcl10 mRNA upregulation was 
also investigated.  Tbk1
+/+
 MEFs induced Cxcl10 robustly after infection with MVA for 8 h, 
however this induction was completely absent in MEFs lacking Tbk1 (Figure 3.20). This 
indicates that TBK-1, as well as its kinase substrate IRF-3, are both required for the 
upregulation of Cxcl10 mRNA following infection with MVA. These data indicate that 
DNA-PK, TBK-1 and IRF-3 are all required for innate immune activation following MVA 
infection, as they are for DNA transfection, and this implies that during the course of 
infection MVA DNA stimulates IRF-3 dependent genes in MEFs. 
Since DNA-PK localised to viral factories and was found to be required for full 
activation of innate immune signalling in response to MVA, and that IRF-3 and TBK-1 were 
also found to be required for innate immune signalling activation in response to MVA, the 
localisation of both TBK-1 & IRF-3 during MVA infection was subsequently investigated. 
To assess the localisation of these molecules during MVA infection, HeLa cells were infected 
with MVA and immunofluorescent staining was performed (Figure 3.21).  
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Figure 3.21. Localisation of TBK-1 and IRF-3 during MVA infection. HeLa cells were 
infected for 16 h at 2 p.f.u. / cell, fixed with paraformaldehyde and then stained with DAPI 
and either antibodies raised against TBK-1 or IRF-3 followed by an anti-mouse-FITC-
conjugated secondary antibody. Scale bars, 5 m. 
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Infection of HeLa cells with MVA lead to the formation of characteristic cytoplasmic 
virus factories. TBK-1 in uninfected cells had a diffuse localisation, however upon infection 
with MVA, TBK-1 was found to co-localise with the discrete cytoplasmic MVA virus 
factories (Figure 3.21), indicating that TBK-1 is recruited to sites of viral replication, as is the 
case with DNA-PK (Figure 3.17).  
IRF-3, was found to have a broadly cytoplasmic localisation in uninfected cells, 
consistent with previous literature, reviewed in previously (Honda and Taniguchi, 2006). 
However, in contrast to TBK-1, upon infection with MVA IRF-3 was found to translocate to 
the nucleus (Figure 3.21), consistent with its role as a transcription factor and the activation 
of IRF-3 in response to MVA infection (Figure 3.21 and Ishii et al., 2006).  
Together, these data suggest that TBK-1 is found at sites of DNA replication during 
VACV infection, along with Ku70 and DNA-PKcs and that IRF-3 is activated during VACV 
infection. 
 DNA-PK has been shown to phosphorylate IRF-3 at its N terminus (Karpova et al., 
2002). Phosphorylation of IRF-3 at its C terminus, however, is the phosphorylation event 
which leads to the dimerisation and nuclear translocation involved in its role in innate 
immune signalling (Lin et al., 1999; Kumar et al., 2000). The role of the N-terminal 
phosphorylation by DNA-PK, if any, is unlikely to play a part in DNA-mediated innate 
immune activation since DNA sensing operates normally in cells lacking the kinase domain 
of DNA-PK (Shirota et al., 2006). In addition, if DNA-PK-mediated phosphorylation of IRF-
3 was sufficient for activation of innate immune signalling, TBK-1 and other intermediate 
molecules would likely be dispensable- and the evidence presented demonstrate that this is 
not the case. The role of N-terminal phosphorylation of IRF-3 by DNA-PK, if any, in innate 
immune signalling remains to be elucidated.  
128 
 
 The observation that TBK-1, is recruited to sites of MVA replication, along with 
DNA-PK suggests that phosphorylation of IRF-3 occurs close to the viral factories. However, 
STING has been shown to translocate to perinuclear vesicles after stimulation by DNA 
(Ishikawa et al., 2009; Saitoh et al., 2009). STING is likely to be upstream of TBK-1 in the 
DNA-mediated innate immune activation pathway since STING shows DNA-specific 
activation whereas TBK-1 is activated by DNA and RNA, so the location of STING during 
DNA virus infection, such as MVA, merits attention. The role of the documented perinuclear 
vesicles during infection, and indeed whether or not these vesicles are formed upon infection, 
or whether these are recruited to viral factories is also of interest. However, the localisation of 
STING during MVA infection has not yet been assessed due to reagent availability. 
  Collectively, these data strongly suggest that viral DNA acts as a PAMP during MVA 
infection. Understanding that it is this DNA which leads to innate immune activation upon 
infection with MVA might lead to a better basis for MVA-based vaccine design since it is 
commonly used as a vaccine vector. 
3.4. GAGA is an immunostimulatory DNA sequence 
 
 Previously, it had been noted that Ku binds to a DNA sequence, termed NRE1, in the 
mouse mammary tumour virus (MMTV) genome, specifically 5’GAGAAAGAGAA3’ 
(which we have termed ‘GAGA’) on both ssDNA (Torrance et al., 1998) and dsDNA (Giffin 
et al., 1996). Intriguingly, by inspection of the genomic sequences of several orthopoxviruses, 
it was found that this sequence also occurs at a high frequency in the genomes of some of 
these viruses. For example, despite the number of base pairs required to have expected the 
sequence to occur once being approximately 4 × 10
6
, the MVA genome, with a genome 
length of approximately 1.78 x 10
5
 contains 134 copies of GAGA (Table 3.2). Notably, the 
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GAGA sequences were found exclusively at the termini of the genome. In highly passaged 
VACV strains (e.g. MVA), multiple copies of GAGA were observed, however in all variola 
virus strains examined (such as India 1953 New Delhi, Tanzania 1965 & UK 1946 Harvey), 
only one copy of GAGA was noted. 
   
Virus Genome Length 
(kbp) 
Occurrences of 
GAGAAAGAGA (range 
of distance from genome 
terminus in kbp) 
Occurrences of 
GAGAAAGAGAA (range 
of distance from genome 
terminus in kbp) 
VACV-WR 194.7 88 (0.2-3.3) 26 (1.1-3.3) 
VACV-COP 191.7 104 (0.2-4.0) 28 (2.8-4.0) 
VACV-MVA 177.9 170 (0.3-6.0) 134 (0.8-6.0) 
VARV- UK1946 
Harvey 
185.7 4 (0.1-0.6) 1 (0.6) 
VARV- India 1953 
New Delhi 
186.7 17 (0.1-1.4) 1 (1.4) 
VARV- Tanzania 
1965 
185.8 10 (0.1-0.5) 1 (0.5) 
ECTV-Moscow 209.8 20 (0.4-1.3) 2 (1.3) 
MOCV – Subtype 1 190.3 2 (28.7) 1 (28.7) 
Camelpox-CMS 202.2 8 (0.1-0.3) 2 (0.3) 
Cowpox- Brighton 
Red 
224.5 68 (0.2-2.4) 68 (0.2-2.4) 
Monkeypox – Sierra 
Leone 
198.8 2 (0.1) 0 (0) 
Fowlpox- Iowa 288.5 1 (133.3) 1 (133.3) 
Fowlpox- FP9 266.0 1 (117.0) 0 (0) 
Table 3.2 Table showing the prevalence of GAGA in several orthopoxviruses and 
molluscum contagiosum virus. The above genome sequences were interrogated for 5’ 
GAGAAAGAGA 3’ and 5’ GAGAAAGAGAA 3’ occurrences. The distances of the GAGA 
sequences from the genome termini are given in kbp to represent nearest and furthest 
occurrences of GAGA from the genome terminus. VARV; variola virus, ECTV; ectromelia 
virus, MOCV, molluscum contagiosum virus. 
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Table 3.2 demonstrates several interesting features of GAGA and poxviruses. Firstly, 
GAGA is highly prevalent across multiple members of the Orthopoxvirus genus, including 
VACV, variola virus, molluscum contagiosum virus, camelpox virus, cowpox virus, 
monkeypox virus and ectromelia virus. An abbreviated version of GAGA, lacking the final 3’ 
adenine was also searched for and in many instances there were many more copies of the 
shortened sequence of GAGA. The minimum sequence required for Ku binding to GAGA 
has not been determined and it is possible that the final adenine is not required for specific 
Ku binding.  
Secondly, with the exception of MOCV, GAGA is found exclusively at the genome 
termini. For example; MVA has 134 copies of GAGA, yet these are not evenly distributed 
across the genome but are packaged tightly between 849-bp and 5,963-bp from each end of 
the genome. In addition, when only one copy of GAGA is found, such as the three strains of 
VARV examined- GAGA is located between 544-bp (Tanzania) and 1426-bp (India, New 
Delhi, 1953) from the genome terminus. 
Thirdly, there is a loose correlation between the number of passages of virus in tissue 
culture and GAGA copy number. Primary virus isolates, such as the variola virus strains, tend 
to have fewer copies of GAGA, whereas extensively passaged viruses, such as MVA and 
CPXV strain Brighton Red, appear to have accumulated GAGA copies.  The reason for this 
difference in GAGA copy number requires further investigation. It is possible that the low 
copy number of GAGA in primary virus isolates might imply negative selection in the 
presence of a functional immune system. 
Furthermore, GAGA was only shown to be present once in the Fowlpox virus strains 
Iowa and FP9, indicating that GAGA is not common to all poxviruses. In the MOCV and 
Fowlpox virus strains containing only one copy of GAGA, it was not found in the ITRs. 
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Poxvirus ITRs vary enormously in length and it is thought that ITR sequences can be 
duplicated and transposed (Moyer et al., 1980), and the amount of duplication and 
transposition will likely depend on passage number. Therefore, the variability of GAGA 
occurrence across different strains is likely to be function of chance and passage number of 
the virus strain.   
 However, since Ku has been found previously to bind to GAGA, that Ku has been 
characterised as a potential cytoplasmic DNA sensor, and that poxviruses, especially highly 
attenuated strains, had large numbers of GAGA in their genomes, the relative 
immunogenicity of DNA molecules with or without GAGA was investigated. 
 
 
Figure 3.22 NRE1 is more immunostimulatory than a control DNA sequence. WT MEFs 
were stimulated with 5 g/ml 90-bp oligonucleotides of the indicated DNA species. qRT-
PCR analysis was performed on RNA extracted 8 h post stimulation. NS, Non-stimulated. 
Stimulation was calculated relative to Hprt. Error bars +/- SEM (N≥3), * p<0.05  
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Quantitative RT-PCR analysis was performed in MEFs transfected with different 
DNA species (Figure 3.22). ISD DNA, a DNA sequence used extensively in the literature and 
does not contain a GAGA sequence was compared with the NRE1 sequence, which is a 45-bp 
sequence with one copy of GAGA, originally identified as the target for Ku binding (Giffin et 
al., 1996). Relative to the control ISD sequence, NRE1 was more immunostimulatory than 
ISD as measured by qRT-PCR analysis of Cxcl10 mRNA induction. In addition, this 
immunostimulatory potential was observed to be dose-dependent because 100-bp 
oligonucleotides containing 2 copies of the NRE1 sequence was more immunostimulatory 
than an oligonucleotide containing 1 copy of NRE1 and 1 copy of ISD, which in turn 
stimulated higher levels of Cxcl10 mRNA induction than an oligonucleotide containing 2 
copies of the ISD control sequence (Figure 3.22, right panel).   
 Together, these observations provide evidence that GAGA is an immunostimulatory 
DNA sequence presumably mediated by its specific interaction with Ku. Further work will be 
required to confirm these initial findings and explore the potential contributions GAGA has 
to poxviral replication and any potential role for inclusion of GAGA in DNA vaccines for 
enhanced immunostimlatory effects.  
 
.  
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3.5. The role of C16 in VACV infection 
 
 
3.5.1. C16 blocks DNA sensing, but not RNA sensing 
 
As C16 interacts with Ku, and Ku binds to DNA and activates an IRF-3-dependent 
innate immune response, it was hypothesised that C16 might be acting to inhibit this pathway 
to avoid activation of the immune response mediated by VACV DNA during infection. To 
assess this, MEFs were transfected with a plasmid containing a C16 open reading frame that 
had been codon optimised for expression in mammalian cells (pcDNA4/TO-coC16) or an 
empty vector (pcDNA4/TO) along with greater masses of linear DNA or poly (I:C) (Figure 
3.23). Transfection of MEFs with plasmid DNA induces activation of the innate immune 
system in the manner described previously. To assess the contribution of C16 to subversion 
of DNA-mediated innate immune activation, simultaneous transfection of plasmid and linear 
DNA or poly (I:C) was required. 
Codon optimisation of the C16 ORF was required since the virally-encoded C16 
mRNA, along with many other VACV mRNAs, was found to have cryptic splice sites. 
During the course of infection, the splice sites are not significant as the transcription of these 
ORFs occurs in the cytoplasm. However, during expression of C16 via plasmid transfection 
the mRNA is exposed to nuclear splicing machinery and therefore the relative protein 
production is dramatically reduced compared with virus infection (data not shown). 
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Figure 3.23. Cxcl10 and Il-6 ELISA following DNA and RNA stimulation of MEFs. Wild 
type (Trp53
-/-
 Xrcc5
+/+
) MEFs were transfected with 200 ng/ml pcDNA4/TO (EV) or 
pcDNA4/TO encoding codon optimised C16 (pcDNA4/TO-coC16) and 5 g/ml 
concatamerised DNA or 2 g/ml poly (I:C). The presence of Cxcl10 or Il-6 were measured in 
the supernatants at 24 h post transfection. Error bars +/- SEM (N≥3), ** p<0.01. 
 
Transfection of cells with plasmid and either DNA or poly (I:C) produced robust 
responses to these molecules, including the production of Cxcl10 and Il-6. In the presence of 
C16, there was significantly lower production of both Cxcl10 and Il-6 in the supernatants of 
transfected cells when DNA was co-transfected, however no such difference was observed in 
either Cxcl10 or Il-6 secretion when poly (I:C) was co-transfected (Figure 3.23), indicating 
that the inhibitory effect of C16 is specific to DNA and not RNA sensing pathways. These 
observations strongly indicate that the C16 protein can act to inhibit the innate immune 
response to DNA. 
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Figure 3.24. Disruption of the C16 ORF ablates inhibition of DNA sensing. (a.) WT 
MEFs were transfected with 5 g/ml of pcDNA4/TO-coC16 that had been linearised by 
digestion with either BspMI or MluI. Agarose gel electrophoresis and subsequent purification 
was used to isolate digested plasmid.  After 16 h the amount of Cxcl10 in the culture medium 
was measured by ELISA. Error bars +/- SEM (N≥3), ** p<0.01. (b.) Schematic 
demonstrating locations of BspMI and MluI restriction digestion sites on the pcDNA4/TO-
coC16 plasmid. 
 
 To control for any irregularities presented by co-transfection of circular plasmid and 
linear dsDNA oligonucleotides, the pcDNA4/TO-coC16 plasmid was linearised by digestion 
with either the enzyme MluI, which leaves the C16 ORF and promoter intact, or BspMI 
which cleaves the plasmid within the C16 ORF rendering the plasmid unable to express C16 
protein after transfection. In this way, the stimulus is also the delivery vehicle for C16 
expression, thus no cell stimulated with DNA would be without the pcDNA4/TO-coC16 
plasmid.  
 Transfection of MEFs with pcDNA4/TO-coC16 digested with MluI (i.e. with the C16 
ORF intact) lead to a significantly lower production of Cxcl10 compared with pcDNA4/TO-
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coC16 digested with BspMI (which destroys the C16 ORF). These data are consistent with, 
and support, the hypothesis that C16 inhibits innate immune activation following DNA 
stimulation, and it was hypothesised that this inhibitory function was mediated by its 
interaction with Ku. 
3.5.2. The inhibition of cytokine/chemokine production mediated by C16 is 
dependent on Ku 
 
To investigate if this immunomodulatory effect of C16 was mediated by targeting Ku, 
the same transfection assay with empty vector control or plasmid expressing C16 in 
combination with immunostimulatory linear DNA was performed in Xrcc5
-/-
 MEFs (Figure 
3.25) and Cxcl10 and Il-6 protein production were measured by ELISA. 
 
Figure 3.25. Cxcl10 and Il-6 ELISA following DNA and RNA stimulation of Ku80
-/-
 
MEFs. Trp53
-/-
Ku80
-/-
 MEF were transfected with 200 ng/ml pcDNA4/TO (EV) or 
pcDNA4/TO encoding codon optimised C16 (C16) and 5 g/ml concatamerised DNA or 2 
g/ml poly (I:C). The presence of Cxcl10 and Il-6 were measured by ELISA in the 
supernatant at 24 h post transfection. Error bars +/- SEM (N≥3).  
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The transfection of plasmid and immunostimulatory DNA induced Cxcl10 and Il-6 
production in Xrcc5
-/-
 MEFs (Figure 3.25), however the concentrations of these proteins were 
considerably lower compared to those observed in wild-type MEFs on the same plate on the 
same day (Figure 3.23), which supports the hypothesis that Ku is a DNA sensor. The fact that 
some activation of Xrcc5
-/-
 cells was observed can be explained by either the activation of an 
alternative DNA sensor such as IFI16 (Unterholzner et al., 2010) occurring in Xrcc5
-/-
 MEFs, 
or the Ku heterodimer aiding detection of DNA by DNA-PK but not being an absolute 
requirement. This latter explanation would be consistent with the ability of DNA-PKcs to 
bind to DNA in the absence of Ku, albeit less efficiently (Yaneva et al., 1997; Hammarsten 
and Chu, 1998).  
Whilst C16 displayed a strong negative immunomodulatory effect to DNA sensing in 
wild-type cells, no such effect was seen in Xrcc5
-/-
 MEFs, since transfection with either C16 
or empty vector induced similar levels of Cxcl10 and Il-6 production (Figure 3.25), 
suggesting that the function of C16 is dependent on its interaction with the Ku heterodimer. A 
slight reduction was observed in Cxcl10 production following transfection with C16; 
however this was not statistically significant.  
 
3.5.3. Absence of C16 leads to increased production of cytokines and 
chemokines in vivo following infection by VACV 
 
Whilst C16 blocked DNA sensing in cell culture, and this effect was mediated by Ku, 
it was not clear what effect this host-virus protein interaction might have in vivo due to the 
redundancy reported previously in DNA sensing (Wang et al., 2008) and also because VACV 
produces many other inhibitors of innate immune signalling. To address the role of C16, and 
indirectly the role of Ku, in vivo, BALB/c mice were infected intranasally with wild-type 
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(WR), C16-knockout (vC16) and revertant (rev) viruses and the innate immune response 
was measured over the first 72 h (Figure 3.26). 
 
 
Figure 3.26. C16 affects Cxcl10 and Il-6 production in vivo. Groups of five BALB/c mice 
were infected intranasally with 5 × 10
4
 p.f.u. per mouse of wild-type (WR) C16 knockout 
(vC16) or revertant viruses. Mice were sacrificed at the indicated time points and the 
amount of Cxcl-10 and Il-6 in BAL fluid were measured by ELISA. Error bars +/- SEM 
(N≥3). * p<0.05, ** p<0.01. 
 
ELISA analysis of bronchoalveolar lavage (BAL) fluid from mice infected 
intranasally  with 5 × 10
4
 p.f.u. showed that infection with VACV induced the production of 
Cxcl10 and Il-6, however infection with vC16 lead to an enhanced production of both of 
these molecules (Figure 3.26). This effect was statistically significant at 24 and 48 h post 
infection for Cxcl10, and at 24 h for Il-6, but by 72 h post infection the presence of C16 made 
no statistically significant difference to the concentration of these molecules in BAL fluid 
(Figure 3.26). 
 
139 
 
 
Figure 3.27. C16 affects Ccl5 and Ifnb mRNA transcription in vivo. Groups of five 
BALB/c mice were infected intranasally with 5 x 10
4
 p.f.u. of wild-type (WR) C16 knockout 
(vC16) or revertant viruses. Mice were sacrificed 24 h post infection and qRT-PCR analysis 
was performed on RNA extracted from tracheas. Data were normalised to Hprt. Fold 
induction refers to induction relative to mock-infected mice. Error bars +/- SEM (N≥3). * 
p<0.05. 
 
Ifnwas undetectable in BAL fluid from mice infected with this dose of virus in this 
model at these time points tested. Explanations for this might be that the levels of Ifn 
produced in this system are below the detection limits of current ELISA kits, or that the 
VACV of B18 protein, which binds type-1 IFNs (Symons et al., 1995) prevents detection of 
Ifnby ELISA. To circumvent these potential difficulties, Ifnb mRNA levels in tracheal cells 
were analysed by qRT-PCR (Figure 3.27).  This demonstrated that Ifnb mRNA transcription 
was at a higher level in vC16 infected mice than either vC16 or revC16 infected mice at 24 
h post infection. A similar result was observed for Ccl5, indicating that C16 inhibits the 
transcription of type I IFN as well as Cxcl10, Il-6 and Ccl5 in vivo.   
Previous work within our laboratory had demonstrated that after infection of mice 
intranasally the production of IL-1 was not affected by the absence of C16 (Fahy, 
unpublished data). This was consistent with the previous observation that the production of 
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this molecule in response to VACV infection is largely due to DNA sensing leading to the 
activation of the AIM2 inflammasome (Rathinam et al., 2010) and that Ku is not likely to be 
involved in the formation of this inflammasome (Burckstummer et al., 2009).  
These data add to data published previously by our laboratory showing that more 
leukocytes were recruited to the lungs of mice infected with vC16 compared with wild-type 
and revertant viruses early in the course of infection (Fahy et al., 2008).  This data adds more 
detail to the report published previously regarding the mechanism of action of C16 in virus 
infection and strongly supports the hypothesis that DNA-PK-mediated activation of the 
innate immune response to VACV is of biological significance. Although indirect, this data 
provides the first in vivo example of an IRF-3-activating DNA sensor having significant in 
vivo effects in the context of virus infection. 
 
3.5.4. C16 inhibits the interaction of Ku with DNA 
 
Data presented thus far indicate that C16 bound to Ku, blocked Ku-dependent DNA-
mediated innate immune signalling in vitro, and reduced cytokine production in VACV-
infected mice. However, the mechanism of action of C16 was not yet clear. 
 To address how C16 might be exerting its immunomodulatory effects on Ku, the 
interaction of the DNA-PK components with DNA in the presence or absence of C16 was 
investigated using biotinylated DNA to pull down protein complexes from cells . 
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Figure 3.28. C16 affects binding of DNA-PK to DNA. HeLa cells were transfected with 2 
g/ml pcDNA4/TO (EV) or pcDNA4/TO-coC16 (C16). After 24 h, cells were transfected 
with 5 g/ml biotinylated DNA for 30 min. Cells were then lysed and  biotinylated DNA was 
affinity purified using streptavidin beads. Inputs and Affinity Purified (AP) complexes were 
resolved by SDS-PAGE and immunoblotted with antibodies against proteins indicated on the 
right. Approximate molecular masses of proteins are indicated in kDa. Images were obtained 
using a Licor Odyssey scanner (Section 2.2.4.2). 
 
In the whole cell lysates it was noted that the level of DNA-PKcs and Ku70 were 
similar in the presence or absence of DNA, and whether or not C16 was expressed. 
Quantification of the expression levels using LICOR was performed, and showed a slight but 
statistically insignificant different increase in DNA-PK components in the presence of C16 
(Figure 3.29). The equivalent levels of DNA-PK component molecules rule out the 
possibility that C16 might degrade, or mark for degradation, the Ku heterodimer. 
In the affinity purified samples, C16 did not co-precipitate with DNA (Figure 3.28). 
This finding ruled out the possibility that C16 bound to DNA directly and thereby would 
prevent either Ku or DNA-PKcs from binding to DNA. This finding also suggests that it is 
also unlikely that C16 inhibits Ku after Ku has bound to DNA, since no C16 was detected to 
co-precipitate with DNA, although Ku was bound to DNA.  In addition it was seen that in 
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cells expressing C16, the amounts of both Ku and DNA-PKcs that co-purified with DNA 
were reduced compared with cells transfected with empty vector. This inhibition was much 
more profound for Ku70 than for DNA-PKcs. 
 
Figure 3.29. C16 affects binding of DNA-PK to DNA. Three wells each of a 6-well plate of 
HeLa cells were transfected with 2 g/ml pcDNA4/TO (EV) or pcDNA4/TO-C16 (C16). 
After 24 h, cells were then transfected with 5 g/ml biotinylated DNA for 30 min. Affinity 
purification (AP) was performed on the biotinylated DNA using streptavidin beads. Inputs 
and affinity purified complexes were resolved by SDS-PAGE and immunoblotted with Ku70 
and DNA-PKcs antibodies. Integrated intensity was calculated using infrared imaging by a 
Licor Odyssey scanner. 
 
The experiment documented in Figure 3.28 was repeated in triplicate and the 
integrated intensity of the bands was assessed using infrared imaging (Figure 3.29). A 
statistically significant reduction in Ku70 and DNA-PKcs binding to DNA in the presence of 
C16 compared with empty vector was demonstrated. The effect of C16 inhibiting the 
recruitment of Ku to DNA is both quantifiable and reproducible, providing strong evidence 
that C16 inhibits the recruitment of Ku to DNA and that this is the mechanism by which C16 
blocks innate immune signalling in response to DNA.  
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These data suggest that C16 prevents Ku from binding to DNA, and that DNA-PKcs 
binding to DNA was reduced in consequence. It is known that DNA-PKcs binding to DNA is 
increased in the presence of Ku via recruitment to DNA by the C-terminal domain of Ku80 
(Gell and Jackson, 1999), but can also occur less efficiently without it (Hammarsten and Chu, 
1998). This could explain why C16 does not bind to DNA-PKcs, but nonetheless affects the 
binding of this molecule to DNA. 
Upon binding of DNA by Ku, DNA-dependent conformational changes occur in the 
Ku heterodimer, and these conformational changes contribute to the recruitment of DNA-
PKcs (Lehman et al., 2008). The indication that C16 inhibits the binding of DNA by Ku is 
entirely consistent with the finding described in Figure 3.3 that C16 interacts with Ku, but not 
DNA-PKcs, since C16 is inhibiting DNA binding by Ku and therefore inhibits the formation 
of DNA-PK. Put another way, C16-bound Ku has inhibited DNA-binding activity, and 
therefore the DNA-PK complex is not assembled, thus C16 would not be expected to also 
interact indirectly with DNA-PKcs. 
Inhibition of Ku binding to DNA by C16 therefore inhibits the assembly of the DNA-
PK complex on DNA and it is likely that through this mechanism C16 modulates the host 
innate immune response to VACV. 
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3.6. Summary – C16 and Ku 
 
Using an unbiased proteomics-based approach, binding partners for VACV C16 were 
identified. C16 was found to bind to the Ku heterodimer, a well characterised DNA-repair 
complex involved in the non-homologous end joining (NHEJ) DNA repair pathway (Downs 
and Jackson, 2004). Whilst binding partners were found using this method, it is possible that 
other C16 ligands may exist but were not detected, due to binding being obscured by the 
TAP-tag.  
C16 was not found to have any common binding partners with icIL-1Ra with this 
method. However, it is possible that common binding partners do exist. For instance, the 
region of homology between C16 and icIL-1Ra is a short 6 amino acid peptide at the C 
terminus of both molecules, and the use of a C-terminal TAP-tag might have obscured the 
positive identification of common binding partners. N-terminal TAP-tagging of C16 might 
avoid this problem. Alternatively, C16 and icIL-1Ra might share common binding partners 
pulled down during the TAP experiment but were not identified with Coomassie or silver-
staining.  
Additionally, another technique now used in our laboratory is the generation of 
VACV expressing TAP-tagged proteins of interest. Generation of VACV expressing TAP-
tagged C16 might highlight binding partners which only interact upon virus infection. For 
instance, C16 has been shown previously using yeast two-hybrid assays to interact with 
VACV protein K1 (McCraith et al., 2000), which might suggest that C16 could interact with 
additional proteins when other virus proteins are produced in the same cell. 
However, the finding that C16 interacts with Ku presented an intriguing issue as to 
the role of C16, a VACV virulence factor, interacting with a protein principally characterised 
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as a nuclear DNA repair protein. Subsequently, DNA-PK was shown to interact with 
cytoplasmic DNA, and importantly it also co-localised with sites of viral DNA replication in 
VACV-infected cells. Binding of DNA-PK to cytoplasmic DNA, and, perhaps more 
importantly, to VACV factories suggested a role in DNA sensing. 
DNA-PK components, Ku70, Ku80 and DNA-PKcs were shown to be important for 
the transcription of multiple genes including Cxcl10 and Il-6 upon stimulation of cells with 
DNA, this provided the first evidence that DNA-PK was acting as a DNA sensing PRR. 
Importantly, DNA-PK was found to be responsible for DNA-mediated activation of innate 
immunity but was not required for LPS- or poly (I:C)-mediated activation. This suggests a 
DNA specific effect, and is consistent with DNA-PK binding to DNA therefore acting 
upstream in the DNA-mediated IRF-3 activation pathway. 
Previously, DNA-PK had been ruled out as a candidate DNA sensor because BMDMs 
from mice lacking Ku70 or DNA-PKcs were shown to be as responsive as wild-type cells to 
DNA-mediated IFNupregulation (Stetson and Medzhitov, 2006). Our study, however, has 
demonstrated that DNA-PK is not expressed in these cells, and therefore this supports the 
findings of the aforementioned report. In contrast, our study shows that DNA-PK is 
expressed in MEFs and, furthermore, is crucial for DNA sensing in these cells. Since VACV 
is capable of infecting many cell types, the epithelial cells and underlying fibroblasts are 
likely to be the first cells infected during a poxvirus infection and therefore the activation of 
innate immunity in these cells is of fundamental importance. The presence of DNA-PK at 
high levels in these cells is also consistent with a role as a primary sensor of infection, unlike 
other putative DNA sensors, such as DAI which is not detectable at a steady-state but is 
induced subsequently by IFN (Takaoka et al., 2007; DeFilippis et al., 2010).  
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IRF-3 is well characterised for its role in innate immune signalling (Tamura et al., 
2008), and is also critical for the induction of various cytokines and chemokines in response 
to transfected DNA (Ishii et al., 2006; Stetson and Medzhitov, 2006). DNA-PK was shown to 
be required for the translocation of IRF-3 in response to DNA, but not RNA, suggesting that 
DNA-PK is upstream of IRF-3 in a DNA-specific innate immune signalling pathway. A role 
has also been demonstrated for the signalling components TBK-1 (Ishii et al., 2008) and 
STING (Ishikawa et al., 2009) in DNA-mediated activation of innate immunity, and these 
findings were confirmed in this study. Along with Ku70 and DNA-PKcs, TBK-1 was also 
found to be recruited to viral factories during MVA infection. TBK-1 is likely to be 
downstream of STING in the DNA-sensing pathway, because it is the IRF-3 kinase 
(Fitzgerald et al., 2003; McWhirter et al., 2004). However, the location of STING during 
MVA infection has not been determined, due to a lack of reagent availability. STING has 
been reported to translocate to perinuclear vesicles after DNA transfection (Ishikawa et al., 
2009; Saitoh et al., 2009), and is also ubiquitylated by TRIM56, resulting in its interaction 
with TBK-1 (Tsuchida et al., 2010). Therefore, it will be interesting in the future to determine 
the location of STING during MVA infection and also the role, if any, of the STING-docked 
perinuclear vesicles during virus infection.  
DNA-PK was also shown to be important for the transcriptional induction of Cxcl10 
and Il6 in response to infection with VACV. MEFs lacking either Ku80 or DNA-PKcs had 
impaired induction of pro-inflammatory molecules during MVA infection, suggesting that 
DNA-PK is required for the full activation of the innate immune response to VACV. Also, it 
was demonstrated that the activation of innate immune signalling pathways during MVA 
infection of fibroblasts is likely to be principally due to viral DNA activating a DNA-PK- 
dependent DNA-sensing pathway. This is in contrast with a previous study that reported that 
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MDA-5 is required for activation of the innate immune response to MVA in macrophages 
(Delaloye et al., 2009).   
GAGA is a DNA sequence reported previously to be bound by Ku with a particularly 
high affinity (Giffin et al., 1996). GAGA was also noted to be present at a particularly high 
frequency in the termini of various poxvirus strains. Stimulation of cells with a DNA 
sequence including GAGA was found to stimulate cells more strongly than a control DNA 
sequence lacking GAGA, suggesting that this sequence might represent a particularly 
immunogenic sequence detected by DNA-PK. However, why poxviruses would maintain this 
sequence in the genome at all merits attention. Notably, virus strains heavily passaged in 
tissue culture such as MVA and WR had high copy numbers of GAGA whereas clinical 
isolates of VARV and MOCV contained very few copies. It is possible that GAGA is under 
constant negative selective pressure in vivo, but in tissue culture the absence of a functioning 
immune system might permit the expansion of GAGA copy numbers. Interestingly, MVA, a 
highly immunogenic VACV strain was found to have the highest number of GAGA copies in 
its genome, suggesting that GAGA might play a role in its immunogenicity. Further work on 
GAGA insertions or deletions into VACV strains will help to establish the role, if any, of 
GAGA in the innate immune response to VACV and GAGA in poxvirus biology. 
The fact that DNA-PK is required V(D)J recombination raises issues with the 
interpretation of in vivo experiments using Ku or DNA-PKcs deficient mice. The lack of 
V(D)J recombination leads to a SCID phenotype, and SCID mice are highly susceptible to a 
variety of pathogens, independently of any role DNA-PK plays in DNA sensing. 
Accordingly, infection of DNA-PK deficient mice with VACV will result in a much more 
severe phenotype than a wild-type control mouse, but attributing any difference in disease 
severity to either the adaptive or innate immune systems would be highly problematic. One 
argument is that assessment of production of chemokines and cytokines very early on in the 
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course of infection would only allow for the innate immune response to be assessed, however 
this temporal separation will not account for differences in local leukocyte populations 
secondary to impaired B and T cell development. For example, SCID mice lack Thy-1
+
 
dendritic epidermal cells (Nixon-Fulton et al., 1987), which may play a role in intradermal 
infections of mice with VACV.  
One way around this difficult in vivo problem is the use of viral antagonists of the 
sensor. After identification of DNA-PK as a DNA sensor, the role of C16 in DNA sensing 
was investigated since Ku was initially studied and proposed as a DNA sensor due to its 
interaction with C16. Ku was found to bind to C16 via a cell line-based over-expression and 
proteomics-based system and was subsequently confirmed in the context of virus infection.  
It was found that C16 was able to inhibit DNA, but not RNA, sensing and that this 
inhibition was likely due to its interaction with Ku since the absence of Ku lead to the loss of 
the inhibitory function of C16. C16 appeared to inhibit the binding of Ku to DNA. The use of 
biotinylated DNA pull-downs demonstrated that the presence of C16 reduced the amount of 
Ku binding to DNA, and it is likely that through this mechanism C16 exerts its effects on 
DNA sensing. This can also explain the observation that C16 does not bind to DNA-PKcs, 
since the recruitment of DNA-PKcs by Ku is dependent on its interaction with DNA (Lehman 
et al., 2008).  
It is likely that C16 has evolved as a viral countermeasure to DNA detection by DNA-
PK, and as such the loss of C16 contributes to the attenuation of the virus in vivo. The role of 
C16 in vivo has been described previously (Fahy et al., 2008), and data in the present study 
add to the findings of this report. During intranasal VACV infection with wild-type, vC16, 
or revertant control viruses, it was found that infection with vC16 caused enhanced 
production of the chemokines Cxcl10, Ccl5 and the cytokine Il-6. Given the chemoattractive 
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properties of Cxcl10 and Ccl5, this is consistent with earlier findings that infection with 
vC16 lead to enhanced recruitment of leukocytes to lungs during infection. This effect was 
particularly noticeable early in the course of infection and by day 3 the absence of C16 had 
no statistically significant effect on the production of Cxcl10 or Il-6 in BAL fluid, although 
the trend remained, suggesting that C16 modulation of the innate immune response affects 
principally the initial stages of infection, in agreement with the hypothesis that DNA-PK acts 
as a frontline DNA sensor.  
Whilst there have been multiple DNA sensors proposed recently, only AIM2 so far 
has been shown to biologically relevant in vivo (Fernandes-Alnemri et al., 2010; Rathinam et 
al., 2010). Therefore, the finding that C16 affects the production cytokines and chemokines in 
vivo provides the first, albeit indirect, example of a DNA sensor being important for the 
induction of IRF-3-mediated innate immune signalling in vivo, and the fact that VACV has 
evolved an inhibitor of this DNA sensor also adds significant support to the hypothesis that 
DNA-PK acts as a DNA sensor in vivo. This represents a major advance in the understanding 
of induction of immune responses against VACV and possibly other pathogens. 
Together, this work has identified a novel DNA sensor responsible for the detection of 
cytoplasmic DNA in fibroblasts and has also characterised a viral inhibitor of this PRR. 
These findings contribute towards to an enhanced understanding of the immune response to 
ectopic DNA. 
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Chapter 4: VACV and Hypoxia-Inducible 
Factor (HIF) 
 
4.1. The N-terminal half of C16 is predicted to have a PHD2-like 
fold 
 
Analysis of the primary amino-acid sequence indicated that this protein has no 
identifiable homology to known cellular proteins other than in the final ten residues which 
show homology to icIL1-ra (Fahy 2008, Kluczyk 2002), and there is no structure of C16 
available. Therefore, in an attempt to learn more about the potential three-dimensional 
structure of C16, sequence-structure homology analysis was carried out using the FUGUE 
software (Shi et al., 2001). 
The first 205 amino acid residues of C16 were subjected to a sequence-structure 
homology recognition analysis using the FUGUE software (Shi et al., 2001). Notably, when 
the entire C16 sequence was used, FUGUE returned no positive matches. FUGUE takes a 
given query sequence and scans the HOMSTRAD database of structure profiles for potential 
matches. The summation of environment-specific substitution tables and structure-dependent 
gap penalties for each amino acid alignment can be used to generate a compatibility score, 
indicating the accuracy of each prediction. The homology modelling software MODELLER 
(Sali et al., 1995) was used to create 30 potential models of this domain. The model with the 
lowest energy and fewest spatial violations was selected as the most accurate representation 
of this domain. Three-dimensional structure visualization and image generation was carried 
out using Pymol software (DeLano, 2002) (Figure 4.2). 
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Rank Hit Species z-score 
1 Prolyl-4-Hydroxylase Shewanella Baltica 9.26 
2 Prolyl-4-Hydroxylase Chlamydia Reinhardtii 8.84 
3 Egln-1/PHD2 Homo Sapiens 5.14 
Table 4.1 Structural predictions of the N-terminal half of C16. The N-terminal 205 amino 
acids of C16 were uploaded to the FUGUE structural prediction program 
(http://tardis.nibio.go.jp/fugue/) and the HOMSTRAD database was used to find structural 
predictions. The Z-score represents a confidence rating, with >4 meaning ‘likely’ (90% 
confidence) and >6 meaning ‘very likely’ (95% confidence) >8 meaning ‘certain’ (99% 
confidence). 
 
Uploading of the N-terminal half of C16 to the FUGUE structural prediction program 
yielded several strong hits from a family of prolyl-4-hydroxylases, with the prolyl-4-
hydroxylases from Shewanella baltica and Chlamydia reinhardtii having the highest z-scores 
and Homo sapiens Egln-1/PHD2 having the third highest z-score. Similar analysis of the C-
terminal region of C16 yielded no predicted hits and, as such, structural information of this 
region of the protein remains unavailable. Alignment of the primary sequences of C16 
residues 1 - 205 and the sequence of human PHD2 corresponding to the C-terminal region, 
consisting of amino acids 181-426, of this protein whose structure has been solved 
(McDonough et al., 2006) (Fig 4.1) indicated that the overall secondary structure  is 
conserved although the first two N-terminal -helices of the known PHD2 structure are 
absent in C16. Overall this analysis provided a strong indication that the N-terminal region of 
C16 may have a three-dimensional structure similar to that of this large family of enzymes. 
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Figure 4.1. JOY alignment of C16 and PHD2. Primary amino acid sequence alignment 
between C16 and PHD2 (PDB code: 2g19) as generated by  FUGUE. Letters in red 
correspond to predicted alpha-helices and are denoted with ‘a’ underneath the corresponding 
amino acids. Blue letters correspond to beta-sheets and are denoted with ‘b’ beneath the 
corresponding amino acids. Maroon letters correspond to a predicted 310 helix and are 
denoted with a ‘3’ beneath the corresponding amino acids. 
 
 Using this sequence alignment it was possible to generate a structure prediction for 
corresponding the region of C16 using the Modeller software (Sali et al., 1995). This analysis 
led to a predicted structure of C16 based upon the known structure of PHD2 (Fig 4.2). The 
structures show the typical double stranded  helix fold of this enzyme family, although the 
C16 structure is missing the first two alpha-helices the remainder of structural features of the 
PHD2 fold predicted to be conserved in the C16 model. 
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Figure 4.2. Structural prediction of C16 based on PHD2 using modeller. The left panel 
shows the predicted structure of residues 1 - 205 of C16 based on the solved structure of 
amino acids 181-426 of PHD2 (right panel). 
  
The C-terminal structural domain has been shown to be the site responsible for the 
interaction with HIF-1 (Chowdhury et al., 2009) and is indicated  with ‘HBS’ in Figure 4.2. 
This structural domain is conserved between the modelled C16 structure and PHD2, however 
key catalytic residues of PHD2 (His 313, Asp 315 and His 372) required for binding Fe
2+
 
(McDonough et al., 2006) are not conserved in C16. Together, these data suggest that C16 
might adopt a general PHD2-like conformation, but it is not likely to be catalytically active.  
4.2. C16 binds PHD2 
 
Using an unbiased proteomics approach, C16 was found to bind PHD2 as well as the 
Ku complex (see section 3.1.2). The interaction with PHD2 was particularly interesting given 
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that the N-terminal part of C16 is predicted to have a PHD2-like fold. However, independent 
evidence was needed to confirm the mass spectrometry data, and this was obtained by 
immunoblotting with PHD2 specific antibodies (Figure 4.3).  
 
Figure 4.3. Confirmation of C16 binding partners using immunoblotting. Ten flasks of each of 
the indicated cell lines were grown and expression of either C16 or icIL-1Ra was induced by 
the addition of tetracycline for 24 h. Protein complexes were then purified by tandem affinity 
protein purification using STREP and FLAG beads and the final eluates were resolved by 
SDS-PAGE and immunoblotted with the antibodies against the indicated proteins. Molecular 
mass markers are indicated in kDa. 
 
Immunoblotting of the final elutions from the TAP procedure with the indicated 
antibodies showed that, as well as a band of approximately 70 kDa, which was recognised 
with the anti-Ku70 antibody, there was a band of approximately 50 kDa which was 
recognised by an anti-PHD2 antibody (Figure 4.3). This confirmed the mass spectrometric 
analysis that identified PHD2 as a binding partner of C16. Importantly, neither Ku70 nor 
PHD2 co-precipitated with a TAP-tagged icIL-1Ra, indicating that the co-precipitation of 
these molecules with C16 was neither due to non-specific binding to beads nor due to 
nonspecific binding to the TAP-tag. 
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As was the case with the C16-Ku interaction, the biological relevance of C16 binding 
PHD2 was not immediately obvious. 
  
4.3.  PHD2 and hypoxia 
  
 PHD2 is an approximately 50-kDa prolyl-hydroxylase enzyme best characterised for 
its role in the hydroxylation of HIF-1 (Bruick and McKnight, 2001).  
 The ability of cells to respond to hypoxia (low oxygen concentration) is conferred by 
a system which culminates in the activation of HIFs 1 and 2, though HIF-1 is the better 
studied to date. HIF-1 is composed of a regulatory subunit (HIF-1) and a constitutive beta 
subunit (HIF-1) (Wang et al., 1995). Under normoxic conditions, HIF-1 is constitutively 
degraded, meaning that the hypoxic transcriptional program consisting of genes such as 
vascular endothelium derived growth factor (VEGF), glucose transporter-1 (GLUT1) and 
erythropoietin (EPO) is not active. This hydroxylation is achieved by a system consisting of 
prolyl- and asparaginyl-hydroxylases  and an E3 ubiquitin ligase, Von Hippel-Lindau (VHL) 
and has been extensively reviewed (Fong and Takeda, 2008; Kaelin and Ratcliffe, 2008; 
Walmsley et al., 2008).  
 Briefly, prolyl-hydroxylases (PHDs) (Bruick and McKnight, 2001; Masson et al., 
2001; Yu et al., 2001b; Yu et al., 2001a), mainly PHD2 (Berra et al., 2003) and an 
asparaginyl-hydroxylase (Lando et al., 2002), factor inhibiting HIF (FIH), use molecular 
oxygen as a substrate to hydroxylate HIF-1 on specific proline and asparagine residues. 
This hydroxylation leads to the binding of VHL which polyubiquitinates HIF-1 resulting in 
its proteasomal degradation (Ivan et al., 2001; Jaakkola et al., 2001; Yu et al., 2001a). When 
the oxygen concentration falls, this process can no longer occur and HIF-1 translocates to 
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the nucleus, where it associates with HIF-1 to form the transcription factor HIF-1 (Wang et 
al., 1995). HIF-1 activates a hypoxic transcriptional programme whereby genes containing a 
HIF-response element (HRE) in their promoter are transcribed (Wenger, 2002). The HIF- 
pathway is illustrated in Figure 4.4. 
 
 
Figure 4.4. Illustration of hypoxic signalling. In the presence of molecular oxygen, PHD2 
hydroxylates HIF-1, which allows for interaction with the E3 ubiquitin ligase Von-Hippel 
Lindau (VHL), resulting in proteasomal degradation. In the absence of molecular oxygen 
(hypoxia), PHD2 can no longer hydroxylate HIF-1, which results in the nuclear 
translocation of HIF-1, upon which the transcription factor HIF-1 is formed by the 
interaction of HIF-1 and HIF-1. HIF-1 binds to the HIF-response element (HRE) in the 
promoters of hypoxia-related genes. 
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The finding that C16 bound to PHD2 was surprising given the work showing a prolyl-
hydroxylase domain-like fold prediction preceding the discovery. PHDs have not been shown 
previously to dimerise or oligomerise, although crystallographically PHD2 has been shown to 
homotrimerise (McDonough et al., 2006). Since PHD2 has been described principally 
hitherto as an oxygen sensor and in the degradation of HIF, the state of HIF-1in cells 
infected with VACV was investigated. 
4.4. VACV infection stabilises HIF-1
 
                     
Figure 4.3 VACV infection leads to HIF-1stabilisation. HeLa cells were either mock-
infected (NI), treated with 1 mM dimethyloxalylglycine (DMOG) or infected with VACV 
strain WR at 1 p.f.u. / cell. Cell lysates were prepared 16 h later and proteins were resolved 
by SDS-PAGE and analysed by immunoblotting with the indicated antibodies. The positions 
of molecular mass markers are shown on the left hand side. 
To assess the state of hypoxic signalling within VACV-infected cells, HeLa cells 
were infected with VACV for 16 h at 1 p.f.u per cell and cell lysates were immunoblotted 
with anti-HIF-1 antibody (Figure 4.3). In the non-infected cells, no band was detected with 
the anti-HIF-1 antibody, consistent with its well documented degradation under normoxic 
conditions. The addition of DMOG, a pan-hydroxylase inhibitor, induced the stabilisation of 
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the 120-kDa HIF-1as expected. Interestingly, infection with VACV strain WR also 
induced the stabilisation of HIF-1 suggesting that hypoxic signalling within VACV-infected 
cells might be activated.This is the first demonstration of the stabilisation of HIF-1during a 
poxvirus infection.  
HIF-1 stabilisation has been demonstrated during infection with other pathogens, 
such as bacteria and parasites (Nizet and Johnson, 2009) and other viruses including 
respiratory syncitial virus (RSV) (Kilani et al., 2004), vesicular stomatitis virus (VSV) 
(Hwang et al., 2006), hepatitis B virus (HBV) (Yoo et al., 2003), hepatitis C virus (HCV) 
(Ripoli et al., 2009), human papilloma virus (HPV) type 16 (Lu et al., 2007; Tang et al., 
2007; Nakamura et al., 2009; Bodily et al., 2010), and human herpesvirus 8 (Carroll et al., 
2006; Cai et al., 2007). Importantly, the stabilisation of HIF-1during viral infection is 
without hypoxia, i.e. the hypoxic signalling is modulated rather than there being a drop in O2 
concentration. This suggests that HIF-1stabilisation is a common feature of infection with 
viruses. 
To assess whether HIF-1 stabilisation was accompanied by transcriptional activation 
of HIF-1-responsive genes, RNA was extracted from cells treated as before and analysed by 
qRT-PCR (Figure 4.4). 
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Figure 4.4. qRT-PCR analysis of-VEGF and GLUT1 in VACV infected cells. HeLa cells 
were infected with VACV strain WR at 2 p.f.u. / cell for 16 h. RNA was extracted from, 
these cells and the levels of mRNA for vascular endothelium derived growth factor (VEGF) 
and GLUT-1 were determined by qRT-PCR. mRNA induction was calculated relative to the 
glyceraldehyde phosphate dehydrogenase (GAPDH) gene. Error bars +/- SEM, ** p<0.01, * 
p<0.05 
 
 Intriguingly, infection with VACV lead to the statistically significant transcriptional 
upregulation of the hypoxia-related genes VEGF and GLUT1 (Figure 4.4). Therefore, VACV 
infection is not only inducing stabilisation of HIF-1 but HIF-1dependent gene 
transcription. Additionally, HIF-1 nuclear translocation has now been shown in our 
laboratory by immunofluorescent staining of HIF-1during VACV infection (Stuart Ember, 
unpublished data).  
Whilst VACV infection induces HIF-1 stabilisation, the factors involved in the 
stabilisation needed to be determined. A plausible hypothesis was that the interaction of C16 
160 
 
with PHD2 inhibits PHD2 activity leading to HIF-1 stabilisation. This hypothesis was tested 
next.  
4.5.  C16 induces hypoxic gene up-regulation  
 
 
 
Figure 4.5. C16 can activate hypoxic signalling, and this is independent of Ku. WT and 
Xrcc5
-/-
 MEFs were transfected with 100 ng of either pcDNA4/TO (Empty vector- EV) or 
pcDNA4/TO-C16 (C16) along with 100 ng HRE-luciferase and 10 ng TK-Renilla luciferase 
(Table 2.1) and left to incubate for 24 h. Cells were then lysed with passive lysis buffer and 
luminescence was measured. Fold-inductions are relative to empty vector. Error bars +/- 
SEM, * p<0.05. 
 
 To assess whether C16 altered HIF-1stability, a plasmid encoding luciferase (Luc) 
driven from a Hypoxia response element (HRE-Luc) was co-transfected into cells with either 
empty plasmid vector control or the same plasmid expressing C16 (Figure 4.5). In WT MEFs 
C16 induced a roughly 6-fold stimulation of HRE-Luc, indicating that C16 promotes HIF-1-
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dependent transcription. Therefore C16 alone, is actively promoting hypoxic signalling, 
possibly via interacting with PHD2.  
Interestingly, this effect was also noted in Xrcc5
-/-
 MEFs, indicating that the effect of 
C16 on hypoxic signalling is mechanistically distinct from its effects on DNA-sensing 
(Figure 4.5). As C16 promotes HRE-Luc activity, it seemed likely that PHD2 is inhibited by 
C16 and so HIF1- may be stabilised due to PHD2 inhibition.  
 
Figure 4.6. C16 can activate hypoxic signalling. HeLa cells were transfected with 1 g/ml 
of either pcDNA4/TO (Empty vector- EV) or pcDNA4/TO-C16 (C16) for 24 h. RNA was 
extracted and the amount of VEGF mRNA was determined by qRT-PCR with the amount of 
18S rRNA serving as a control. Error bars +/- SEM, * p<0.05 
 
 Concurrent with the observation that C16 activates HRE-Luc activity, it was observed 
that C16 activates expression of a HIF-1 responsive gene, VEGF (Figure 4.6). Cells 
transfected with C16 induced approximately 30% more VEGF mRNA compared with empty 
vector control-transfected cells. Combined, these data suggest that C16 can induce the 
transcription of hypoxia-related genes. 
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Figure 4.7. C16 can activate hypoxic signalling. HeLa cells in a 96- well plate were 
transfected with the indicated mass of pcDNA4/TO-C16 (C16) per well for 24 h. VEGF 
ELISA was performed on supernatants. NS, non-stimulated. Error bars +/- SEM, *** 
p<0.001 
 
 To assess whether the effect of C16 on hypoxic gene induction could also be seen at 
the protein level, the amount of VEGF in the culture medium of cells expressing C16 was 
measured by ELISA (Figure 4.7). Cells transfected with increasing amounts of a plasmid 
encoding C16 produced a dose-dependent, significantly-higher amount of VEGF. This 
indicates that C16 has an effect on hypoxic signalling at the transcriptional level that can also 
be observed at the protein level. 
 Having addressed the effects of C16 on hypoxic signalling, the role of PHD2 in this 
process was assessed next using PHD1/2/3
-/- 
MEFs (Figure 4.8). 
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Figure 4.8. C16 can activate hypoxic signalling, and this is dependent on PHDs and 
independent of Ku. WT, two individual clones of PHD1/2/3
-/-
 (all 3 hypoxia-related PHD 
molecules knocked out) and Xrcc5
-/-
 MEFs were transfected with 100 ng of either 
pcDNA4/TO (Empty vector- EV), pcDNA4/TO-C16 (C16), pcDNA4/TO-frame shifted C16 
(fsC16) or pcDNA3.1-PHD2 (PHD2) along with 100 ng HRE-Luciferase and 10 ng TK-
Renilla luciferase and incubated for 24 h. Cells were then lysed with passive lysis buffer and 
luminescence was measured. Fold stimulations for each cell type are relative to empty vector. 
Error bars +/- SEM, * p<0.05, *** p<0.001 
 
 As noted previously, in wild-type MEFs C16 enhanced hypoxic signalling, as 
indicated by increased luminescence in an HRE-Luciferase assay. In contrast, over-
expression of PHD2 has an inhibitory effect, compared to the empty vector control (Figure 
4.8). This suggests an antagonistic relationship between the two molecules. In MEFs with all 
three hypoxia-related PHD genes deleted, C16 no longer has an effect on HRE-Luc, whereas 
over-expression of PHD2 maintains an inhibitory effect on hypoxic signalling. A plasmid 
encoding the C16 gene in which the translational initiation codon was mutated so that the 
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protein could not be expressed (frame-shifted C16) also has no effect on HRE driven 
luminescence, confirming that C16 protein, and not mRNA is responsible for this effect.  
 The fact that C16 does not have a hypoxia-enhancing effect in the absence of PHD 
molecules suggests that C16 requires the presence of at least PHD2 to enhance hypoxic 
signalling above the basal level. This result also confirms that C16 does not interact with the 
luciferase protein to enhance luminescence.  
 
4.6. Potential additional role of PHDs in innate immunity 
 
 Whilst the effect of C16 on hypoxic signalling is reproducible, there has been 
increasing attention on non-hypoxia related functions of PHD molecules (Kaelin and 
Ratcliffe, 2008). A recent study provided evidence that PHD1 negatively-regulated 
IKKunder normoxic conditions, and that this negative effect was alleviated under hypoxic 
conditions to potentiate NF-B signalling (Cummins et al., 2006). Another study reported a 
different mechanism for activation of NF-B by hypoxia involving calcium/calmodulin 
kinase (CaMK2)- dependent activation of TAK1 (Culver et al., 2010).  
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Figure 4.9. PHD1/2/3
-/-
 MEFs are deficient in responses to poly (I:C) and Ifn. WT or 
PHD1/2/3
-/- 
MEFs were transfected with 5 g/ml poly (I:C) or treated with Ifn- (2000 
U/ml). After 24 h, supernatants were taken and levels of IL-6 and CXCL10 were assessed by 
ELISA. Error bars +/- SEM, *p<0.05 ** p<0.01 ***p<0.001 
  
 To assess any potential role for PHD molecules in innate immune signalling, a variety 
of different innate immune ligands were tested on WT and PHD1/2/3
-/-
 MEFs. Intriguingly, 
PHD1/2/3
-/-
 MEFs had decreased production of both Cxcl10 and Il-6 following stimulation 
with both Ifn and transfection with poly (I:C). These results suggest either a potential role of 
one PHD molecule in the ISRE pathway (since the ISRE pathway is a common transduction 
network activated with both poly (I:C) transfection and Ifn- treatment) or alternatively that 
multiple PHDs might have a role in various innate immune signalling networks. Notably, 
C16 has previously been demonstrated to inhibit the ISRE pathway within our laboratory 
(Aodhnait Fahy, unpublished data). 
 Whilst these preliminary data are intriguing, it should be noted here that a stimulus 
evoking an equal activation of innate immune signalling across the wild-type and knockout 
MEFs has not been found, perhaps suggesting a general defect in innate immune signalling 
within these cells in our laboratory, which might be independent of a bona fide in vivo role. 
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4.7. Summary – C16 and Hypoxia 
 
 PHD2 was identified as a binding partner of C16 using an unbiased approach of TAP-
tagging and identification by mass spectrometry. Interestingly, the N-terminal half of C16 
was also predicted to adopt a PHD2-like conformation using unbiased structural prediction 
programs. C16 was also found to induce hypoxic signalling by using a hypoxia-luciferase 
reporter assay approach, and furthermore C16 was found to induce the production of VEGF 
after transfection into HeLa cells. For the first time, VACV was shown to induce the 
stabilisation of HIF-1 and this stabilisation also coincided with the transcriptional induction 
of HIF1-dependent genes including VEGF and GLUT1. 
HIF-1stabilisation during the course of viral infection has had numerous 
explanations. In the case of RSV, HIF-1stabilisation is reported to be due to RSV-mediated 
nitric oxide release as blockade of nitric oxide inhibited RSV-mediated HIF-1stabilisation 
(Kilani et al, 2004) and as such is thought to represent a host-response to a noxious stimulus. 
A report regarding VSV-mediated HIF-1 stabilisation demonstrated that HIF-1 enhanced 
antiviral innate immune responses such as the transcription of IFN, and suggested that HIF-
1  stabilisation was part of a host defence against viruses (Hwang et al, 2006). In the case of 
HBV, HCV, and HPV-type 16, HIF-1stabilisation has been investigated in the context of 
oncogenesis, where HIF-1stabilisation is promoted by virally encoded proteins leading to 
neovascularisation and tumour growth, perhaps explaining the propensity of these viruses to 
cause cancer, but few insights into the reasons why viruses might promote hypoxic signalling 
in the first place are offered by the literature.  
Hypoxia and hypoxic signalling have been shown to have an increasingly important 
role in inflammation (Nizet and Johnson, 2009), and literature in this field is growing rapidly. 
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Hypoxia has largely been demonstrated to enhance inflammatory responses, such as TNF-
mediated NF-B activation (Cummins et al., 2006; Culver et al., 2010). In addition, an 
interdependent link between HIF-1 and NF-B has been described (Rius et al., 2008), 
showing that HIF-1 mRNA transcription is dependent on NF-B signalling. It has also been 
shown that hypoxia increases the expression and signalling potential of TLRs 2 and 6 
(Kuhlicke et al., 2007). Furthermore, myeloid cells such as neutrophils have HIF-dependent 
ways of functioning in oxygen-depleted environments (Cramer et al., 2003), and HIF-1 has 
been shown to be important for phagocyte clearance of bacteria (Cramer et al., 2003; 
Peyssonnaux et al., 2005). HIF-1 activation in neutrophils has also been shown to enhance 
survival via NF-B activation (Walmsley et al., 2005).  
Together, the majority of the available literature suggests that hypoxia is a feature of 
inflammation, and the two systems cooperate to tackle infection: NF-B upregulates Hif1a 
mRNA (Rius et al., 2008), and hypoxia potentiates NF-B signalling (Cummins et al., 2006; 
Culver et al., 2010). The question, then, as to why VACV encodes a protein which seems to 
be enhancing hypoxic signalling by inhibiting PHD2 is pertinent and merits further attention.  
One important point is the distinction between hypoxia and HIF-1 activity. Studies 
demonstrating enhancement of NF-B signalling by hypoxia show that it is independent of 
HIF-1 activity (Cummins et al, 2006), and it is the low oxygen concentration which enhances 
the NF-B signalling. There has not been a prominent example of a virus inducing hypoxia, 
rather virus infection often induces HIF-1 activity instead. 
Two findings might support a potentially advantageous activation of hypoxia by 
VACV. Firstly, HIF-1 stabilisation leads to the transcription of EPO. The HRE-luciferase 
plasmid used in this study was in fact based on the EPO promoter, containing several HRE 
168 
 
sites, driving the expression of luciferase protein, so C16 is expected to enhance the 
transcription of EPO. EPO was recently reported to act on macrophages to suppress NF-B 
pathways (Nairz et al., 2011), though the exact mechanism for this is not yet established. 
 A second hypoxia-upregulated gene, netrin-1, was also found to be upregulated in 
epithelial cells when HIF-activity was induced. Netrin-1 was also found to attenuate 
inflammation by inhibiting trans-epithelial migration of neutrophils by binding A2B 
adenosine receptors on neutrophils (Rosenberger et al., 2009). These studies combined 
illustrate the HIF-1 activity, and not hypoxia per se, upregulate anti-inflammatory molecules 
which could benefit VACV during the course of infection.    
Secondly, HIF-1 stabilisation has a negative effect on T cell microbicidal activity. 
HIF-1 stabilisation was shown to negatively regulate T cell receptor signalling (Neumann et 
al., 2005), demonstrating that HIF-1 activity is not universally pro-inflammatory. 
Additionally, increased production of HIF-1 induces a CD4+ T cell polarisation shift from a 
T helper (Th)-1 to Th2 type, decreasing IFN- production by T cells (Ben-Shoshan et al., 
2009), however the exact mechanism of this is unclear. Specifically, it is unclear whether or 
not it is T cell-intrinsic expression of HIF-1 (i.e. whether it is the T cell itself in which HIF-
1 is active) that leads to this phenotype, or other cell types producing hypoxia-related 
cytokines results in a T cell shift. Furthermore, T cell intrinsic HIF-1 activation promotes 
the differentiation of regulatory T cells (Ben-Shoshan et al., 2008).  
Together, the literature suggests that hypoxia plays a dual role in inflammation. 
Whilst myeloid cell-intrinsic hypoxia, i.e. HIF-1 stabilisation and HIF-1 transcriptional 
activity within myeloid cells appears to promote activation and phagocytosis, HIF-1 
activation in other tissues conversely leads to the production of EPO and netrin-1, which 
results in dampening of myeloid cell NF-B activation. On the other hand, hypoxia and HIF-
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1 activation appears to attenuate lymphoid cell-mediated inflammation. Whether C16 is 
modulating any of these effects merits further attention. 
C16-mediated inhibition of PHD2 might also be primarily independent of 
inflammatory effects of hypoxia. PHDs have been shown to have targets other than HIF-1 
for prolyl-hydroxylation (Kaelin and Ratcliffe, 2008), and it might be one of these other 
targets that is the prime target for C16-mediated inhibition, and perhaps hypoxic signalling is 
a by-product of inhibiting PHD2 for these other functions. 
A third possible reason for modulation of hypoxic signalling might be that activation 
of a hypoxic signalling programme, such as genes involved in glycolysis, might favour the 
metabolic demands of a cell for producing virus. Cell lines constitutively expressing HCV 
proteins were shown to induce the upregulation of hypoxia-related glycolytic genes, and this 
resulted in an 80% increase in cellular ATP levels (Ripoli et al., 2009). Preliminary data 
within our laboratory suggest that VACV growth is equivalent in WT and PHD1/2/3-/- MEFs 
(data not shown), suggesting that hypoxic signalling does not affect VACV production, 
though these data are preliminary and the role of hypoxia in virus production has not been 
fully assessed. However, another study regarding the usage of VACV in oncolytic therapy for 
hypoxic tumours has reported that VACV replicates equally well in hypoxic or normoxic 
conditions, and VACV protein expression was not affected either (Hiley et al., 2010). 
Furthermore, deletion of C16 did not appear to affect virus growth in tissue culture, though a 
slightly reduced plaque size was observed (Fahy et al., 2008), although in vivo models would 
be better suited to address this. 
Whilst the role of the C16-PHD2 interaction in VACV infection is yet to be fully 
established, the demonstration that VACV induces hypoxic signalling and appears to actively 
promote this via encoding a PHD2-like molecule represents a novel finding. Modulation of 
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hypoxic signalling in various physiological or pathological conditions is attracting attention, 
and small molecules based on a C16-PHD2 interaction could potentially lead to novel 
therapeutic approaches to various conditions in which hypoxia may play a role in disease 
(Fraisl et al., 2009). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
171 
 
Chapter 5: Discussion and future work 
5.1. DNA-sensing 
 
5.1.1. Redundancy in DNA sensing molecules 
 
 Broadly speaking, there are two major mechanisms of intracellular ectopic DNA-
mediated (hereafter termed DNA-mediated) activation of the innate immune system; the first 
is the activation of the inflammasome and the second is the activation of IRF-3 and NF-B. 
Activation of the inflammasome by VACV is thought to occur via AIM2 (Rathinam et al., 
2010) and NALP3 (Delaloye et al., 2009) in macrophages. In the case of AIM2, there is in 
vivo evidence that the absence of AIM2 leads to diminished production of IL-1 and IL-18 
(Rathinam et al., 2010). However, despite a large number of molecules shown to activate 
IRF-3 and NF-B in response to DNA, including DAI (Takaoka et al., 2007), RNA 
polymerase III (Ablasser et al., 2009; Chiu et al., 2009), LRRFIP1 (Yang et al., 2010), DHX9 
(Kim et al., 2010) and IFI16 (Unterholzner et al., 2010), the roles of these molecules, if any, 
in vivo have not been established.  
 Data presented in this thesis support the conclusion that DNA-PK is important for the 
full activation of IRF-3-dependent cytokines and chemokines in response to DNA and VACV 
in vitro. Furthermore, the absence of an inhibitor of this complex, C16, leads to an enhanced 
production of the same cytokines and chemokines during VACV infection in vivo, suggesting 
that DNA-PK plays a role in the immune response to poxviruses. However, the role of the 
other DNA sensors is of interest. For example, many DNA sensors have so far only been 
reported in certain cell types such as macrophages in the case of LRRFIP1 (Yang et al., 
2010), and plasmacytoid dendritic cells in the case of DHX9 (Kim et al., 2010). Furthermore, 
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RNA-polymerase III is not thought to act to upregulate IFN in fibroblastic cells because 
MAVS is not required for the upregulation of this molecules in response to poly (dA:dT) 
DNA (Kumar et al., 2006; Sun et al., 2006). It may be the case that different cell types 
employ different sensing mechanisms to elicit similar responses to DNA. 
In addition, the putative DNA sensor DAI is not detectable in resting cells, but is 
upregulated substantially in cells treated with type I IFN (Takaoka et al., 2007; DeFilippis et 
al., 2010), suggesting temporal differences in DNA sensing mechanisms. Even further 
complexity might result from the nuclear/cytoplasmic divide of DNA sensing mechanisms, as 
AIM2 responds to cytoplasmic, but not nuclear pathogens to activate an inflammasome 
(Rathinam et al., 2010), whereas IFI16 is shown to activate an inflammasome in response to 
the nuclear pathogen KSHV (Kerur et al., 2011). 
These reports suggest a great deal of complexity in the cell-type, temporal and cell-
fraction specific mechanisms of DNA sensing (Table 1.1). In addition, data from this thesis 
show that DNA-PK is expressed in fibroblasts but not macrophages and that it is expressed at 
constitutively high levels. The cellular location in which DNA-PK acts as a DNA sensor has 
not been established, though investigation of which viruses activate IRF-3 via DNA-PK-
dependent mechanisms may shed some light on this aspect of DNA-PK-mediated activation 
of innate immunity. 
IFI16 & DNA-PK 
 
 Whilst data presented in this thesis are consistent with a key role for DNA-PK in 
DNA-mediated innate immune activation in MEFs, another study published recently has 
demonstrated a role for IFI16 in DNA sensing in MEFs (Unterholzner et al., 2010). There 
are, however, differences between these studies. Firstly, the DNA used to stimulate cells was 
different: in MEFs the DNA used to stimulate cells in the IFI16 study was 70-bp in length, 
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whereas DNA used in this study was either MVA genome via MVA infection or DNA at 
least 200-bp in length. Secondly, in primary MEFs, the absence of DNA-PKcs did not 
completely abrogate the induction of cytokines (Brian Ferguson, unpublished data), in 
contrast to transformed MEFs. Likewise, when IFI16 is knocked down in MEFs, some 
residual upregulation of Ifnb mRNA is detectable. This suggests that DNA-PK and IFI16 
might somehow cooperate in MEFs to achieve full activation of the DNA-mediated innate 
immune response, for example DNA-PK might enhance the binding of IFI16 to DNA, or 
IFI16 might bring into STING into proximity with DNA-PK as IFI16 is reported to interact 
with STING (Unterholzner et al., 2010). The characterisation of the differential roles these 
molecules play in vitro and in vivo requires further work.  
 
5.1.2.  Characterisation of DNA-PK-mediated DNA sensing in vivo 
 
 Given the SCID phenotype of DNA-PK-deficient mice, the characterisation of DNA-
PK-mediated innate immune activation by DNA is highly problematic. However, it will be 
necessary, given the redundancy in DNA sensing systems, to assess the role of DNA-PK in 
vivo.  
Our laboratory is now in possession of Prkdc
-/-
 mice and these are currently being 
bred with a view to performing in vivo experiments in the near future. Reconstitution of 
DNA-PKcs-deficient mice with wild-type bone marrow is one way of avoiding the problem 
of differing leukocyte populations presented by the SCID phenotype, but the role of DNA-
PKcs in DNA repair means that knockout mice would be exquisitely sensitive to the radio-
ablation of the bone marrow used during this procedure, perhaps resulting in anomalies such 
as enhanced pro-inflammatory cytokine production due to persistent DNA damage as 
reported previously (Rodier et al., 2009).  
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It is also possible that a conditional knockout mouse could be generated such that 
there is targeted deletion of DNA-PKcs or Ku in fibroblastic cells, this would allow for a 
more rigorous assessment of the contribution of DNA-PK in innate immune sensing of 
pathogens.  
Further work on the in vivo contributions of DNA-PK to viral innate immunity will 
occur within our laboratory, however the significance and relevance of various other DNA 
sensors have not yet been characterised. The roles of these different sensors in different cell 
types are not known, therefore a serious effort using various pathogens with different cell 
tropisms will be required to begin to unravel the relevance of certain DNA sensors occupying 
biological niches. Understanding the contributions of these DNA sensors to different 
pathogens will enhance our understanding of the innate immune response and is likely to 
become a focus of research in future years. 
 
5.1.3. N-terminal phosphorylation of IRF-3 by DNA-PK, the role of the 
kinase domain of DNA-PK 
 
 The N-terminal phosphorylation of IRF-3 by DNA-PK has been reported previously 
(Karpova et al., 2002). Activation of IRF-3 for transcriptional activity normally occurs at the 
C terminus (Fitzgerald et al., 2003; Sharma et al., 2003). However, preliminary data from our 
laboratory have shown that the kinase activity of DNA-PK is dispensable for the upregulation 
of Cxcl10 in response to DNA. This conclusion comes from two separate experiments: 
firstly, treatment with the DNA-PK kinase inhibitor, NU7026, created originally for 
enhancing radiotherapy by decreasing radiotherapy-induced DNA damage repair (Willmore 
et al., 2004), did not affect DNA sensing capacity (Brian Ferguson, unpublished data). 
Secondly, the use of MEFs from Bosma SCID mice, which have a point mutation ablating 
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DNA-PKcs kinase activity (Blunt et al., 1995; Blunt et al., 1996), also showed normal 
upregulation of Cxcl10 mRNA in response to stimulation with DNA (Brian Ferguson, 
unpublished data). However, the role, if any, of the kinase activity of DNA-PK in DNA 
sensing is of interest given the reported phosphorylation of IRF-3 by DNA-PK. 
 The question as to the signalling mechanism initiated by DNA-PK remains open. 
Given the preliminary data that the kinase domain of DNA-PK is dispensable for DNA-PK-
mediated innate immune activation by DNA, it is probable that DNA-PK provides a 
structural scaffold for the assembly of a complex which initiates the pathway leading to IRF-
3 activation. Study of this mechanism is key to a full understanding DNA-PK-mediated DNA 
sensing. 
 
5.1.4. Potential role for DNA-PK in and autoimmunity and detection of 
retroviruses  
 
Autoimmune conditions are characterised by immune responses against host 
molecules and tissues. These conditions are frequently associated with inflammation, and the 
causative factors of many autoimmune conditions are not yet understood, yet deregulation of 
immune signalling may lead to autoimmunity in some instances (Diamond, 2008). 
 TRex1, a cytosolic exonuclease, has been shown to be linked to Aicardi-Goutières 
syndrome (AGS) (Crow et al., 2006). AGS is characterised by early onset severe encephalitis, 
lymphocytosis in the cerebrospinal fluid and elevated type I IFN production (Stephenson, 
2008). TRex1 is now thought to be involved in the degradation of DNA, preventing cell-
intrinsic responses to cytoplasmic DNA (Stetson et al., 2008). In addition, mutations of 
TRex1 inhibiting the catalytic domain are associated with systemic lupus erythematosus 
(SLE), which is the prototypic systemic autoimmune condition characterised by 
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autoantibodies to DNA and is thought to be caused by inappropriate activation of the immune 
system by DNA, often following apoptosis (Rahman and Isenberg, 2008). Chilblain lupus is 
characterised by lesions at the extremities such as fingers, toes and ears. Mutations in TRex1 
impairing catalytic activity are linked to both regular and chilblain SLE (Lee-Kirsch et al., 
2007a; Lee-Kirsch et al., 2007b).  
The function of TRex1 is the cytoplasmic degradation of DNA, and failure of this 
process leads to intracellular accumulation of DNA and a subsequent innate immune 
response, including MEFs (Stetson et al., 2008). Therefore, it is possible that DNA-PK is also 
associated with the induction of this type I IFN response, and therefore might play a role in 
AGS.  
Along similar lines, mice lacking DNAse ii, another enzyme involved in the 
degradation of DNA have been shown recently to exhibit a severe autoinflammatory 
polyarthritis. Intracellular accumulation of undigested DNA in macrophages is thought to be 
responsible (Kawane et al., 2006) and this DNA activates an innate immune response 
dependent on IRF-3 and IRF-7 (Okabe et al., 2008).  
Collectively, there appears to be a role for DNA sensing in these conditions associated 
with the failure of DNA digestion. Furthermore, the role of DNA sensing in SLE is also 
coming under intense investigation (Kontaki and Boumpas, 2010). AIM2 was shown to be 
expressed at higher levels in a murine model of lupus, the BXSB mouse (Roberts et al., 
2009), and subsequent investigation of renal biopsies from patients with SLE-mediated 
nephritis have also been shown to have upregulated AIM2 (Kimkong et al., 2009). The exact 
role of AIM2 in SLE, if any, is unclear. However, because SLE is characterised by 
inappropriate immune responses to DNA, the role of DNA sensing in this disease should be 
investigated. Interestingly, a large proportion of patients with SLE and systemic sclerosis 
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have autoantibodies to Ku (Cavazzana et al., 2008), and interestingly another DNA sensor, 
RNA polymerase III is also the target of autoantibodies in systemic sclerosis (Cavazzana et 
al., 2009).  
There is increasing interest in the role of antiviral nucleic acid sensing and 
autoimmunity, since many autoimmune conditions are associated with an IFN signature. This 
subject has been reviewed recently (Stetson, 2009; Kontaki and Boumpas, 2010).  The 
answer to the question as to whether DNA-PK has a role in nucleic acid driven autoimmunity 
could be very interesting and knowledge of this role, if any, could open important therapeutic 
avenues. 
TRex1, in addition to the previously described role in Aicardi-Goutières syndrome, 
has also been shown to be important in innate immune activation following Human 
immunodeficiency virus (HIV) infection. It was reported that TRex1 bound to cytoplasmic 
HIV pro-viral DNA and digested it. However, in the absence of TRex1, the HIV DNA 
accumulated and this lead to an enhanced activation of IRF-3 and production of type I IFN 
(Yan et al., 2010). This suggests that HIV DNA is a PAMP involved in HIV infection and the 
study has lead to an enhanced knowledge regarding the innate immune detection of HIV. 
Whether DNA-PK is involved in the innate immune recognition of HIV remains to be 
determined, however DNA-PK is expressed in T cells as it has a critical role in V(D)J 
recombination, so therefore could be involved in the innate immune detection of HIV and 
other retroviruses such as human T cell leukaemia virus (HTLV)-1. HIV infects macrophages 
and CD4+ T cells, and data presented in this thesis suggest that DNA-PK is not expressed in 
macrophages.  
Extensive study elsewhere has demonstrated that DNA-PK is critical for the 
development of T cells, so proving a role for DNA-PK in HIV-mediated innate immune 
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activation would be technically difficult, but would merit further study given the profound 
impact this virus has worldwide. 
 
5.1.5. GAGA 
 
 The role of GAGA, if any, in the innate immune response to VACV is of great 
interest. Specifically, whether GAGA can enhance innate immune responses and increase 
potency of DNA vaccines in vivo should be given much further attention. Studies are 
underway within our laboratory to assess the role of GAGA during vaccination. It will also be 
interesting to study the role of GAGA in virus infection, and results from these studies may 
enhance understanding of poxvirus biology. Notably, GAGA is also present in strains of 
other DNA viruses, such as HSV-1, which might imply a broader role for GAGA in DNA 
viruses. 
5.1.6. Possible role for alternative IRF molecules in DNA-PK-mediated 
DNA sensing 
 
 During the writing of this thesis, a study was published reporting that Ku70 acts as a 
DNA sensor in HEK cells (Zhang et al., 2011). HEK cells have been reported to be 
unresponsive to DNA types other than poly (dA:dT) as evidenced by lack of production of 
type I IFN (Ablasser et al., 2009; Chiu et al., 2009), however this study shows a potent 
upregulation of type III IFN in response to non-poly (dA:dT) DNA which was dependent on 
Ku70, and also on IRF1 and IRF7. Whilst this study did not show a role for Ku80 or DNA-
PKcs in this system, it will be of interest to investigate the roles of IRF1 and IRF7 in the 
context of DNA-PK-mediated innate immune activation in other cell types, such as MEFs. 
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5.2. HIF and VACV 
 
 The role of hypoxic signalling in VACV infection remains uncharacterised. However, 
whilst data presented suggest that C16 is promoting HIF stabilisation, the timing of this 
response remains unclear. C16 is expressed early in infection (Assarsson et al., 2008; Fahy et 
al., 2008), yet the work regarding C16 and HIF stabilisation assessed the HIF activity after 
longer periods of infection. Assessment of the timing of HIF activity during VACV infection 
may help to guide future characterisation of the role of hypoxic signalling in virus infection. 
For instance, if HIF stabilisation occurs very late in infection, then it is perhaps unlikely that 
VACV is targeting this signalling pathway in order to induce the upregulation of EPO and 
netrin-1 as described in Section 4.6, because later on during the course of infection there is a 
severe impairment to the production of any new host proteins due to VACV infection. If HIF 
activity is only induced late, then VACV may instead be targeting PHD2 for some other as 
yet undefined function.  
 The use of the vC16 virus will help to further establish a role for C16 in hypoxic 
signalling. Preliminary data show that infection with vC16 induces less stabilisation of HIF-
1 compared with wild type virus (Stuart Ember, unpublished data) although this has yet to 
be assessed thoroughly. However, qRT-PCR studies with WR and vC16 could also be used 
to define a role for C16 in hypoxic signalling.  
 C4, a closely related VACV protein to C16, is also predicted to encode a PHD2-like 
protein and the role of C4, if any, in hypoxic signalling merits further attention. Preliminary 
work suggest that C16 and C4 both contribute to HIF-1stabilisation, and a double deletion 
virus (vC16C4) has been made within the laboratory and in vivo studies with this virus are 
underway. 
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 Recombinant C16 produced and purified from E. coli can also be used to assess 
PHD2 hydroxylase activity in vitro. To this end, collaboration has been established with a 
group based at Oxford University, and initial data are showing that C16 is inhibiting PHD2 
hydroxylase activity, consistent with work presented in this thesis (Christoph Loenarz, 
unpublished data). This assay will prove useful in confirming other biochemical and 
functional data regarding C16 and secondly might be used to assess mutants of C16 for their 
ability to impair PHD2 enzymatic function and further characterise the molecular mechanism 
of this inhibition. 
 
5.3. C16 
 
 C16, a highly conserved protein found in VACV and many other poxviruses, such as 
VARV, was shown previously to be a virulence factor in vivo (Fahy et al., 2008), however 
the mechanism of enhancing virulence was not understood. Two functions of C16 have been 
described in this thesis via the identification of binding partners and subsequent work. 
However, ascribing the in vivo phenotype (namely both the enhanced production of 
chemokines and cytokines and recruitment of leukocytes in vC16 infection relative to wild-
type virus) to the DNA sensing inhibition or HIF-1 stabilising functions of C16 will require 
further work.  
In order to distinguish the roles of C16, structural studies are ongoing with C16 in 
collaboration with two laboratories to examine the structure of C16 by crystallography, and 
studies of co-crystal structures of C16 with Ku or PHD2 are also being attempted. If a co-
structure with either of these molecules is obtained, it might be possible to generate mutant 
C16 molecules capable of performing one function (i.e. inhibition of DNA sensing or 
enhancing hypoxic signalling) but not the other. Generation of viruses lacking one of these 
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functions would help to establish the relative contributions of these roles of C16 to the in vivo 
phenotype observed. 
Many avenues of research have been opened up by the discovery of C16 binding 
partners, and this adds support to the continued research of host-pathogen interactions 
occurring within VACV infection. This study provides yet another example of how 
investigation of a virus, even a vaccine for an eliminated disease, can enhance the 
understanding of other fields of research.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
182 
 
Bibliography 
Ablasser, A., Bauernfeind, F., Hartmann, G., Latz, E., Fitzgerald, K.A. and Hornung, V. (2009) RIG-
I-dependent sensing of poly(dA:dT) through the induction of an RNA polymerase III-
transcribed RNA intermediate. Nat Immunol, 10, 1065-1072. 
Alcami, A. and Smith, G.L. (1992) A soluble receptor for interleukin-1 beta encoded by vaccinia 
virus: a novel mechanism of virus modulation of the host response to infection. Cell, 71, 153-
167. 
Alcami, A. and Smith, G.L. (1995) Vaccinia, cowpox, and camelpox viruses encode soluble gamma 
interferon receptors with novel broad species specificity. J Virol, 69, 4633-4639. 
Alcami, A. and Smith, G.L. (1996) A mechanism for the inhibition of fever by a virus. Proc Natl 
Acad Sci U S A, 93, 11029-11034. 
Alcami, A., Symons, J.A., Collins, P.D., Williams, T.J. and Smith, G.L. (1998) Blockade of 
chemokine activity by a soluble chemokine binding protein from vaccinia virus. J Immunol, 
160, 624-633. 
Alexopoulou, L., Holt, A.C., Medzhitov, R. and Flavell, R.A. (2001) Recognition of double-stranded 
RNA and activation of NF-kappaB by Toll-like receptor 3. Nature, 413, 732-738. 
Andrejeva, J., Childs, K.S., Young, D.F., Carlos, T.S., Stock, N., Goodbourn, S. and Randall, R.E. 
(2004) The V proteins of paramyxoviruses bind the IFN-inducible RNA helicase, mda-5, and 
inhibit its activation of the IFN-beta promoter. Proc Natl Acad Sci U S A, 101, 17264-17269. 
Ank, N. and Paludan, S.R. (2009) Type III IFNs: new layers of complexity in innate antiviral 
immunity. Biofactors, 35, 82-87. 
Antoine, G., Scheiflinger, F., Dorner, F. and Falkner, F.G. (1998) The complete genomic sequence of 
the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology, 244, 
365-396. 
Assarsson, E., Greenbaum, J.A., Sundstrom, M., Schaffer, L., Hammond, J.A., Pasquetto, V., Oseroff, 
C., Hendrickson, R.C., Lefkowitz, E.J., Tscharke, D.C., Sidney, J., Grey, H.M., Head, S.R., 
Peters, B. and Sette, A. (2008) Kinetic analysis of a complete poxvirus transcriptome reveals 
an immediate-early class of genes. Proc Natl Acad Sci U S A, 105, 2140-2145. 
Bacon, K., Baggiolini, M., Broxmeyer, H., Horuk, R., Lindley, I., Mantovani, A., Maysushima, K., 
Murphy, P., Nomiyama, H., Oppenheim, J., Rot, A., Schall, T., Tsang, M., Thorpe, R., Van 
Damme, J., Wadhwa, M., Yoshie, O., Zlotnik, A. and Zoon, K. (2002) Chemokine/chemokine 
receptor nomenclature. J Interferon Cytokine Res, 22, 1067-1068. 
Bahar, M.W., Kenyon, J.C., Putz, M.M., Abrescia, N.G., Pease, J.E., Wise, E.L., Stuart, D.I., Smith, 
G.L. and Grimes, J.M. (2008) Structure and function of A41, a vaccinia virus chemokine 
binding protein. PLoS Pathog, 4, e5. 
Bajszar, G., Wittek, R., Weir, J.P. and Moss, B. (1983) Vaccinia virus thymidine kinase and 
neighboring genes: mRNAs and polypeptides of wild-type virus and putative nonsense 
mutants. J Virol, 45, 62-72. 
Balachandran, S., Thomas, E. and Barber, G.N. (2004) A FADD-dependent innate immune 
mechanism in mammalian cells. Nature, 432, 401-405. 
Barbalat, R., Ewald, S.E., Mouchess, M.L. and Barton, G.M. (2011) Nucleic acid recognition by the 
innate immune system. Annu Rev Immunol, 29, 185-214. 
Barbalat, R., Lau, L., Locksley, R.M. and Barton, G.M. (2009) Toll-like receptor 2 on inflammatory 
monocytes induces type I interferon in response to viral but not bacterial ligands. Nat 
Immunol, 10, 1200-1207. 
Bartlett, N., Symons, J.A., Tscharke, D.C. and Smith, G.L. (2002) The vaccinia virus N1L protein is 
an intracellular homodimer that promotes virulence. J Gen Virol, 83, 1965-1976. 
Bartlett, N.W., Buttigieg, K., Kotenko, S.V. and Smith, G.L. (2005) Murine interferon lambdas (type 
III interferons) exhibit potent antiviral activity in vivo in a poxvirus infection model. J Gen 
Virol, 86, 1589-1596. 
Barton, G.M., Kagan, J.C. and Medzhitov, R. (2006) Intracellular localization of Toll-like receptor 9 
prevents recognition of self DNA but facilitates access to viral DNA. Nat Immunol, 7, 49-56. 
183 
 
Bauer, S., Kirschning, C.J., Hacker, H., Redecke, V., Hausmann, S., Akira, S., Wagner, H. and 
Lipford, G.B. (2001) Human TLR9 confers responsiveness to bacterial DNA via species-
specific CpG motif recognition. Proc Natl Acad Sci U S A, 98, 9237-9242. 
Beattie, E., Denzler, K.L., Tartaglia, J., Perkus, M.E., Paoletti, E. and Jacobs, B.L. (1995) Reversal of 
the interferon-sensitive phenotype of a vaccinia virus lacking E3L by expression of the 
reovirus S4 gene. J Virol, 69, 499-505. 
Beck, C.G., Studer, C., Zuber, J.F., Demange, B.J., Manning, U. and Urfer, R. (2001) The viral CC 
chemokine-binding protein vCCI inhibits monocyte chemoattractant protein-1 activity by 
masking its CCR2B-binding site. J Biol Chem, 276, 43270-43276. 
Ben-Shoshan, J., Afek, A., Maysel-Auslender, S., Barzelay, A., Rubinstein, A., Keren, G. and George, 
J. (2009) HIF-1alpha overexpression and experimental murine atherosclerosis. Arterioscler 
Thromb Vasc Biol, 29, 665-670. 
Ben-Shoshan, J., Maysel-Auslender, S., Mor, A., Keren, G. and George, J. (2008) Hypoxia controls 
CD4+CD25+ regulatory T-cell homeostasis via hypoxia-inducible factor-1alpha. Eur J 
Immunol, 38, 2412-2418. 
Berra, E., Benizri, E., Ginouves, A., Volmat, V., Roux, D. and Pouyssegur, J. (2003) HIF prolyl-
hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in 
normoxia. Embo J, 22, 4082-4090. 
Bhoj, V.G. and Chen, Z.J. (2009) Ubiquitylation in innate and adaptive immunity. Nature, 458, 430-
437. 
Blanchard, T.J., Alcami, A., Andrea, P. and Smith, G.L. (1998) Modified vaccinia virus Ankara 
undergoes limited replication in human cells and lacks several immunomodulatory proteins: 
implications for use as a human vaccine. J Gen Virol, 79 ( Pt 5), 1159-1167. 
Blunt, T., Finnie, N.J., Taccioli, G.E., Smith, G.C., Demengeot, J., Gottlieb, T.M., Mizuta, R., 
Varghese, A.J., Alt, F.W., Jeggo, P.A. and et al. (1995) Defective DNA-dependent protein 
kinase activity is linked to V(D)J recombination and DNA repair defects associated with the 
murine scid mutation. Cell, 80, 813-823. 
Blunt, T., Gell, D., Fox, M., Taccioli, G.E., Lehmann, A.R., Jackson, S.P. and Jeggo, P.A. (1996) 
Identification of a nonsense mutation in the carboxyl-terminal region of DNA-dependent 
protein kinase catalytic subunit in the scid mouse. Proc Natl Acad Sci U S A, 93, 10285-
10290. 
Bodily, J.M., Mehta, K.P. and Laimins, L.A. (2010) Human papillomavirus E7 enhances hypoxia-
inducible factor 1-mediated transcription by inhibiting binding of histone deacetylases. 
Cancer Res, 71, 1187-1195. 
Born, T.L., Morrison, L.A., Esteban, D.J., VandenBos, T., Thebeau, L.G., Chen, N., Spriggs, M.K., 
Sims, J.E. and Buller, R.M. (2000) A poxvirus protein that binds to and inactivates IL-18, and 
inhibits NK cell response. J Immunol, 164, 3246-3254. 
Bowie, A., Kiss-Toth, E., Symons, J.A., Smith, G.L., Dower, S.K. and O'Neill, L.A. (2000) A46R and 
A52R from vaccinia virus are antagonists of host IL-1 and toll-like receptor signaling. Proc 
Natl Acad Sci U S A, 97, 10162-10167. 
Bowie, A.G. and Unterholzner, L. (2008) Viral evasion and subversion of pattern-recognition receptor 
signalling. Nat Rev Immunol, 8, 911-922. 
Broyles, S.S. (1993) Vaccinia virus encodes a functional dUTPase. Virology, 195, 863-865. 
Bruick, R.K. and McKnight, S.L. (2001) A conserved family of prolyl-4-hydroxylases that modify 
HIF. Science, 294, 1337-1340. 
Bukowski, J.F., Woda, B.A., Habu, S., Okumura, K. and Welsh, R.M. (1983) Natural killer cell 
depletion enhances virus synthesis and virus-induced hepatitis in vivo. J Immunol, 131, 1531-
1538. 
Burckstummer, T., Baumann, C., Bluml, S., Dixit, E., Durnberger, G., Jahn, H., Planyavsky, M., 
Bilban, M., Colinge, J., Bennett, K.L. and Superti-Furga, G. (2009) An orthogonal proteomic-
genomic screen identifies AIM2 as a cytoplasmic DNA sensor for the inflammasome. Nat 
Immunol, 10, 266-272. 
Cai, Q., Murakami, M., Si, H. and Robertson, E.S. (2007) A potential alpha-helix motif in the amino 
terminus of LANA encoded by Kaposi's sarcoma-associated herpesvirus is critical for nuclear 
accumulation of HIF-1alpha in normoxia. J Virol, 81, 10413-10423. 
184 
 
Carroll, M.W., Overwijk, W.W., Chamberlain, R.S., Rosenberg, S.A., Moss, B. and Restifo, N.P. 
(1997) Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant 
vector: a murine tumor model. Vaccine, 15, 387-394. 
Carroll, P.A., Kenerson, H.L., Yeung, R.S. and Lagunoff, M. (2006) Latent Kaposi's sarcoma-
associated herpesvirus infection of endothelial cells activates hypoxia-induced factors. J 
Virol, 80, 10802-10812. 
Carroll, T.P., Greene, C.M., Taggart, C.C., Bowie, A.G., O'Neill, S.J. and McElvaney, N.G. (2005) 
Viral inhibition of IL-1- and neutrophil elastase-induced inflammatory responses in bronchial 
epithelial cells. J Immunol, 175, 7594-7601. 
Carter, G.C., Law, M., Hollinshead, M. and Smith, G.L. (2005) Entry of the vaccinia virus 
intracellular mature virion and its interactions with glycosaminoglycans. J Gen Virol, 86, 
1279-1290. 
Cavazzana, I., Angela, C., Paolo, A., Stefania, Z., Angela, T. and Franco, F. (2009) Anti-RNA 
polymerase III antibodies: a marker of systemic sclerosis with rapid onset and skin thickening 
progression. Autoimmun Rev, 8, 580-584. 
Cavazzana, I., Ceribelli, A., Quinzanini, M., Scarsi, M., Airo, P., Cattaneo, R. and Franceschini, F. 
(2008) Prevalence and clinical associations of anti-Ku antibodies in systemic autoimmune 
diseases. Lupus, 17, 727-732. 
Chang, H.W. and Jacobs, B.L. (1993) Identification of a conserved motif that is necessary for binding 
of the vaccinia virus E3L gene products to double-stranded RNA. Virology, 194, 537-547. 
Chang, H.W., Uribe, L.H. and Jacobs, B.L. (1995) Rescue of vaccinia virus lacking the E3L gene by 
mutants of E3L. J Virol, 69, 6605-6608. 
Chang, H.W., Watson, J.C. and Jacobs, B.L. (1992) The E3L gene of vaccinia virus encodes an 
inhibitor of the interferon-induced, double-stranded RNA-dependent protein kinase. Proc Natl 
Acad Sci U S A, 89, 4825-4829. 
Chang, M., Jin, W. and Sun, S.C. (2009) Peli1 facilitates TRIF-dependent Toll-like receptor signaling 
and proinflammatory cytokine production. Nat Immunol, 10, 1089-1095. 
Chen, R.A., Ryzhakov, G., Cooray, S., Randow, F. and Smith, G.L. (2008) Inhibition of IkappaB 
kinase by vaccinia virus virulence factor B14. PLoS Pathog, 4, e22. 
Chiu, Y.H., Macmillan, J.B. and Chen, Z.J. (2009) RNA polymerase III detects cytosolic DNA and 
induces type I interferons through the RIG-I pathway. Cell, 138, 576-591. 
Chowdhury, R., McDonough, M.A., Mecinovic, J., Loenarz, C., Flashman, E., Hewitson, K.S., 
Domene, C. and Schofield, C.J. (2009) Structural basis for binding of hypoxia-inducible 
factor to the oxygen-sensing prolyl hydroxylases. Structure, 17, 981-989. 
Clark, R.H., Kenyon, J.C., Bartlett, N.W., Tscharke, D.C. and Smith, G.L. (2006) Deletion of gene 
A41L enhances vaccinia virus immunogenicity and vaccine efficacy. J Gen Virol, 87, 29-38. 
Clemens, M.J. and Williams, B.R. (1978) Inhibition of cell-free protein synthesis by 
pppA2'p5'A2'p5'A: a novel oligonucleotide synthesized by interferon-treated L cell extracts. 
Cell, 13, 565-572. 
Colamonici, O.R., Domanski, P., Sweitzer, S.M., Larner, A. and Buller, R.M. (1995) Vaccinia virus 
B18R gene encodes a type I interferon-binding protein that blocks interferon alpha 
transmembrane signaling. J Biol Chem, 270, 15974-15978. 
Collis, S.J., DeWeese, T.L., Jeggo, P.A. and Parker, A.R. (2005) The life and death of DNA-PK. 
Oncogene, 24, 949-961. 
Cramer, T., Yamanishi, Y., Clausen, B.E., Forster, I., Pawlinski, R., Mackman, N., Haase, V.H., 
Jaenisch, R., Corr, M., Nizet, V., Firestein, G.S., Gerber, H.P., Ferrara, N. and Johnson, R.S. 
(2003) HIF-1alpha is essential for myeloid cell-mediated inflammation. Cell, 112, 645-657. 
Crow, Y.J., Hayward, B.E., Parmar, R., Robins, P., Leitch, A., Ali, M., Black, D.N., van Bokhoven, 
H., Brunner, H.G., Hamel, B.C., Corry, P.C., Cowan, F.M., Frints, S.G., Klepper, J., 
Livingston, J.H., Lynch, S.A., Massey, R.F., Meritet, J.F., Michaud, J.L., Ponsot, G., Voit, T., 
Lebon, P., Bonthron, D.T., Jackson, A.P., Barnes, D.E. and Lindahl, T. (2006) Mutations in 
the gene encoding the 3'-5' DNA exonuclease TREX1 cause Aicardi-Goutieres syndrome at 
the AGS1 locus. Nat Genet, 38, 917-920. 
Culver, C., Sundqvist, A., Mudie, S., Melvin, A., Xirodimas, D. and Rocha, S. (2010) Mechanism of 
hypoxia-induced NF-kappaB. Mol Cell Biol, 30, 4901-4921. 
185 
 
Cummins, E.P., Berra, E., Comerford, K.M., Ginouves, A., Fitzgerald, K.T., Seeballuck, F., Godson, 
C., Nielsen, J.E., Moynagh, P., Pouyssegur, J. and Taylor, C.T. (2006) Prolyl hydroxylase-1 
negatively regulates IkappaB kinase-beta, giving insight into hypoxia-induced NFkappaB 
activity. Proc Natl Acad Sci U S A, 103, 18154-18159. 
Curtis, J.L. and Kaltreider, H.B. (1989) Characterization of bronchoalveolar lymphocytes during a 
specific antibody-forming cell response in the lungs of mice. Am Rev Respir Dis, 139, 393-
400. 
Decker, T., Lew, D.J., Mirkovitch, J. and Darnell, J.E., Jr. (1991) Cytoplasmic activation of GAF, an 
IFN-gamma-regulated DNA-binding factor. Embo J, 10, 927-932. 
DeFilippis, V.R., Alvarado, D., Sali, T., Rothenburg, S. and Fruh, K. (2010) Human cytomegalovirus 
induces the interferon response via the DNA sensor ZBP1. J Virol, 84, 585-598. 
Delaloye, J., Roger, T., Steiner-Tardivel, Q.G., Le Roy, D., Knaup Reymond, M., Akira, S., Petrilli, 
V., Gomez, C.E., Perdiguero, B., Tschopp, J., Pantaleo, G., Esteban, M. and Calandra, T. 
(2009) Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by 
TLR2-TLR6, MDA-5 and the NALP3 inflammasome. PLoS Pathog, 5, e1000480. 
DeLano, W.L. (2002) The PyMOL Molecular Graphics System. DeLano Scientific, San Carlos, CA. 
. 
Diamond, B. (2008) Immunologic Mechanisms in Disease. In Paul, W.E. (ed.), Fundamental 
Immunology. Lippincott, Williams & Wilkins, Vol. 1, pp. 1291-1331. 
Dinc, G. and Ulman, Y.I. (2007) The introduction of variolation 'A La Turca' to the West by Lady 
Mary Montagu and Turkey's contribution to this. Vaccine, 25, 4261-4265. 
DiPerna, G., Stack, J., Bowie, A.G., Boyd, A., Kotwal, G., Zhang, Z., Arvikar, S., Latz, E., Fitzgerald, 
K.A. and Marshall, W.L. (2004) Poxvirus protein N1L targets the I-kappaB kinase complex, 
inhibits signaling to NF-kappaB by the tumor necrosis factor superfamily of receptors, and 
inhibits NF-kappaB and IRF3 signaling by toll-like receptors. J Biol Chem, 279, 36570-
36578. 
Downs, J.A. and Jackson, S.P. (2004) A means to a DNA end: the many roles of Ku. Nat Rev Mol 
Cell Biol, 5, 367-378. 
Drexler, I., Heller, K., Wahren, B., Erfle, V. and Sutter, G. (1998) Highly attenuated modified 
vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus 
propagation, but not in various human transformed and primary cells. J Gen Virol, 79 ( Pt 2), 
347-352. 
Du, S. and Traktman, P. (1996) Vaccinia virus DNA replication: two hundred base pairs of telomeric 
sequence confer optimal replication efficiency on minichromosome templates. Proc Natl 
Acad Sci U S A, 93, 9693-9698. 
Dumbell, K. and Richardson, M. (1993) Virological investigations of specimens from buffaloes 
affected by buffalopox in Maharashtra State, India between 1985 and 1987. Arch Virol, 128, 
257-267. 
Dynan, W.S. and Yoo, S. (1998) Interaction of Ku protein and DNA-dependent protein kinase 
catalytic subunit with nucleic acids. Nucleic Acids Res, 26, 1551-1559. 
Edelmann, K.H., Richardson-Burns, S., Alexopoulou, L., Tyler, K.L., Flavell, R.A. and Oldstone, 
M.B. (2004) Does Toll-like receptor 3 play a biological role in virus infections? Virology, 
322, 231-238. 
Elbahesh, H., Jha, B.K., Silverman, R.H., Scherbik, S.V. and Brinton, M.A. (2011) The Flvr-encoded 
murine oligoadenylate synthetase 1b (Oas1b) suppresses 2-5A synthesis in intact cells. 
Virology, 409, 262-270. 
Ermolaeva, M.A., Michallet, M.C., Papadopoulou, N., Utermohlen, O., Kranidioti, K., Kollias, G., 
Tschopp, J. and Pasparakis, M. (2008) Function of TRADD in tumor necrosis factor receptor 
1 signaling and in TRIF-dependent inflammatory responses. Nat Immunol, 9, 1037-1046. 
Errami, A., Smider, V., Rathmell, W.K., He, D.M., Hendrickson, E.A., Zdzienicka, M.Z. and Chu, G. 
(1996) Ku86 defines the genetic defect and restores X-ray resistance and V(D)J 
recombination to complementation group 5 hamster cell mutants. Mol Cell Biol, 16, 1519-
1526. 
186 
 
Fahy, A.S., Clark, R.H., Glyde, E.F. and Smith, G.L. (2008) Vaccinia virus protein C16 acts 
intracellularly to modulate the host response and promote virulence. J Gen Virol, 89, 2377-
2387. 
Fenner, F. (1993) Smallpox: emergence, global spread, and eradication. Hist Philos Life Sci, 15, 397-
420. 
Fernandes-Alnemri, T., Yu, J.W., Datta, P., Wu, J. and Alnemri, E.S. (2009) AIM2 activates the 
inflammasome and cell death in response to cytoplasmic DNA. Nature, 458, 509-513. 
Fernandes-Alnemri, T., Yu, J.W., Juliana, C., Solorzano, L., Kang, S., Wu, J., Datta, P., McCormick, 
M., Huang, L., McDermott, E., Eisenlohr, L., Landel, C.P. and Alnemri, E.S. (2010) The 
AIM2 inflammasome is critical for innate immunity to Francisella tularensis. Nat Immunol, 
11, 385-393. 
Fewell, J.W. and Kuff, E.L. (1996) Intracellular redistribution of Ku immunoreactivity in response to 
cell-cell contact and growth modulating components in the medium. J Cell Sci, 109 ( Pt 7), 
1937-1946. 
Fitzgerald, K.A., McWhirter, S.M., Faia, K.L., Rowe, D.C., Latz, E., Golenbock, D.T., Coyle, A.J., 
Liao, S.M. and Maniatis, T. (2003) IKKepsilon and TBK1 are essential components of the 
IRF3 signaling pathway. Nat Immunol, 4, 491-496. 
Fitzgerald, K.A., Palsson-McDermott, E.M., Bowie, A.G., Jefferies, C.A., Mansell, A.S., Brady, G., 
Brint, E., Dunne, A., Gray, P., Harte, M.T., McMurray, D., Smith, D.E., Sims, J.E., Bird, T.A. 
and O'Neill, L.A. (2001) Mal (MyD88-adapter-like) is required for Toll-like receptor-4 signal 
transduction. Nature, 413, 78-83. 
Fong, G.H. and Takeda, K. (2008) Role and regulation of prolyl hydroxylase domain proteins. Cell 
Death Differ, 15, 635-641. 
Fraisl, P., Aragones, J. and Carmeliet, P. (2009) Inhibition of oxygen sensors as a therapeutic strategy 
for ischaemic and inflammatory disease. Nat Rev Drug Discov, 8, 139-152. 
Frasca, D., Barattini, P., Tocchi, G., Guidi, L., Pierelli, L. and Doria, G. (2001) Role of DNA-
dependent protein kinase in recognition of radiation-induced DNA damage in human 
peripheral blood mononuclear cells. Int Immunol, 13, 791-797. 
Fredericksen, B.L., Keller, B.C., Fornek, J., Katze, M.G. and Gale, M., Jr. (2008) Establishment and 
maintenance of the innate antiviral response to West Nile Virus involves both RIG-I and 
MDA5 signaling through IPS-1. J Virol, 82, 609-616. 
Fujita, T., Kimura, Y., Miyamoto, M., Barsoumian, E.L. and Taniguchi, T. (1989) Induction of 
endogenous IFN-alpha and IFN-beta genes by a regulatory transcription factor, IRF-1. 
Nature, 337, 270-272. 
Gack, M.U., Albrecht, R.A., Urano, T., Inn, K.S., Huang, I.C., Carnero, E., Farzan, M., Inoue, S., 
Jung, J.U. and Garcia-Sastre, A. (2009) Influenza A virus NS1 targets the ubiquitin ligase 
TRIM25 to evade recognition by the host viral RNA sensor RIG-I. Cell Host Microbe, 5, 439-
449. 
Gack, M.U., Kirchhofer, A., Shin, Y.C., Inn, K.S., Liang, C., Cui, S., Myong, S., Ha, T., Hopfner, 
K.P. and Jung, J.U. (2008) Roles of RIG-I N-terminal tandem CARD and splice variant in 
TRIM25-mediated antiviral signal transduction. Proc Natl Acad Sci U S A, 105, 16743-
16748. 
Gack, M.U., Shin, Y.C., Joo, C.H., Urano, T., Liang, C., Sun, L., Takeuchi, O., Akira, S., Chen, Z., 
Inoue, S. and Jung, J.U. (2007) TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-
I-mediated antiviral activity. Nature, 446, 916-920. 
Gedey, R., Jin, X.L., Hinthong, O. and Shisler, J.L. (2006) Poxviral regulation of the host NF-kappaB 
response: the vaccinia virus M2L protein inhibits induction of NF-kappaB activation via an 
ERK2 pathway in virus-infected human embryonic kidney cells. J Virol, 80, 8676-8685. 
Gell, D. and Jackson, S.P. (1999) Mapping of protein-protein interactions within the DNA-dependent 
protein kinase complex. Nucleic Acids Res, 27, 3494-3502. 
Giffin, W., Torrance, H., Rodda, D.J., Prefontaine, G.G., Pope, L. and Hache, R.J. (1996) Sequence-
specific DNA binding by Ku autoantigen and its effects on transcription. Nature, 380, 265-
268. 
Gilliet, M., Cao, W. and Liu, Y.J. (2008) Plasmacytoid dendritic cells: sensing nucleic acids in viral 
infection and autoimmune diseases. Nat Rev Immunol, 8, 594-606. 
187 
 
Gitlin, L., Barchet, W., Gilfillan, S., Cella, M., Beutler, B., Flavell, R.A., Diamond, M.S. and 
Colonna, M. (2006) Essential role of mda-5 in type I IFN responses to 
polyriboinosinic:polyribocytidylic acid and encephalomyocarditis picornavirus. Proc Natl 
Acad Sci U S A, 103, 8459-8464. 
Gloeckner, C.J., Boldt, K., Schumacher, A., Roepman, R. and Ueffing, M. (2007) A novel tandem 
affinity purification strategy for the efficient isolation and characterisation of native protein 
complexes. Proteomics, 7, 4228-4234. 
Gossen, M. and Bujard, H. (1992) Tight control of gene expression in mammalian cells by 
tetracycline-responsive promoters. Proc Natl Acad Sci U S A, 89, 5547-5551. 
Gottlieb, T.M. and Jackson, S.P. (1993) The DNA-dependent protein kinase: requirement for DNA 
ends and association with Ku antigen. Cell, 72, 131-142. 
Graham, K.A., Lalani, A.S., Macen, J.L., Ness, T.L., Barry, M., Liu, L.Y., Lucas, A., Clark-Lewis, I., 
Moyer, R.W. and McFadden, G. (1997) The T1/35kDa family of poxvirus-secreted proteins 
bind chemokines and modulate leukocyte influx into virus-infected tissues. Virology, 229, 12-
24. 
Graham, S.C., Bahar, M.W., Cooray, S., Chen, R.A., Whalen, D.M., Abrescia, N.G., Alderton, D., 
Owens, R.J., Stuart, D.I., Smith, G.L. and Grimes, J.M. (2008) Vaccinia virus proteins A52 
and B14 Share a Bcl-2-like fold but have evolved to inhibit NF-kappaB rather than apoptosis. 
PLoS Pathog, 4, e1000128. 
Gubser, C., Hue, S., Kellam, P. and Smith, G.L. (2004) Poxvirus genomes: a phylogenetic analysis. J 
Gen Virol, 85, 105-117. 
Guerra, S., Caceres, A., Knobeloch, K.P., Horak, I. and Esteban, M. (2008) Vaccinia virus E3 protein 
prevents the antiviral action of ISG15. PLoS Pathog, 4, e1000096. 
Guo, B. and Cheng, G. (2007) Modulation of the interferon antiviral response by the TBK1/IKKi 
adaptor protein TANK. J Biol Chem, 282, 11817-11826. 
Hacker, H., Redecke, V., Blagoev, B., Kratchmarova, I., Hsu, L.C., Wang, G.G., Kamps, M.P., Raz, 
E., Wagner, H., Hacker, G., Mann, M. and Karin, M. (2006) Specificity in Toll-like receptor 
signalling through distinct effector functions of TRAF3 and TRAF6. Nature, 439, 204-207. 
Hammarsten, O. and Chu, G. (1998) DNA-dependent protein kinase: DNA binding and activation in 
the absence of Ku. Proc Natl Acad Sci U S A, 95, 525-530. 
Hao, S. and Baltimore, D. (2009) The stability of mRNA influences the temporal order of the 
induction of genes encoding inflammatory molecules. Nat Immunol, 10, 281-288. 
Harte, M.T., Haga, I.R., Maloney, G., Gray, P., Reading, P.C., Bartlett, N.W., Smith, G.L., Bowie, A. 
and O'Neill, L.A. (2003) The poxvirus protein A52R targets Toll-like receptor signaling 
complexes to suppress host defense. J Exp Med, 197, 343-351. 
Hemmi, H., Takeuchi, O., Sato, S., Yamamoto, M., Kaisho, T., Sanjo, H., Kawai, T., Hoshino, K., 
Takeda, K. and Akira, S. (2004) The roles of two IkappaB kinase-related kinases in 
lipopolysaccharide and double stranded RNA signaling and viral infection. J Exp Med, 199, 
1641-1650. 
Henderson, D.A. (1976) The eradication of smallpox. Sci Am, 235, 25-33. 
Henderson, D.A. (2009) Smallpox: The Death of a Disease. Prometheus Books. 
Hiley, C.T., Yuan, M., Lemoine, N.R. and Wang, Y. (2010) Lister strain vaccinia virus, a potential 
therapeutic vector targeting hypoxic tumours. Gene Ther, 17, 281-287. 
Hinthong, O., Jin, X.L. and Shisler, J.L. (2008) Characterization of wild-type and mutant vaccinia 
virus M2L proteins' abilities to localize to the endoplasmic reticulum and to inhibit NF-
kappaB activation during infection. Virology, 373, 248-262. 
Holtmann, H., Enninga, J., Kalble, S., Thiefes, A., Dorrie, A., Broemer, M., Winzen, R., Wilhelm, A., 
Ninomiya-Tsuji, J., Matsumoto, K., Resch, K. and Kracht, M. (2001) The MAPK kinase 
kinase TAK1 plays a central role in coupling the interleukin-1 receptor to both transcriptional 
and RNA-targeted mechanisms of gene regulation. J Biol Chem, 276, 3508-3516. 
Honda, K. and Taniguchi, T. (2006) IRFs: master regulators of signalling by Toll-like receptors and 
cytosolic pattern-recognition receptors. Nat Rev Immunol, 6, 644-658. 
Hopkins, D.R. (2002) The greatest killer: smallpox in history, with a new introduction. The 
University of Chicago Press. 
188 
 
Hornung, V., Ablasser, A., Charrel-Dennis, M., Bauernfeind, F., Horvath, G., Caffrey, D.R., Latz, E. 
and Fitzgerald, K.A. (2009) AIM2 recognizes cytosolic dsDNA and forms a caspase-1-
activating inflammasome with ASC. Nature, 458, 514-518. 
Hornung, V., Ellegast, J., Kim, S., Brzozka, K., Jung, A., Kato, H., Poeck, H., Akira, S., Conzelmann, 
K.K., Schlee, M., Endres, S. and Hartmann, G. (2006) 5'-Triphosphate RNA is the ligand for 
RIG-I. Science, 314, 994-997. 
Horvath, C.M., Stark, G.R., Kerr, I.M. and Darnell, J.E., Jr. (1996) Interactions between STAT and 
non-STAT proteins in the interferon-stimulated gene factor 3 transcription complex. Mol Cell 
Biol, 16, 6957-6964. 
Hovanessian, A.G. and Justesen, J. (2007) The human 2'-5'oligoadenylate synthetase family: unique 
interferon-inducible enzymes catalyzing 2'-5' instead of 3'-5' phosphodiester bond formation. 
Biochimie, 89, 779-788. 
Howard, A.D., Palyha, O.C., Griffin, P.R., Peterson, E.P., Lenny, A.B., Ding, G.J., Pickup, D.J., 
Thornberry, N.A., Schmidt, J.A. and Tocci, M.J. (1995) Human IL-1 beta processing and 
secretion in recombinant baculovirus-infected Sf9 cells is blocked by the cowpox virus serpin 
crmA. J Immunol, 154, 2321-2332. 
Hruby, D.E., Maki, R.A., Miller, D.B. and Ball, L.A. (1983) Fine structure analysis and nucleotide 
sequence of the vaccinia virus thymidine kinase gene. Proc Natl Acad Sci U S A, 80, 3411-
3415. 
Huang, S., Hendriks, W., Althage, A., Hemmi, S., Bluethmann, H., Kamijo, R., Vilcek, J., 
Zinkernagel, R.M. and Aguet, M. (1993) Immune response in mice that lack the interferon-
gamma receptor. Science, 259, 1742-1745. 
Hutchens, M., Luker, K.E., Sottile, P., Sonstein, J., Lukacs, N.W., Nunez, G., Curtis, J.L. and Luker, 
G.D. (2008) TLR3 increases disease morbidity and mortality from vaccinia infection. J 
Immunol, 180, 483-491. 
Hwang, II, Watson, I.R., Der, S.D. and Ohh, M. (2006) Loss of VHL confers hypoxia-inducible factor 
(HIF)-dependent resistance to vesicular stomatitis virus: role of HIF in antiviral response. J 
Virol, 80, 10712-10723. 
Ichihashi, Y. (1996) Extracellular enveloped vaccinia virus escapes neutralization. Virology, 217, 
478-485. 
Isaacs, A. and Lindenmann, J. (1957) Virus interference. I. The interferon. Proc R Soc Lond B Biol 
Sci, 147, 258-267. 
Isaacs, A., Lindenmann, J. and Valentine, R.C. (1957) Virus interference. II. Some properties of 
interferon. Proc R Soc Lond B Biol Sci, 147, 268-273. 
Isaacs, S.N., Kotwal, G.J. and Moss, B. (1992) Vaccinia virus complement-control protein prevents 
antibody-dependent complement-enhanced neutralization of infectivity and contributes to 
virulence. Proc Natl Acad Sci U S A, 89, 628-632. 
Ishii, K.J., Coban, C., Kato, H., Takahashi, K., Torii, Y., Takeshita, F., Ludwig, H., Sutter, G., 
Suzuki, K., Hemmi, H., Sato, S., Yamamoto, M., Uematsu, S., Kawai, T., Takeuchi, O. and 
Akira, S. (2006) A Toll-like receptor-independent antiviral response induced by double-
stranded B-form DNA. Nat Immunol, 7, 40-48. 
Ishii, K.J., Kawagoe, T., Koyama, S., Matsui, K., Kumar, H., Kawai, T., Uematsu, S., Takeuchi, O., 
Takeshita, F., Coban, C. and Akira, S. (2008) TANK-binding kinase-1 delineates innate and 
adaptive immune responses to DNA vaccines. Nature, 451, 725-729. 
Ishikawa, H. and Barber, G.N. (2008) STING is an endoplasmic reticulum adaptor that facilitates 
innate immune signalling. Nature, 455, 674-678. 
Ishikawa, H., Ma, Z. and Barber, G.N. (2009) STING regulates intracellular DNA-mediated, type I 
interferon-dependent innate immunity. Nature, 461, 788-792. 
Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J.M., Lane, W.S. 
and Kaelin, W.G., Jr. (2001) HIFalpha targeted for VHL-mediated destruction by proline 
hydroxylation: implications for O2 sensing. Science, 292, 464-468. 
Iwasaki, A. and Medzhitov, R. (2010) Regulation of adaptive immunity by the innate immune system. 
Science, 327, 291-295. 
Jaakkola, P., Mole, D.R., Tian, Y.M., Wilson, M.I., Gielbert, J., Gaskell, S.J., Kriegsheim, A., 
Hebestreit, H.F., Mukherji, M., Schofield, C.J., Maxwell, P.H., Pugh, C.W. and Ratcliffe, P.J. 
189 
 
(2001) Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-
regulated prolyl hydroxylation. Science, 292, 468-472. 
Jacobs, N., Chen, R.A., Gubser, C., Najarro, P. and Smith, G.L. (2006) Intradermal immune response 
after infection with Vaccinia virus. J Gen Virol, 87, 1157-1161. 
Janeway, C.A., Jr. (1989) Approaching the asymptote? Evolution and revolution in immunology. 
Cold Spring Harb Symp Quant Biol, 54 Pt 1, 1-13. 
Jeggo, P.A., Jackson, S.P. and Taccioli, G.E. (1996) Identification of the catalytic subunit of DNA 
dependent protein kinase as the product of the mouse scid gene. Curr Top Microbiol 
Immunol, 217, 79-89. 
Kaelin, W.G. (2005) Proline hydroxylation and gene expression. Annu Rev Biochem, 74, 115-128. 
Kaelin, W.G., Jr. and Ratcliffe, P.J. (2008) Oxygen sensing by metazoans: the central role of the HIF 
hydroxylase pathway. Mol Cell, 30, 393-402. 
Kagan, J.C. and Medzhitov, R. (2006) Phosphoinositide-mediated adaptor recruitment controls Toll-
like receptor signaling. Cell, 125, 943-955. 
Kakuta, S., Shibata, S. and Iwakura, Y. (2002) Genomic structure of the mouse 2',5'-oligoadenylate 
synthetase gene family. J Interferon Cytokine Res, 22, 981-993. 
Karpova, A.Y., Trost, M., Murray, J.M., Cantley, L.C. and Howley, P.M. (2002) Interferon regulatory 
factor-3 is an in vivo target of DNA-PK. Proc Natl Acad Sci U S A, 99, 2818-2823. 
Karupiah, G., Fredrickson, T.N., Holmes, K.L., Khairallah, L.H. and Buller, R.M. (1993) Importance 
of interferons in recovery from mousepox. J Virol, 67, 4214-4226. 
Kato, H., Sato, S., Yoneyama, M., Yamamoto, M., Uematsu, S., Matsui, K., Tsujimura, T., Takeda, 
K., Fujita, T., Takeuchi, O. and Akira, S. (2005) Cell type-specific involvement of RIG-I in 
antiviral response. Immunity, 23, 19-28. 
Kato, H., Takeuchi, O., Mikamo-Satoh, E., Hirai, R., Kawai, T., Matsushita, K., Hiiragi, A., 
Dermody, T.S., Fujita, T. and Akira, S. (2008) Length-dependent recognition of double-
stranded ribonucleic acids by retinoic acid-inducible gene-I and melanoma differentiation-
associated gene 5. J Exp Med, 205, 1601-1610. 
Kato, H., Takeuchi, O., Sato, S., Yoneyama, M., Yamamoto, M., Matsui, K., Uematsu, S., Jung, A., 
Kawai, T., Ishii, K.J., Yamaguchi, O., Otsu, K., Tsujimura, T., Koh, C.S., Reis e Sousa, C., 
Matsuura, Y., Fujita, T. and Akira, S. (2006) Differential roles of MDA5 and RIG-I helicases 
in the recognition of RNA viruses. Nature, 441, 101-105. 
Kawagishi-Kobayashi, M., Silverman, J.B., Ung, T.L. and Dever, T.E. (1997) Regulation of the 
protein kinase PKR by the vaccinia virus pseudosubstrate inhibitor K3L is dependent on 
residues conserved between the K3L protein and the PKR substrate eIF2alpha. Mol Cell Biol, 
17, 4146-4158. 
Kawagoe, T., Sato, S., Matsushita, K., Kato, H., Matsui, K., Kumagai, Y., Saitoh, T., Kawai, T., 
Takeuchi, O. and Akira, S. (2008) Sequential control of Toll-like receptor-dependent 
responses by IRAK1 and IRAK2. Nat Immunol, 9, 684-691. 
Kawai, T. and Akira, S. (2010) The role of pattern-recognition receptors in innate immunity: update 
on Toll-like receptors. Nat Immunol, 11, 373-384. 
Kawai, T., Takahashi, K., Sato, S., Coban, C., Kumar, H., Kato, H., Ishii, K.J., Takeuchi, O. and 
Akira, S. (2005) IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon 
induction. Nat Immunol, 6, 981-988. 
Kawane, K., Ohtani, M., Miwa, K., Kizawa, T., Kanbara, Y., Yoshioka, Y., Yoshikawa, H. and 
Nagata, S. (2006) Chronic polyarthritis caused by mammalian DNA that escapes from 
degradation in macrophages. Nature, 443, 998-1002. 
Kerr, I.M., Brown, R.E. and Hovanessian, A.G. (1977) Nature of inhibitor of cell-free protein 
synthesis formed in response to interferon and double-stranded RNA. Nature, 268, 540-542. 
Kerur, N., Veettil, M.V., Sharma-Walia, N., Bottero, V., Sadagopan, S., Otageri, P. and Chandran, B. 
(2011) IFI16 Acts as a Nuclear Pathogen Sensor to Induce the Inflammasome in Response to 
Kaposi Sarcoma-Associated Herpesvirus Infection. Cell Host Microbe, 9, 363-375. 
Kessler, D.S., Veals, S.A., Fu, X.Y. and Levy, D.E. (1990) Interferon-alpha regulates nuclear 
translocation and DNA-binding affinity of ISGF3, a multimeric transcriptional activator. 
Genes Dev, 4, 1753-1765. 
190 
 
Kettle, S., Alcami, A., Khanna, A., Ehret, R., Jassoy, C. and Smith, G.L. (1997) Vaccinia virus serpin 
B13R (SPI-2) inhibits interleukin-1beta-converting enzyme and protects virus-infected cells 
from TNF- and Fas-mediated apoptosis, but does not prevent IL-1beta-induced fever. J Gen 
Virol, 78 ( Pt 3), 677-685. 
Kilani, M.M., Mohammed, K.A., Nasreen, N., Tepper, R.S. and Antony, V.B. (2004) RSV causes 
HIF-1alpha stabilization via NO release in primary bronchial epithelial cells. Inflammation, 
28, 245-251. 
Kim, T., Pazhoor, S., Bao, M., Zhang, Z., Hanabuchi, S., Facchinetti, V., Bover, L., Plumas, J., 
Chaperot, L., Qin, J. and Liu, Y.J. (2010) Aspartate-glutamate-alanine-histidine box motif 
(DEAH)/RNA helicase A helicases sense microbial DNA in human plasmacytoid dendritic 
cells. Proc Natl Acad Sci U S A, 107, 15181-15186. 
Kimkong, I., Avihingsanon, Y. and Hirankarn, N. (2009) Expression profile of HIN200 in leukocytes 
and renal biopsy of SLE patients by real-time RT-PCR. Lupus, 18, 1066-1072. 
Kluczyk, A., Siemion, I.Z., Szewczuk, Z. and Wieczorek, Z. (2002) The immunosuppressive activity 
of peptide fragments of vaccinia virus C10L protein and a hypothesis on the role of this 
protein in the viral invasion. Peptides, 23, 823-834. 
Kontaki, E. and Boumpas, D.T. (2010) Innate immunity in systemic lupus erythematosus: sensing 
endogenous nucleic acids. J Autoimmun, 35, 206-211. 
Korkmaz, B., Moreau, T. and Gauthier, F. (2008) Neutrophil elastase, proteinase 3 and cathepsin G: 
physicochemical properties, activity and physiopathological functions. Biochimie, 90, 227-
242. 
Kotwal, G.J., Isaacs, S.N., McKenzie, R., Frank, M.M. and Moss, B. (1990) Inhibition of the 
complement cascade by the major secretory protein of vaccinia virus. Science, 250, 827-830. 
Kotwal, G.J. and Moss, B. (1988) Vaccinia virus encodes a secretory polypeptide structurally related 
to complement control proteins. Nature, 335, 176-178. 
Kuhlicke, J., Frick, J.S., Morote-Garcia, J.C., Rosenberger, P. and Eltzschig, H.K. (2007) Hypoxia 
inducible factor (HIF)-1 coordinates induction of Toll-like receptors TLR2 and TLR6 during 
hypoxia. PLoS One, 2, e1364. 
Kumar, H., Kawai, T., Kato, H., Sato, S., Takahashi, K., Coban, C., Yamamoto, M., Uematsu, S., 
Ishii, K.J., Takeuchi, O. and Akira, S. (2006) Essential role of IPS-1 in innate immune 
responses against RNA viruses. J Exp Med, 203, 1795-1803. 
Kumar, K.P., McBride, K.M., Weaver, B.K., Dingwall, C. and Reich, N.C. (2000) Regulated nuclear-
cytoplasmic localization of interferon regulatory factor 3, a subunit of double-stranded RNA-
activated factor 1. Mol Cell Biol, 20, 4159-4168. 
Lambris, J.D., Ricklin, D. and Geisbrecht, B.V. (2008) Complement evasion by human pathogens. 
Nat Rev Microbiol, 6, 132-142. 
Lamkanfi, M. and Dixit, V.M. (2009) The inflammasomes. PLoS Pathog, 5, e1000510. 
Lando, D., Peet, D.J., Whelan, D.A., Gorman, J.J. and Whitelaw, M.L. (2002) Asparagine 
hydroxylation of the HIF transactivation domain a hypoxic switch. Science, 295, 858-861. 
Law, M., Carter, G.C., Roberts, K.L., Hollinshead, M. and Smith, G.L. (2006) Ligand-induced and 
nonfusogenic dissolution of a viral membrane. Proc Natl Acad Sci U S A, 103, 5989-5994. 
Leddy, J.P., Simons, R.L. and Douglas, R.G. (1977) Effect of selective complement deficiency on the 
rate of neutralization of enveloped viruses by human sera. J Immunol, 118, 28-34. 
Lee-Kirsch, M.A., Chowdhury, D., Harvey, S., Gong, M., Senenko, L., Engel, K., Pfeiffer, C., Hollis, 
T., Gahr, M., Perrino, F.W., Lieberman, J. and Hubner, N. (2007a) A mutation in TREX1 that 
impairs susceptibility to granzyme A-mediated cell death underlies familial chilblain lupus. J 
Mol Med, 85, 531-537. 
Lee-Kirsch, M.A., Gong, M., Chowdhury, D., Senenko, L., Engel, K., Lee, Y.A., de Silva, U., Bailey, 
S.L., Witte, T., Vyse, T.J., Kere, J., Pfeiffer, C., Harvey, S., Wong, A., Koskenmies, S., 
Hummel, O., Rohde, K., Schmidt, R.E., Dominiczak, A.F., Gahr, M., Hollis, T., Perrino, 
F.W., Lieberman, J. and Hubner, N. (2007b) Mutations in the gene encoding the 3'-5' DNA 
exonuclease TREX1 are associated with systemic lupus erythematosus. Nat Genet, 39, 1065-
1067. 
Lehman, J.A., Hoelz, D.J. and Turchi, J.J. (2008) DNA-dependent conformational changes in the Ku 
heterodimer. Biochemistry, 47, 4359-4368. 
191 
 
Lenschow, D.J., Giannakopoulos, N.V., Gunn, L.J., Johnston, C., O'Guin, A.K., Schmidt, R.E., 
Levine, B. and Virgin, H.W.t. (2005) Identification of interferon-stimulated gene 15 as an 
antiviral molecule during Sindbis virus infection in vivo. J Virol, 79, 13974-13983. 
Lew, D.J., Decker, T., Strehlow, I. and Darnell, J.E. (1991) Overlapping elements in the guanylate-
binding protein gene promoter mediate transcriptional induction by alpha and gamma 
interferons. Mol Cell Biol, 11, 182-191. 
Lin, R., Heylbroeck, C., Pitha, P.M. and Hiscott, J. (1998) Virus-dependent phosphorylation of the 
IRF-3 transcription factor regulates nuclear translocation, transactivation potential, and 
proteasome-mediated degradation. Mol Cell Biol, 18, 2986-2996. 
Lin, R., Mamane, Y. and Hiscott, J. (1999) Structural and functional analysis of interferon regulatory 
factor 3: localization of the transactivation and autoinhibitory domains. Mol Cell Biol, 19, 
2465-2474. 
Liu, L., Chavan, R. and Feinberg, M.B. (2008) Dendritic cells are preferentially targeted among 
hematolymphocytes by Modified Vaccinia Virus Ankara and play a key role in the induction 
of virus-specific T cell responses in vivo. BMC Immunol, 9, 15. 
Loeb, K.R. and Haas, A.L. (1992) The interferon-inducible 15-kDa ubiquitin homolog conjugates to 
intracellular proteins. J Biol Chem, 267, 7806-7813. 
Loo, Y.M., Fornek, J., Crochet, N., Bajwa, G., Perwitasari, O., Martinez-Sobrido, L., Akira, S., Gill, 
M.A., Garcia-Sastre, A., Katze, M.G. and Gale, M., Jr. (2008) Distinct RIG-I and MDA5 
signaling by RNA viruses in innate immunity. J Virol, 82, 335-345. 
Lu, G., Reinert, J.T., Pitha-Rowe, I., Okumura, A., Kellum, M., Knobeloch, K.P., Hassel, B. and 
Pitha, P.M. (2006) ISG15 enhances the innate antiviral response by inhibition of IRF-3 
degradation. Cell Mol Biol (Noisy-le-grand), 52, 29-41. 
Lu, Z.H., Wright, J.D., Belt, B., Cardiff, R.D. and Arbeit, J.M. (2007) Hypoxia-inducible factor-1 
facilitates cervical cancer progression in human papillomavirus type 16 transgenic mice. Am J 
Pathol, 171, 667-681. 
Luber, C.A., Cox, J., Lauterbach, H., Fancke, B., Selbach, M., Tschopp, J., Akira, S., Wiegand, M., 
Hochrein, H., O'Keeffe, M. and Mann, M. (2010) Quantitative proteomics reveals subset-
specific viral recognition in dendritic cells. Immunity, 32, 279-289. 
Luker, K.E., Hutchens, M., Schultz, T., Pekosz, A. and Luker, G.D. (2005) Bioluminescence imaging 
of vaccinia virus: effects of interferon on viral replication and spread. Virology, 341, 284-300. 
Lysakova-Devine, T., Keogh, B., Harrington, B., Nagpal, K., Halle, A., Golenbock, D.T., Monie, T. 
and Bowie, A.G. (2010) Viral inhibitory peptide of TLR4, a peptide derived from vaccinia 
protein A46, specifically inhibits TLR4 by directly targeting MyD88 adaptor-like and TRIF-
related adaptor molecule. J Immunol, 185, 4261-4271. 
Macdonald, A. and Downie, A.W. (1950) Serological study of the soluble antigens of variola, 
vaccinia, cowpox and ectromelia viruses. Br J Exp Pathol, 31, 784-788. 
Mack, T.M. (1972) Smallpox in Europe, 1950-1971. J Infect Dis, 125, 161-169. 
Mackett, M. and Smith, G.L. (1986) Vaccinia virus expression vectors. J Gen Virol, 67 ( Pt 10), 
2067-2082. 
Malathi, K., Dong, B., Gale, M., Jr. and Silverman, R.H. (2007) Small self-RNA generated by RNase 
L amplifies antiviral innate immunity. Nature, 448, 816-819. 
Malech, H.L. (2007) The role of neutrophils in the immune system: an overview. Methods Mol Biol, 
412, 3-11. 
Mann, B.A., Huang, J.H., Li, P., Chang, H.C., Slee, R.B., O'Sullivan, A., Anita, M., Yeh, N., Klemsz, 
M.J., Brutkiewicz, R.R., Blum, J.S. and Kaplan, M.H. (2008) Vaccinia virus blocks Stat1-
dependent and Stat1-independent gene expression induced by type I and type II interferons. J 
Interferon Cytokine Res, 28, 367-380. 
Martinez-Moczygemba, M., Gutch, M.J., French, D.L. and Reich, N.C. (1997) Distinct STAT 
structure promotes interaction of STAT2 with the p48 subunit of the interferon-alpha-
stimulated transcription factor ISGF3. J Biol Chem, 272, 20070-20076. 
Martinez, J., Huang, X. and Yang, Y. (2010) Toll-like receptor 8-mediated activation of murine 
plasmacytoid dendritic cells by vaccinia viral DNA. Proc Natl Acad Sci U S A, 107, 6442-
6447. 
192 
 
Mashimo, T., Lucas, M., Simon-Chazottes, D., Frenkiel, M.P., Montagutelli, X., Ceccaldi, P.E., 
Deubel, V., Guenet, J.L. and Despres, P. (2002) A nonsense mutation in the gene encoding 2'-
5'-oligoadenylate synthetase/L1 isoform is associated with West Nile virus susceptibility in 
laboratory mice. Proc Natl Acad Sci U S A, 99, 11311-11316. 
Masson, N., Willam, C., Maxwell, P.H., Pugh, C.W. and Ratcliffe, P.J. (2001) Independent function 
of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl 
hydroxylation. Embo J, 20, 5197-5206. 
Matsui, K., Kumagai, Y., Kato, H., Sato, S., Kawagoe, T., Uematsu, S., Takeuchi, O. and Akira, S. 
(2006) Cutting edge: Role of TANK-binding kinase 1 and inducible IkappaB kinase in IFN 
responses against viruses in innate immune cells. J Immunol, 177, 5785-5789. 
Matsuyama, T., Kimura, T., Kitagawa, M., Pfeffer, K., Kawakami, T., Watanabe, N., Kundig, T.M., 
Amakawa, R., Kishihara, K., Wakeham, A. and et al. (1993) Targeted disruption of IRF-1 or 
IRF-2 results in abnormal type I IFN gene induction and aberrant lymphocyte development. 
Cell, 75, 83-97. 
Mayr, A. and Danner, K. (1978) Vaccination against pox diseases under immunosuppressive 
conditions. Dev Biol Stand, 41, 225-234. 
Mayr, A., Stickl, H., Muller, H.K., Danner, K. and Singer, H. (1978) [The smallpox vaccination strain 
MVA: marker, genetic structure, experience gained with the parenteral vaccination and 
behavior in organisms with a debilitated defence mechanism (author's transl)]. Zentralbl 
Bakteriol [B], 167, 375-390. 
McCraith, S., Holtzman, T., Moss, B. and Fields, S. (2000) Genome-wide analysis of vaccinia virus 
protein-protein interactions. Proc Natl Acad Sci U S A, 97, 4879-4884. 
McDonough, M.A., Li, V., Flashman, E., Chowdhury, R., Mohr, C., Lienard, B.M., Zondlo, J., 
Oldham, N.J., Clifton, I.J., Lewis, J., McNeill, L.A., Kurzeja, R.J., Hewitson, K.S., Yang, E., 
Jordan, S., Syed, R.S. and Schofield, C.J. (2006) Cellular oxygen sensing: Crystal structure of 
hypoxia-inducible factor prolyl hydroxylase (PHD2). Proc Natl Acad Sci U S A, 103, 9814-
9819. 
McWhirter, S.M., Fitzgerald, K.A., Rosains, J., Rowe, D.C., Golenbock, D.T. and Maniatis, T. (2004) 
IFN-regulatory factor 3-dependent gene expression is defective in Tbk1-deficient mouse 
embryonic fibroblasts. Proc Natl Acad Sci U S A, 101, 233-238. 
Meager, A., Visvalingam, K., Dilger, P., Bryan, D. and Wadhwa, M. (2005) Biological activity of 
interleukins-28 and -29: comparison with type I interferons. Cytokine, 31, 109-118. 
Medzhitov, R. (2008) Origin and physiological roles of inflammation. Nature, 454, 428-435. 
Medzhitov, R. (2009) Approaching the asymptote: 20 years later. Immunity, 30, 766-775. 
Meek, K., Dang, V. and Lees-Miller, S.P. (2008) DNA-PK: the means to justify the ends? Adv 
Immunol, 99, 33-58. 
Meisinger-Henschel, C., Schmidt, M., Lukassen, S., Linke, B., Krause, L., Konietzny, S., Goesmann, 
A., Howley, P., Chaplin, P., Suter, M. and Hausmann, J. (2007) Genomic sequence of 
chorioallantois vaccinia virus Ankara, the ancestor of modified vaccinia virus Ankara. J Gen 
Virol, 88, 3249-3259. 
Mercer, J. and Helenius, A. (2008) Vaccinia virus uses macropinocytosis and apoptotic mimicry to 
enter host cells. Science, 320, 531-535. 
Merika, M. and Thanos, D. (2001) Enhanceosomes. Curr Opin Genet Dev, 11, 205-208. 
Meyer, H., Sutter, G. and Mayr, A. (1991) Mapping of deletions in the genome of the highly 
attenuated vaccinia virus MVA and their influence on virulence. J Gen Virol, 72 ( Pt 5), 
1031-1038. 
Meylan, E., Curran, J., Hofmann, K., Moradpour, D., Binder, M., Bartenschlager, R. and Tschopp, J. 
(2005) Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis 
C virus. Nature, 437, 1167-1172. 
Michallet, M.C., Meylan, E., Ermolaeva, M.A., Vazquez, J., Rebsamen, M., Curran, J., Poeck, H., 
Bscheider, M., Hartmann, G., Konig, M., Kalinke, U., Pasparakis, M. and Tschopp, J. (2008) 
TRADD protein is an essential component of the RIG-like helicase antiviral pathway. 
Immunity, 28, 651-661. 
Mihm, S., Frese, M., Meier, V., Wietzke-Braun, P., Scharf, J.G., Bartenschlager, R. and Ramadori, G. 
(2004) Interferon type I gene expression in chronic hepatitis C. Lab Invest, 84, 1148-1159. 
193 
 
Mimori, T. and Hardin, J.A. (1986) Mechanism of interaction between Ku protein and DNA. J Biol 
Chem, 261, 10375-10379. 
Mori, M., Yoneyama, M., Ito, T., Takahashi, K., Inagaki, F. and Fujita, T. (2004) Identification of 
Ser-386 of interferon regulatory factor 3 as critical target for inducible phosphorylation that 
determines activation. J Biol Chem, 279, 9698-9702. 
Moss, B. (2007) Poxviruses. Lippincott, Williams & Wilkins, . 
Moss, B., Carroll, M.W., Wyatt, L.S., Bennink, J.R., Hirsch, V.M., Goldstein, S., Elkins, W.R., 
Fuerst, T.R., Lifson, J.D., Piatak, M., Restifo, N.P., Overwijk, W., Chamberlain, R., 
Rosenberg, S.A. and Sutter, G. (1996) Host range restricted, non-replicating vaccinia virus 
vectors as vaccine candidates. Adv Exp Med Biol, 397, 7-13. 
Moss, B., Smith, G.L. and Mackett, M. (1983) Use of vaccinia virus as an infectious molecular 
cloning and expression vector. Gene Amplif Anal, 3, 201-213. 
Mossman, K., Upton, C., Buller, R.M. and McFadden, G. (1995) Species specificity of ectromelia 
virus and vaccinia virus interferon-gamma binding proteins. Virology, 208, 762-769. 
Moyer, R.W., Graves, R.L. and Rothe, C.T. (1980) The white pock (mu) mutants of rabbit poxvirus. 
III. Terminal DNA sequence duplication and transposition in rabbit poxvirus. Cell, 22, 545-
553. 
Murphy, P. (2008) Chemokines. In Paul, W.E. (ed.), Fundamental Immunology. Lippincott, Williams 
& Wilkins, Vol. 1, pp. 804-833. 
Nairz, M., Schroll, A., Moschen, A.R., Sonnweber, T., Theurl, M., Theurl, I., Taub, N., Jamnig, C., 
Neurauter, D., Huber, L.A., Tilg, H., Moser, P.L. and Weiss, G. (2011) Erythropoietin 
contrastingly affects bacterial infection and experimental colitis by inhibiting nuclear factor-
kappaB-inducible immune pathways. Immunity, 34, 61-74. 
Najarro, P., Traktman, P. and Lewis, J.A. (2001) Vaccinia virus blocks gamma interferon signal 
transduction: viral VH1 phosphatase reverses Stat1 activation. J Virol, 75, 3185-3196. 
Nakamura, M., Bodily, J.M., Beglin, M., Kyo, S., Inoue, M. and Laimins, L.A. (2009) Hypoxia-
specific stabilization of HIF-1alpha by human papillomaviruses. Virology, 387, 442-448. 
Neumann, A.K., Yang, J., Biju, M.P., Joseph, S.K., Johnson, R.S., Haase, V.H., Freedman, B.D. and 
Turka, L.A. (2005) Hypoxia inducible factor 1 alpha regulates T cell receptor signal 
transduction. Proc Natl Acad Sci U S A, 102, 17071-17076. 
Ng, A., Tscharke, D.C., Reading, P.C. and Smith, G.L. (2001) The vaccinia virus A41L protein is a 
soluble 30 kDa glycoprotein that affects virus virulence. J Gen Virol, 82, 2095-2105. 
Nixon-Fulton, J.L., Witte, P.L., Tigelaar, R.E., Bergstresser, P.R. and Kumar, V. (1987) Lack of 
dendritic Thy-1+ epidermal cells in mice with severe combined immunodeficiency disease. J 
Immunol, 138, 2902-2905. 
Nizet, V. and Johnson, R.S. (2009) Interdependence of hypoxic and innate immune responses. Nat 
Rev Immunol, 9, 609-617. 
O'Gorman, W.E., Sampath, P., Simonds, E.F., Sikorski, R., O'Malley, M., Krutzik, P.O., Chen, H., 
Panchanathan, V., Chaudhri, G., Karupiah, G., Lewis, D.B., Thorne, S.H. and Nolan, G.P. 
(2011) Alternate mechanisms of initial pattern recognition drive differential immune 
responses to related poxviruses. Cell Host Microbe, 8, 174-185. 
Oganesyan, G., Saha, S.K., Guo, B., He, J.Q., Shahangian, A., Zarnegar, B., Perry, A. and Cheng, G. 
(2006) Critical role of TRAF3 in the Toll-like receptor-dependent and -independent antiviral 
response. Nature, 439, 208-211. 
Okabe, Y., Kawane, K. and Nagata, S. (2008) IFN regulatory factor (IRF) 3/7-dependent and -
independent gene induction by mammalian DNA that escapes degradation. Eur J Immunol, 
38, 3150-3158. 
Okabe, Y., Sano, T. and Nagata, S. (2009) Regulation of the innate immune response by threonine-
phosphatase of Eyes absent. Nature, 460, 520-524. 
Paillard, S. and Strauss, F. (1991) Analysis of the mechanism of interaction of simian Ku protein with 
DNA. Nucleic Acids Res, 19, 5619-5624. 
Panicali, D. and Paoletti, E. (1982) Construction of poxviruses as cloning vectors: insertion of the 
thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus. 
Proc Natl Acad Sci U S A, 79, 4927-4931. 
194 
 
Panne, D., McWhirter, S.M., Maniatis, T. and Harrison, S.C. (2007) Interferon regulatory factor 3 is 
regulated by a dual phosphorylation-dependent switch. J Biol Chem, 282, 22816-22822. 
Pead, P.J. (2003) Benjamin Jesty: new light in the dawn of vaccination. Lancet, 362, 2104-2109. 
Pedersen, K., Snijder, E.J., Schleich, S., Roos, N., Griffiths, G. and Locker, J.K. (2000) 
Characterization of vaccinia virus intracellular cores: implications for viral uncoating and 
core structure. J Virol, 74, 3525-3536. 
Pedley, C.B. and Cooper, R.J. (1987) The assay, purification and properties of vaccinia virus-induced 
uncoating protein. J Gen Virol, 68 ( Pt 4), 1021-1028. 
Perelygin, A.A., Scherbik, S.V., Zhulin, I.B., Stockman, B.M., Li, Y. and Brinton, M.A. (2002) 
Positional cloning of the murine flavivirus resistance gene. Proc Natl Acad Sci U S A, 99, 
9322-9327. 
Perry, A.K., Chow, E.K., Goodnough, J.B., Yeh, W.C. and Cheng, G. (2004) Differential requirement 
for TANK-binding kinase-1 in type I interferon responses to toll-like receptor activation and 
viral infection. J Exp Med, 199, 1651-1658. 
Pestka, S., Krause, C.D. and Walter, M.R. (2004) Interferons, interferon-like cytokines, and their 
receptors. Immunol Rev, 202, 8-32. 
Peyssonnaux, C., Datta, V., Cramer, T., Doedens, A., Theodorakis, E.A., Gallo, R.L., Hurtado-Ziola, 
N., Nizet, V. and Johnson, R.S. (2005) HIF-1alpha expression regulates the bactericidal 
capacity of phagocytes. J Clin Invest, 115, 1806-1815. 
Pichlmair, A., Schulz, O., Tan, C.P., Naslund, T.I., Liljestrom, P., Weber, F. and Reis e Sousa, C. 
(2006) RIG-I-mediated antiviral responses to single-stranded RNA bearing 5'-phosphates. 
Science, 314, 997-1001. 
Platanias, L.C. (2005) Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev 
Immunol, 5, 375-386. 
Pobezinskaya, Y.L., Kim, Y.S., Choksi, S., Morgan, M.J., Li, T., Liu, C. and Liu, Z. (2008) The 
function of TRADD in signaling through tumor necrosis factor receptor 1 and TRIF-
dependent Toll-like receptors. Nat Immunol, 9, 1047-1054. 
Rahman, A. and Isenberg, D.A. (2008) Systemic lupus erythematosus. N Engl J Med, 358, 929-939. 
Ramirez, M.C. and Sigal, L.J. (2002) Macrophages and dendritic cells use the cytosolic pathway to 
rapidly cross-present antigen from live, vaccinia-infected cells. J Immunol, 169, 6733-6742. 
Randall, R.E. and Goodbourn, S. (2008) Interferons and viruses: an interplay between induction, 
signalling, antiviral responses and virus countermeasures. J Gen Virol, 89, 1-47. 
Rathinam, V.A., Jiang, Z., Waggoner, S.N., Sharma, S., Cole, L.E., Waggoner, L., Vanaja, S.K., 
Monks, B.G., Ganesan, S., Latz, E., Hornung, V., Vogel, S.N., Szomolanyi-Tsuda, E. and 
Fitzgerald, K.A. (2010) The AIM2 inflammasome is essential for host defense against 
cytosolic bacteria and DNA viruses. Nat Immunol, 11, 395-402. 
Reading, P.C. and Smith, G.L. (2003) Vaccinia virus interleukin-18-binding protein promotes 
virulence by reducing gamma interferon production and natural killer and T-cell activity. J 
Virol, 77, 9960-9968. 
Reading, P.C., Symons, J.A. and Smith, G.L. (2003) A soluble chemokine-binding protein from 
vaccinia virus reduces virus virulence and the inflammatory response to infection. J Immunol, 
170, 1435-1442. 
Rice, A.P. and Kerr, I.M. (1984) Interferon-mediated, double-stranded RNA-dependent protein kinase 
is inhibited in extracts from vaccinia virus-infected cells. J Virol, 50, 229-236. 
Ricklin, D., Hajishengallis, G., Yang, K. and Lambris, J.D. (2010) Complement: a key system for 
immune surveillance and homeostasis. Nat Immunol, 11, 785-797. 
Ripoli, M., D'Aprile, A., Quarato, G., Sarasin-Filipowicz, M., Gouttenoire, J., Scrima, R., Cela, O., 
Boffoli, D., Heim, M.H., Moradpour, D., Capitanio, N. and Piccoli, C. (2009) Hepatitis C 
virus-linked mitochondrial dysfunction promotes hypoxia-inducible factor 1 alpha-mediated 
glycolytic adaptation. J Virol, 84, 647-660. 
Rius, J., Guma, M., Schachtrup, C., Akassoglou, K., Zinkernagel, A.S., Nizet, V., Johnson, R.S., 
Haddad, G.G. and Karin, M. (2008) NF-kappaB links innate immunity to the hypoxic 
response through transcriptional regulation of HIF-1alpha. Nature, 453, 807-811. 
195 
 
Rivas, C., Gil, J., Melkova, Z., Esteban, M. and Diaz-Guerra, M. (1998) Vaccinia virus E3L protein is 
an inhibitor of the interferon (i.f.n.)-induced 2-5A synthetase enzyme. Virology, 243, 406-
414. 
Rivera, R., Hutchens, M., Luker, K.E., Sonstein, J., Curtis, J.L. and Luker, G.D. (2007) Murine 
alveolar macrophages limit replication of vaccinia virus. Virology, 363, 48-58. 
Roberts, T.L., Idris, A., Dunn, J.A., Kelly, G.M., Burnton, C.M., Hodgson, S., Hardy, L.L., Garceau, 
V., Sweet, M.J., Ross, I.L., Hume, D.A. and Stacey, K.J. (2009) HIN-200 proteins regulate 
caspase activation in response to foreign cytoplasmic DNA. Science, 323, 1057-1060. 
Rodier, F., Coppe, J.P., Patil, C.K., Hoeijmakers, W.A., Munoz, D.P., Raza, S.R., Freund, A., 
Campeau, E., Davalos, A.R. and Campisi, J. (2009) Persistent DNA damage signalling 
triggers senescence-associated inflammatory cytokine secretion. Nat Cell Biol, 11, 973-979. 
Rodriguez, J.R., Rodriguez, D. and Esteban, M. (1991) Interferon treatment inhibits early events in 
vaccinia virus gene expression in infected mice. Virology, 185, 929-933. 
Rosenberger, P., Schwab, J.M., Mirakaj, V., Masekowsky, E., Mager, A., Morote-Garcia, J.C., Unertl, 
K. and Eltzschig, H.K. (2009) Hypoxia-inducible factor-dependent induction of netrin-1 
dampens inflammation caused by hypoxia. Nat Immunol, 10, 195-202. 
Ryzhakov, G. and Randow, F. (2007) SINTBAD, a novel component of innate antiviral immunity, 
shares a TBK1-binding domain with NAP1 and TANK. Embo J, 26, 3180-3190. 
Sabbah, A., Chang, T.H., Harnack, R., Frohlich, V., Tominaga, K., Dube, P.H., Xiang, Y. and Bose, 
S. (2009) Activation of innate immune antiviral responses by Nod2. Nat Immunol, 10, 1073-
1080. 
Sadler, A.J. and Williams, B.R. (2008) Interferon-inducible antiviral effectors. Nat Rev Immunol, 8, 
559-568. 
Saha, S.K., Pietras, E.M., He, J.Q., Kang, J.R., Liu, S.Y., Oganesyan, G., Shahangian, A., Zarnegar, 
B., Shiba, T.L., Wang, Y. and Cheng, G. (2006) Regulation of antiviral responses by a direct 
and specific interaction between TRAF3 and Cardif. Embo J, 25, 3257-3263. 
Saitoh, T., Fujita, N., Hayashi, T., Takahara, K., Satoh, T., Lee, H., Matsunaga, K., Kageyama, S., 
Omori, H., Noda, T., Yamamoto, N., Kawai, T., Ishii, K., Takeuchi, O., Yoshimori, T. and 
Akira, S. (2009) Atg9a controls dsDNA-driven dynamic translocation of STING and the 
innate immune response. Proc Natl Acad Sci U S A, 106, 20842-20846. 
Sali, A., Potterton, L., Yuan, F., van Vlijmen, H. and Karplus, M. (1995) Evaluation of comparative 
protein modeling by MODELLER. Proteins, 23, 318-326. 
Salzman, N.P. (1960) The rate of formation of vaccinia deoxyribonucleic acid and vaccinia virus. 
Virology, 10, 150-152. 
Samuelsson, C., Hausmann, J., Lauterbach, H., Schmidt, M., Akira, S., Wagner, H., Chaplin, P., 
Suter, M., O'Keeffe, M. and Hochrein, H. (2008) Survival of lethal poxvirus infection in mice 
depends on TLR9, and therapeutic vaccination provides protection. J Clin Invest, 118, 1776-
1784. 
Sasai, M., Shingai, M., Funami, K., Yoneyama, M., Fujita, T., Matsumoto, M. and Seya, T. (2006) 
NAK-associated protein 1 participates in both the TLR3 and the cytoplasmic pathways in type 
I IFN induction. J Immunol, 177, 8676-8683. 
Sato, M., Suemori, H., Hata, N., Asagiri, M., Ogasawara, K., Nakao, K., Nakaya, T., Katsuki, M., 
Noguchi, S., Tanaka, N. and Taniguchi, T. (2000) Distinct and essential roles of transcription 
factors IRF-3 and IRF-7 in response to viruses for IFN-alpha/beta gene induction. Immunity, 
13, 539-548. 
Sato, M., Tanaka, N., Hata, N., Oda, E. and Taniguchi, T. (1998) Involvement of the IRF family 
transcription factor IRF-3 in virus-induced activation of the IFN-beta gene. FEBS Lett, 425, 
112-116. 
Sato, S., Sugiyama, M., Yamamoto, M., Watanabe, Y., Kawai, T., Takeda, K. and Akira, S. (2003) 
Toll/IL-1 receptor domain-containing adaptor inducing IFN-beta (TRIF) associates with TNF 
receptor-associated factor 6 and TANK-binding kinase 1, and activates two distinct 
transcription factors, NF-kappa B and IFN-regulatory factor-3, in the Toll-like receptor 
signaling. J Immunol, 171, 4304-4310. 
196 
 
Satoh, T., Kato, H., Kumagai, Y., Yoneyama, M., Sato, S., Matsushita, K., Tsujimura, T., Fujita, T., 
Akira, S. and Takeuchi, O. (2010) LGP2 is a positive regulator of RIG-I- and MDA5-
mediated antiviral responses. Proc Natl Acad Sci U S A, 107, 1512-1517. 
Schindler, C. and Darnell, J.E., Jr. (1995) Transcriptional responses to polypeptide ligands: the JAK-
STAT pathway. Annu Rev Biochem, 64, 621-651. 
Schlee, M., Roth, A., Hornung, V., Hagmann, C.A., Wimmenauer, V., Barchet, W., Coch, C., Janke, 
M., Mihailovic, A., Wardle, G., Juranek, S., Kato, H., Kawai, T., Poeck, H., Fitzgerald, K.A., 
Takeuchi, O., Akira, S., Tuschl, T., Latz, E., Ludwig, J. and Hartmann, G. (2009) Recognition 
of 5' triphosphate by RIG-I helicase requires short blunt double-stranded RNA as contained in 
panhandle of negative-strand virus. Immunity, 31, 25-34. 
Schmidt, A., Schwerd, T., Hamm, W., Hellmuth, J.C., Cui, S., Wenzel, M., Hoffmann, F.S., 
Michallet, M.C., Besch, R., Hopfner, K.P., Endres, S. and Rothenfusser, S. (2009) 5'-
triphosphate RNA requires base-paired structures to activate antiviral signaling via RIG-I. 
Proc Natl Acad Sci U S A, 106, 12067-12072. 
Schroder, M., Baran, M. and Bowie, A.G. (2008) Viral targeting of DEAD box protein 3 reveals its 
role in TBK1/IKKepsilon-mediated IRF activation. Embo J, 27, 2147-2157. 
Seet, B.T., Singh, R., Paavola, C., Lau, E.K., Handel, T.M. and McFadden, G. (2001) Molecular 
determinants for CC-chemokine recognition by a poxvirus CC-chemokine inhibitor. Proc 
Natl Acad Sci U S A, 98, 9008-9013. 
Sen, R. and Baltimore, D. (1986a) Inducibility of kappa immunoglobulin enhancer-binding protein 
Nf-kappa B by a posttranslational mechanism. Cell, 47, 921-928. 
Sen, R. and Baltimore, D. (1986b) Multiple nuclear factors interact with the immunoglobulin 
enhancer sequences. Cell, 46, 705-716. 
Seth, R.B., Sun, L., Ea, C.K. and Chen, Z.J. (2005) Identification and characterization of MAVS, a 
mitochondrial antiviral signaling protein that activates NF-kappaB and IRF 3. Cell, 122, 669-
682. 
Sharma, S., tenOever, B.R., Grandvaux, N., Zhou, G.P., Lin, R. and Hiscott, J. (2003) Triggering the 
interferon antiviral response through an IKK-related pathway. Science, 300, 1148-1151. 
Shi, J., Blundell, T.L. and Mizuguchi, K. (2001) FUGUE: sequence-structure homology recognition 
using environment-specific substitution tables and structure-dependent gap penalties. J Mol 
Biol, 310, 243-257. 
Shirota, H., Ishii, K.J., Takakuwa, H. and Klinman, D.M. (2006) Contribution of interferon-beta to the 
immune activation induced by double-stranded DNA. Immunology, 118, 302-310. 
Shisler, J.L. and Jin, X.L. (2004) The vaccinia virus K1L gene product inhibits host NF-kappaB 
activation by preventing IkappaBalpha degradation. J Virol, 78, 3553-3560. 
Shors, S.T., Beattie, E., Paoletti, E., Tartaglia, J. and Jacobs, B.L. (1998) Role of the vaccinia virus 
E3L and K3L gene products in rescue of VSV and EMCV from the effects of IFN-alpha. J 
Interferon Cytokine Res, 18, 721-729. 
Silverman, R.H. (2007) Viral encounters with 2',5'-oligoadenylate synthetase and RNase L during the 
interferon antiviral response. J Virol, 81, 12720-12729. 
Singleton, B.K., Priestley, A., Steingrimsdottir, H., Gell, D., Blunt, T., Jackson, S.P., Lehmann, A.R. 
and Jeggo, P.A. (1997) Molecular and biochemical characterization of xrs mutants defective 
in Ku80. Mol Cell Biol, 17, 1264-1273. 
Slabaugh, M., Roseman, N., Davis, R. and Mathews, C. (1988) Vaccinia virus-encoded ribonucleotide 
reductase: sequence conservation of the gene for the small subunit and its amplification in 
hydroxyurea-resistant mutants. J Virol, 62, 519-527. 
Smith, C.A., Smith, T.D., Smolak, P.J., Friend, D., Hagen, H., Gerhart, M., Park, L., Pickup, D.J., 
Torrance, D., Mohler, K., Schooley, K. and Goodwin, R.G. (1997) Poxvirus genomes encode 
a secreted, soluble protein that preferentially inhibits beta chemokine activity yet lacks 
sequence homology to known chemokine receptors. Virology, 236, 316-327. 
Smith, G.L., de Carlos, A. and Chan, Y.S. (1989) Vaccinia virus encodes a thymidylate kinase gene: 
sequence and transcriptional mapping. Nucleic Acids Res, 17, 7581-7590. 
Smith, G.L., Mackett, M. and Moss, B. (1983) Infectious vaccinia virus recombinants that express 
hepatitis B virus surface antigen. Nature, 302, 490-495. 
197 
 
Smith, G.L., Symons, J.A. and Alcami, A. (1999) Immune modulation by proteins secreted from cells 
infected by vaccinia virus. Arch Virol Suppl, 15, 111-129. 
Smith, V.P., Bryant, N.A. and Alcami, A. (2000) Ectromelia, vaccinia and cowpox viruses encode 
secreted interleukin-18-binding proteins. J Gen Virol, 81, 1223-1230. 
Spriggs, M.K., Hruby, D.E., Maliszewski, C.R., Pickup, D.J., Sims, J.E., Buller, R.M. and VanSlyke, 
J. (1992) Vaccinia and cowpox viruses encode a novel secreted interleukin-1-binding protein. 
Cell, 71, 145-152. 
Stack, J., Haga, I.R., Schroder, M., Bartlett, N.W., Maloney, G., Reading, P.C., Fitzgerald, K.A., 
Smith, G.L. and Bowie, A.G. (2005) Vaccinia virus protein A46R targets multiple Toll-like-
interleukin-1 receptor adaptors and contributes to virulence. J Exp Med, 201, 1007-1018. 
Stephenson, J.B. (2008) Aicardi-Goutieres syndrome (AGS). Eur J Paediatr Neurol, 12, 355-358. 
Stetson, D.B. (2009) Connections between antiviral defense and autoimmunity. Curr Opin Immunol, 
21, 244-250. 
Stetson, D.B., Ko, J.S., Heidmann, T. and Medzhitov, R. (2008) Trex1 prevents cell-intrinsic 
initiation of autoimmunity. Cell, 134, 587-598. 
Stetson, D.B. and Medzhitov, R. (2006) Recognition of cytosolic DNA activates an IRF3-dependent 
innate immune response. Immunity, 24, 93-103. 
Sun, Q., Sun, L., Liu, H.H., Chen, X., Seth, R.B., Forman, J. and Chen, Z.J. (2006) The specific and 
essential role of MAVS in antiviral innate immune responses. Immunity, 24, 633-642. 
Sun, S.C., Ganchi, P.A., Ballard, D.W. and Greene, W.C. (1993) NF-kappa B controls expression of 
inhibitor I kappa B alpha: evidence for an inducible autoregulatory pathway. Science, 259, 
1912-1915. 
Symons, J.A., Adams, E., Tscharke, D.C., Reading, P.C., Waldmann, H. and Smith, G.L. (2002a) The 
vaccinia virus C12L protein inhibits mouse IL-18 and promotes virus virulence in the murine 
intranasal model. J Gen Virol, 83, 2833-2844. 
Symons, J.A., Alcami, A. and Smith, G.L. (1995) Vaccinia virus encodes a soluble type I interferon 
receptor of novel structure and broad species specificity. Cell, 81, 551-560. 
Symons, J.A., Tscharke, D.C., Price, N. and Smith, G.L. (2002b) A study of the vaccinia virus 
interferon-gamma receptor and its contribution to virus virulence. J Gen Virol, 83, 1953-
1964. 
Tabeta, K., Georgel, P., Janssen, E., Du, X., Hoebe, K., Crozat, K., Mudd, S., Shamel, L., Sovath, S., 
Goode, J., Alexopoulou, L., Flavell, R.A. and Beutler, B. (2004) Toll-like receptors 9 and 3 as 
essential components of innate immune defense against mouse cytomegalovirus infection. 
Proc Natl Acad Sci U S A, 101, 3516-3521. 
Takahashi-Nishimaki, F., Funahashi, S., Miki, K., Hashizume, S. and Sugimoto, M. (1991) 
Regulation of plaque size and host range by a vaccinia virus gene related to complement 
system proteins. Virology, 181, 158-164. 
Takahasi, K., Yoneyama, M., Nishihori, T., Hirai, R., Kumeta, H., Narita, R., Gale, M., Jr., Inagaki, F. 
and Fujita, T. (2008) Nonself RNA-sensing mechanism of RIG-I helicase and activation of 
antiviral immune responses. Mol Cell, 29, 428-440. 
Takaoka, A., Wang, Z., Choi, M.K., Yanai, H., Negishi, H., Ban, T., Lu, Y., Miyagishi, M., Kodama, 
T., Honda, K., Ohba, Y. and Taniguchi, T. (2007) DAI (DLM-1/ZBP1) is a cytosolic DNA 
sensor and an activator of innate immune response. Nature, 448, 501-505. 
Takeuchi, O. and Akira, S. (2010) Pattern recognition receptors and inflammation. Cell, 140, 805-820. 
Tamura, T., Yanai, H., Savitsky, D. and Taniguchi, T. (2008) The IRF family transcription factors in 
immunity and oncogenesis. Annu Rev Immunol, 26, 535-584. 
Tang, X., Zhang, Q., Nishitani, J., Brown, J., Shi, S. and Le, A.D. (2007) Overexpression of human 
papillomavirus type 16 oncoproteins enhances hypoxia-inducible factor 1 alpha protein 
accumulation and vascular endothelial growth factor expression in human cervical carcinoma 
cells. Clin Cancer Res, 13, 2568-2576. 
Taniguchi, T. and Takaoka, A. (2002) The interferon-alpha/beta system in antiviral responses: a 
multimodal machinery of gene regulation by the IRF family of transcription factors. Curr 
Opin Immunol, 14, 111-116. 
Tattersall, P. and Ward, D.C. (1976) Rolling hairpin model for replication of parvovirus and linear 
chromosomal DNA. Nature, 263, 106-109. 
198 
 
Tengelsen, L.A., Slabaugh, M.B., Bibler, J.K. and Hruby, D.E. (1988) Nucleotide sequence and 
molecular genetic analysis of the large subunit of ribonucleotide reductase encoded by 
vaccinia virus. Virology, 164, 121-131. 
Thanos, D. and Maniatis, T. (1995) Virus induction of human IFN beta gene expression requires the 
assembly of an enhanceosome. Cell, 83, 1091-1100. 
Torrance, H., Giffin, W., Rodda, D.J., Pope, L. and Hache, R.J. (1998) Sequence-specific binding of 
Ku autoantigen to single-stranded DNA. J Biol Chem, 273, 20810-20819. 
Townsley, A.C. and Moss, B. (2007) Two distinct low-pH steps promote entry of vaccinia virus. J 
Virol, 81, 8613-8620. 
Townsley, A.C., Weisberg, A.S., Wagenaar, T.R. and Moss, B. (2006) Vaccinia virus entry into cells 
via a low-pH-dependent endosomal pathway. J Virol, 80, 8899-8908. 
Trilling, M., Le, V.T., Zimmermann, A., Ludwig, H., Pfeffer, K., Sutter, G., Smith, G.L. and Hengel, 
H. (2009) Gamma interferon-induced interferon regulatory factor 1-dependent antiviral 
response inhibits vaccinia virus replication in mouse but not human fibroblasts. J Virol, 83, 
3684-3695. 
Tsuchida, T., Zou, J., Saitoh, T., Kumar, H., Abe, T., Matsuura, Y., Kawai, T. and Akira, S. (2010) 
The ubiquitin ligase TRIM56 regulates innate immune responses to intracellular double-
stranded DNA. Immunity, 33, 765-776. 
Unterholzner, L., Keating, S.E., Baran, M., Horan, K.A., Jensen, S.B., Sharma, S., Sirois, C.M., Jin, 
T., Latz, E., Xiao, T.S., Fitzgerald, K.A., Paludan, S.R. and Bowie, A.G. (2010) IFI16 is an 
innate immune sensor for intracellular DNA. Nat Immunol, 11, 997-1004. 
Vallabhapurapu, S. and Karin, M. (2009) Regulation and function of NF-kappaB transcription factors 
in the immune system. Annu Rev Immunol, 27, 693-733. 
van den Broek, M.F., Muller, U., Huang, S., Zinkernagel, R.M. and Aguet, M. (1995) Immune 
defence in mice lacking type I and/or type II interferon receptors. Immunol Rev, 148, 5-18. 
Vanderplasschen, A., Mathew, E., Hollinshead, M., Sim, R.B. and Smith, G.L. (1998) Extracellular 
enveloped vaccinia virus is resistant to complement because of incorporation of host 
complement control proteins into its envelope. Proc Natl Acad Sci U S A, 95, 7544-7549. 
Vanderplasschen, A. and Smith, G.L. (1999) Using confocal microscopy to study virus binding and 
entry into cells. Methods Enzymol, 307, 591-607. 
Visvanathan, K.V. and Goodbourn, S. (1989) Double-stranded RNA activates binding of NF-kappa B 
to an inducible element in the human beta-interferon promoter. Embo J, 8, 1129-1138. 
Vivier, E., Tomasello, E., Baratin, M., Walzer, T. and Ugolini, S. (2008) Functions of natural killer 
cells. Nat Immunol, 9, 503-510. 
Waibler, Z., Anzaghe, M., Ludwig, H., Akira, S., Weiss, S., Sutter, G. and Kalinke, U. (2007) 
Modified vaccinia virus Ankara induces Toll-like receptor-independent type I interferon 
responses. J Virol, 81, 12102-12110. 
Walker, J.R., Corpina, R.A. and Goldberg, J. (2001) Structure of the Ku heterodimer bound to DNA 
and its implications for double-strand break repair. Nature, 412, 607-614. 
Walmsley, S.R., McGovern, N.N., Whyte, M.K. and Chilvers, E.R. (2008) The HIF/VHL pathway: 
from oxygen sensing to innate immunity. Am J Respir Cell Mol Biol, 38, 251-255. 
Walmsley, S.R., Print, C., Farahi, N., Peyssonnaux, C., Johnson, R.S., Cramer, T., Sobolewski, A., 
Condliffe, A.M., Cowburn, A.S., Johnson, N. and Chilvers, E.R. (2005) Hypoxia-induced 
neutrophil survival is mediated by HIF-1alpha-dependent NF-kappaB activity. J Exp Med, 
201, 105-115. 
Wang, G.L., Jiang, B.H., Rue, E.A. and Semenza, G.L. (1995) Hypoxia-inducible factor 1 is a basic-
helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S 
A, 92, 5510-5514. 
Wang, Z., Choi, M.K., Ban, T., Yanai, H., Negishi, H., Lu, Y., Tamura, T., Takaoka, A., Nishikura, 
K. and Taniguchi, T. (2008) Regulation of innate immune responses by DAI (DLM-1/ZBP1) 
and other DNA-sensing molecules. Proc Natl Acad Sci U S A, 105, 5477-5482. 
Wenger, R.H. (2002) Cellular adaptation to hypoxia: O2-sensing protein hydroxylases, hypoxia-
inducible transcription factors, and O2-regulated gene expression. Faseb J, 16, 1151-1162. 
West, B.C., Eschete, M.L., Cox, M.E. and King, J.W. (1987) Neutrophil uptake of vaccinia virus in 
vitro. J Infect Dis, 156, 597-606. 
199 
 
Weterings, E. and Chen, D.J. (2007) DNA-dependent protein kinase in nonhomologous end joining: a 
lock with multiple keys? J Cell Biol, 179, 183-186. 
Willmore, E., de Caux, S., Sunter, N.J., Tilby, M.J., Jackson, G.H., Austin, C.A. and Durkacz, B.W. 
(2004) A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the 
cytotoxicity of topoisomerase II poisons used in the treatment of leukemia. Blood, 103, 4659-
4665. 
Wu, X. and Lieber, M.R. (1996) Protein-protein and protein-DNA interaction regions within the DNA 
end-binding protein Ku70-Ku86. Mol Cell Biol, 16, 5186-5193. 
Xia, Z.P., Sun, L., Chen, X., Pineda, G., Jiang, X., Adhikari, A., Zeng, W. and Chen, Z.J. (2009) 
Direct activation of protein kinases by unanchored polyubiquitin chains. Nature, 461, 114-
119. 
Xiang, Y., Condit, R.C., Vijaysri, S., Jacobs, B., Williams, B.R. and Silverman, R.H. (2002) Blockade 
of interferon induction and action by the E3L double-stranded RNA binding proteins of 
vaccinia virus. J Virol, 76, 5251-5259. 
Xiang, Y. and Moss, B. (1999) IL-18 binding and inhibition of interferon gamma induction by human 
poxvirus-encoded proteins. Proc Natl Acad Sci U S A, 96, 11537-11542. 
Xu, L.G., Wang, Y.Y., Han, K.J., Li, L.Y., Zhai, Z. and Shu, H.B. (2005) VISA is an adapter protein 
required for virus-triggered IFN-beta signaling. Mol Cell, 19, 727-740. 
Yamaguchi, K., Shirakabe, K., Shibuya, H., Irie, K., Oishi, I., Ueno, N., Taniguchi, T., Nishida, E. 
and Matsumoto, K. (1995) Identification of a member of the MAPKKK family as a potential 
mediator of TGF-beta signal transduction. Science, 270, 2008-2011. 
Yamamoto, M., Sato, S., Hemmi, H., Hoshino, K., Kaisho, T., Sanjo, H., Takeuchi, O., Sugiyama, M., 
Okabe, M., Takeda, K. and Akira, S. (2003a) Role of adaptor TRIF in the MyD88-
independent toll-like receptor signaling pathway. Science, 301, 640-643. 
Yamamoto, M., Sato, S., Hemmi, H., Uematsu, S., Hoshino, K., Kaisho, T., Takeuchi, O., Takeda, K. 
and Akira, S. (2003b) TRAM is specifically involved in the Toll-like receptor 4-mediated 
MyD88-independent signaling pathway. Nat Immunol, 4, 1144-1150. 
Yan, N., Regalado-Magdos, A.D., Stiggelbout, B., Lee-Kirsch, M.A. and Lieberman, J. (2010) The 
cytosolic exonuclease TREX1 inhibits the innate immune response to human 
immunodeficiency virus type 1. Nat Immunol, 11, 1005-1013. 
Yaneva, M., Kowalewski, T. and Lieber, M.R. (1997) Interaction of DNA-dependent protein kinase 
with DNA and with Ku: biochemical and atomic-force microscopy studies. Embo J, 16, 5098-
5112. 
Yang, P., An, H., Liu, X., Wen, M., Zheng, Y., Rui, Y. and Cao, X. (2010) The cytosolic nucleic acid 
sensor LRRFIP1 mediates the production of type I interferon via a beta-catenin-dependent 
pathway. Nat Immunol, 11, 487-494. 
Yao, Y., Li, P., Singh, P., Thiele, A.T., Wilkes, D.S., Renukaradhya, G.J., Brutkiewicz, R.R., Travers, 
J.B., Luker, G.D., Hong, S.C., Blum, J.S. and Chang, C.H. (2007) Vaccinia virus infection 
induces dendritic cell maturation but inhibits antigen presentation by MHC class II. Cell 
Immunol, 246, 92-102. 
Yoneyama, M., Kikuchi, M., Matsumoto, K., Imaizumi, T., Miyagishi, M., Taira, K., Foy, E., Loo, 
Y.M., Gale, M., Jr., Akira, S., Yonehara, S., Kato, A. and Fujita, T. (2005) Shared and unique 
functions of the DExD/H-box helicases RIG-I, MDA5, and LGP2 in antiviral innate 
immunity. J Immunol, 175, 2851-2858. 
Yoneyama, M., Kikuchi, M., Natsukawa, T., Shinobu, N., Imaizumi, T., Miyagishi, M., Taira, K., 
Akira, S. and Fujita, T. (2004) The RNA helicase RIG-I has an essential function in double-
stranded RNA-induced innate antiviral responses. Nat Immunol, 5, 730-737. 
Yoo, Y.G., Oh, S.H., Park, E.S., Cho, H., Lee, N., Park, H., Kim, D.K., Yu, D.Y., Seong, J.K. and 
Lee, M.O. (2003) Hepatitis B virus X protein enhances transcriptional activity of hypoxia-
inducible factor-1alpha through activation of mitogen-activated protein kinase pathway. J 
Biol Chem, 278, 39076-39084. 
Yu, F., White, S.B., Zhao, Q. and Lee, F.S. (2001a) Dynamic, site-specific interaction of hypoxia-
inducible factor-1alpha with the von Hippel-Lindau tumor suppressor protein. Cancer Res, 
61, 4136-4142. 
200 
 
Yu, F., White, S.B., Zhao, Q. and Lee, F.S. (2001b) HIF-1alpha binding to VHL is regulated by 
stimulus-sensitive proline hydroxylation. Proc Natl Acad Sci U S A, 98, 9630-9635. 
Zaslavsky, V. (1985) Uncoating of vaccinia virus. J Virol, 55, 352-356. 
Zeng, W., Sun, L., Jiang, X., Chen, X., Hou, F., Adhikari, A., Xu, M. and Chen, Z.J. (2010) 
Reconstitution of the RIG-I pathway reveals a signaling role of unanchored polyubiquitin 
chains in innate immunity. Cell, 141, 315-330. 
Zhang, X., Brann, T.W., Zhou, M., Yang, J., Oguariri, R.M., Lidie, K.B., Imamichi, H., Huang, D.W., 
Lempicki, R.A., Baseler, M.W., Veenstra, T.D., Young, H.A., Lane, H.C. and Imamichi, T. 
(2011) Cutting edge: Ku70 is a novel cytosolic DNA sensor that induces type III rather than 
type I IFN. J Immunol, 186, 4541-4545. 
Zhao, C., Denison, C., Huibregtse, J.M., Gygi, S. and Krug, R.M. (2005) Human ISG15 conjugation 
targets both IFN-induced and constitutively expressed proteins functioning in diverse cellular 
pathways. Proc Natl Acad Sci U S A, 102, 10200-10205. 
Zhao, Y., De Trez, C., Flynn, R., Ware, C.F., Croft, M. and Salek-Ardakani, S. (2009) The adaptor 
molecule MyD88 directly promotes CD8 T cell responses to vaccinia virus. J Immunol, 182, 
6278-6286. 
Zhou, Z., Hamming, O.J., Ank, N., Paludan, S.R., Nielsen, A.L. and Hartmann, R. (2007) Type III 
interferon (IFN) induces a type I IFN-like response in a restricted subset of cells through 
signaling pathways involving both the Jak-STAT pathway and the mitogen-activated protein 
kinases. J Virol, 81, 7749-7758. 
Zhu, J., Martinez, J., Huang, X. and Yang, Y. (2007) Innate immunity against vaccinia virus is 
mediated by TLR2 and requires TLR-independent production of IFN-beta. Blood, 109, 619-
625. 
 
 
